<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Healthpeak Properties, Inc.</td><td># í—¬ìŠ¤í”¼í¬ í”„ë¡œí¼í‹°ìŠ¤(Healthpeak Properties, Inc.)<br><br>í—¬ìŠ¤í”¼í¬ í”„ë¡œí¼í‹°ìŠ¤ëŠ” ë¯¸êµ­ì˜ ë¶€ë™ì‚° íˆ¬ì ì‹ íƒ(REIT)ìœ¼ë¡œ, ì˜ë£Œ ì‹œì„¤ ë¶€ë™ì‚°ì— íŠ¹í™”ëœ íˆ¬ìë¥¼ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>**ì£¼ìš” ì‚¬ì—… ë¶€ë¬¸:**<br>- ìƒëª…ê³¼í•™ ì—°êµ¬ì‹œì„¤<br>- ì˜ë£Œ ì˜¤í”¼ìŠ¤ ë¹Œë”©<br>- ì™¸ë˜í™˜ì ì˜ë£Œì‹œì„¤<br><br>**íˆ¬ì ì „ëµ:**<br>í—¬ìŠ¤í”¼í¬ëŠ” ê³ í’ˆì§ˆ ì˜ë£Œ ë¶€ë™ì‚° í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ í†µí•´ ì¥ê¸°ì ì´ê³  ì•ˆì •ì ì¸ ìˆ˜ìµì„ ì¶”êµ¬í•˜ë©°, ì¸êµ¬ ê³ ë ¹í™”ì™€ ì˜ë£Œ ìˆ˜ìš” ì¦ê°€ë¼ëŠ” êµ¬ì¡°ì  ì„±ì¥ ë™ë ¥ì„ í™œìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>---<br><br>*ì°¸ê³ : ì‹¤ì œ ì–´ë‹ì½œ ë‚´ìš©ì´ ì œê³µë˜ì§€ ì•Šì•„ íšŒì‚¬ ê°œìš”ë§Œ ì‘ì„±ë˜ì—ˆìŠµë‹ˆë‹¤. ì „ì²´ ì–´ë‹ì½œ transcriptë¥¼ ì œê³µí•´ì£¼ì‹œë©´ ìƒì„¸í•œ ë²ˆì—­ì„ ì§„í–‰í•´ë“œë¦¬ê² ìŠµë‹ˆë‹¤.*</td></tr>
<tr><td>(DOC) Q4 2025 Earnings Call February 3, 2026 10:00 AM EST<br><br>Company Participants<br><br>Andrew Johns - Senior Vice President of Investor Relations<br>Scott Brinker - President, CEO & Director<br>Kelvin Moses - Chief Financial Officer<br>Scott Bohn - Chief Development Officer & Head of Lab<br><br>Conference Call Participants<br><br>Nicholas Yulico - Scotiabank Global Banking and Markets, Research Division<br>Farrell Granath - BofA Securities, Research Division<br>Austin Wurschmidt - KeyBanc Capital Markets Inc., Research Division<br>Richard Anderson - Cantor Fitzgerald & Co., Research Division<br>Nicholas Joseph - Citigroup Inc., Research Division<br>Juan Sanabria - BMO Capital Markets Equity Research<br>Wesley Golladay - Robert W.</td><td># (DOC) 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ<br>2026ë…„ 2ì›” 3ì¼ ì˜¤ì „ 10ì‹œ (ë¯¸êµ­ ë™ë¶€ í‘œì¤€ì‹œ)<br><br>## íšŒì‚¬ ì°¸ì„ì<br><br>ì•¤ë“œë¥˜ ì¡´ìŠ¤ - íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ìˆ˜ì„ ë¶€ì‚¬ì¥<br>ìŠ¤ì½§ ë¸Œë§ì»¤ - ì‚¬ì¥, CEO ê²¸ ì´ì‚¬<br>ì¼ˆë¹ˆ ëª¨ì„¸ìŠ¤ - ìµœê³ ì¬ë¬´ì±…ì„ì(CFO)<br>ìŠ¤ì½§ ë³¸ - ìµœê³ ê°œë°œì±…ì„ì(CDO) ê²¸ ì—°êµ¬ì†Œ ì±…ì„ì<br><br>## ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì„ ì• ë„ë¦¬ìŠ¤íŠ¸<br><br>ë‹ˆì½œë¼ìŠ¤ ìœ¨ë¦¬ì½” - ìŠ¤ì½”ìƒ¤ë±…í¬ ê¸€ë¡œë²Œ ë±…í‚¹ ì•¤ ë§ˆì¼“ì¸ , ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>íŒ¨ëŸ´ ê·¸ë˜ë‚˜ìŠ¤ - ë±…í¬ì˜¤ë¸Œì•„ë©”ë¦¬ì¹´ ì¦ê¶Œ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì˜¤ìŠ¤í‹´ ì›ŒìŠˆë¯¸íŠ¸ - í‚¤ë±…í¬ ìºí”¼íƒˆ ë§ˆì¼“ì¸ , ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë¦¬ì²˜ë“œ ì•¤ë”ìŠ¨ - ìº”í„° í”¼ì¸ ì œëŸ´ë“œ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë‹ˆì½œë¼ìŠ¤ ì¡°ì…‰ - ì”¨í‹°ê·¸ë£¹, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>í›„ì•ˆ ì‚¬ë‚˜ë¸Œë¦¬ì•„ - BMO ìºí”¼íƒˆ ë§ˆì¼“ì¸  ì£¼ì‹ ë¦¬ì„œì¹˜<br>ì›¨ìŠ¬ë¦¬ ê³¨ë¼ë°ì´ - ë¡œë²„íŠ¸ W.</td></tr>
<tr><td>Baird & Co. Incorporated, Research Division<br>Vikram Malhotra - Mizuho Securities USA LLC, Research Division<br>Michael Mueller - JPMorgan Chase & Co, Research Division<br>Omotayo Okusanya - Deutsche Bank AG, Research Division<br>James Kammert - Evercore ISI Institutional Equities, Research Division<br>John Pawlowski - Green Street Advisors, LLC, Research Division<br>James Feldman - Wells Fargo Securities, LLC, Research Division<br><br>Presentation<br><br>Operator<br><br>Good morning, and welcome to the Healthpeak Properties, Inc. Fourth Quarter 2025 Conference Call. [Operator Instructions]<br><br>Please note this event is being recorded.</td><td>ë² ì–´ë“œ ì•¤ ì»´í¼ë‹ˆ ì¸ì½”í¼ë ˆì´í‹°ë“œ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë¹„í¬ëŒ ë§í˜¸íŠ¸ë¼ - ë¯¸ì¦ˆí˜¸ ì¦ê¶Œ USA LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë§ˆì´í´ ë®¬ëŸ¬ - JPëª¨ê±´ ì²´ì´ìŠ¤ ì•¤ ì»´í¼ë‹ˆ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì˜¤ëª¨íƒ€ìš” ì˜¤ì¿ ì†ì•¼ - ë„ì´ì²´ë°©í¬ AG, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì œì„ìŠ¤ ì¹´ë¨¸íŠ¸ - ì—ë²„ì½”ì–´ ISI ê¸°ê´€íˆ¬ìì ì£¼ì‹ë¶€ë¬¸<br>ì¡´ íŒŒë¸”ë¡œìŠ¤í‚¤ - ê·¸ë¦° ìŠ¤íŠ¸ë¦¬íŠ¸ ì–´ë“œë°”ì´ì €ìŠ¤ LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì œì„ìŠ¤ í ë“œë¨¼ - ì›°ìŠ¤íŒŒê³  ì¦ê¶Œ LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br><br>ë°œí‘œ<br><br>ìš´ì˜ì<br><br>ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ. í—¬ìŠ¤í”¼í¬ í”„ë¡œí¼í‹°ìŠ¤ ì£¼ì‹íšŒì‚¬ì˜ 2025ë…„ 4ë¶„ê¸° ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. [ìš´ì˜ì ì•ˆë‚´ì‚¬í•­]<br><br>ë³¸ í–‰ì‚¬ëŠ” ë…¹ìŒë˜ê³  ìˆìŒì„ ì•Œë ¤ë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>I would now like to turn the conference over to Andrew Johns, Senior Vice President, Investor Relations. You may begin. Andrew Johns<br>Senior Vice President of Investor Relations<br><br>Welcome. Today's conference call contains certain forward-looking statements. Although we believe the expectations reflected in any forward-looking statements are based on reasonable assumptions, these statements are subject to risks and uncertainties that may cause actual results to differ materially from expectations. A discussion of risks and risk factors is included in our press release and detailed in our filings with the SEC. We do not undertake a duty to update any forward-looking statements.</td><td>ì´ì œ ì»¨í¼ëŸ°ìŠ¤ë¥¼ ì•¤ë“œë¥˜ ì¡´ìŠ¤ íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ìˆ˜ì„ ë¶€ì‚¬ì¥ì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. ì‹œì‘í•˜ì…”ë„ ë©ë‹ˆë‹¤.<br><br>ì•¤ë“œë¥˜ ì¡´ìŠ¤<br>íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ìˆ˜ì„ ë¶€ì‚¬ì¥<br><br>í™˜ì˜í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ëŠ” íŠ¹ì • ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ (forward-looking statements)ì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì— ë°˜ì˜ëœ ê¸°ëŒ€ì¹˜ê°€ í•©ë¦¬ì ì¸ ê°€ì •ì— ê·¼ê±°í•œë‹¤ê³  ë¯¿ê³  ìˆìœ¼ë‚˜, ì´ëŸ¬í•œ ì§„ìˆ ë“¤ì€ ì‹¤ì œ ê²°ê³¼ê°€ ì˜ˆìƒê³¼ í¬ê²Œ ë‹¤ë¥¼ ìˆ˜ ìˆëŠ” ìœ„í—˜ê³¼ ë¶ˆí™•ì‹¤ì„±ì˜ ì˜í–¥ì„ ë°›ìŠµë‹ˆë‹¤. ìœ„í—˜ ë° ìœ„í—˜ìš”ì¸ì— ëŒ€í•œ ë…¼ì˜ëŠ” ë‹¹ì‚¬ì˜ ë³´ë„ìë£Œì— í¬í•¨ë˜ì–´ ìˆìœ¼ë©°, SEC ì œì¶œ ì„œë¥˜ì— ìƒì„¸íˆ ê¸°ì¬ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì„ ì—…ë°ì´íŠ¸í•  ì˜ë¬´ë¥¼ ì§€ì§€ ì•ŠìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Certain non-GAAP financial measures will be discussed on this call. In exhibit to the 8-K we furnished to the SEC yesterday, we have reconciled all non-GAAP financial measures to the most directly comparable GAAP measures in accordance with Reg G requirements. The exhibit is also available on our website at healthpeak.com. I'll now turn the call over to our President and Chief Executive Officer, Scott Brinker. Scott Brinker<br>President, CEO & Director<br><br>Thanks, A.J., and welcome to Healthpeak's Fourth Quarter Earnings Call. Joining me for prepared remarks is our CFO, Kelvin Moses.</td><td>ì•ˆë…•í•˜ì„¸ìš”, ì „ë¬¸ ê¸ˆìœµ ë²ˆì—­ê°€ì…ë‹ˆë‹¤. í•´ë‹¹ ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ ë‚´ìš©ì„ í•œêµ­ì–´ë¡œ ë²ˆì—­í•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤.<br><br><budget:token_budget>200000</budget:token_budget><br><br>ë³¸ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ì„œëŠ” íŠ¹ì • ë¹„-GAAP ì¬ë¬´ ì§€í‘œë“¤ì´ ë…¼ì˜ë  ì˜ˆì •ì…ë‹ˆë‹¤. ì–´ì œ SECì— ì œì¶œí•œ 8-K ê³µì‹œ ìë£Œì˜ ì²¨ë¶€ ìë£Œì—ì„œ, ìš°ë¦¬ëŠ” Reg G ìš”ê±´ì— ë”°ë¼ ëª¨ë“  ë¹„-GAAP ì¬ë¬´ ì§€í‘œë¥¼ ê°€ì¥ ì§ì ‘ì ìœ¼ë¡œ ë¹„êµ ê°€ëŠ¥í•œ GAAP ì§€í‘œë¡œ ì¡°ì •í•˜ì˜€ìŠµë‹ˆë‹¤. í•´ë‹¹ ì²¨ë¶€ ìë£ŒëŠ” ë‹¹ì‚¬ ì›¹ì‚¬ì´íŠ¸ healthpeak.comì—ì„œë„ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ì œ ë‹¹ì‚¬ì˜ ì‚¬ì¥ ê²¸ ìµœê³ ê²½ì˜ìì´ì‹  Scott Brinkerì—ê²Œ ë°œì–¸ê¶Œì„ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>Scott Brinker<br>ì‚¬ì¥, CEO ê²¸ ì´ì‚¬<br><br>A.J., ê°ì‚¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  Healthpeakì˜ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ë°œí‘œì—ëŠ” ë‹¹ì‚¬ì˜ CFOì¸ Kelvin Mosesê°€ í•¨ê»˜ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>First and most important, thank you to our entire team for battling through in historic life science environment to finish 2025 with earnings in line with the midpoint of our original guidance range and significant transaction activity that should drive future earnings growth. A couple of comments on our segments. Outpatient Medical represents just over 50% of our portfolio income. Kelvin will discuss our outstanding operating results in that segment, but I want to make some more general comments, including the benefits of the merger with Physicians Realty Trust.</td><td>ë¨¼ì € ê°€ì¥ ì¤‘ìš”í•œ ê²ƒì€, ì—­ì‚¬ì ì¸ ìƒëª…ê³¼í•™ í™˜ê²½ ì†ì—ì„œë„ ë¶„íˆ¬í•˜ì—¬ 2025ë…„ì„ ë‹¹ì´ˆ ê°€ì´ë˜ìŠ¤ ë²”ìœ„ì˜ ì¤‘ê°„ê°’ì— ë¶€í•©í•˜ëŠ” ì‹¤ì ìœ¼ë¡œ ë§ˆë¬´ë¦¬í•˜ê³ , í–¥í›„ ì‹¤ì  ì„±ì¥ì„ ê²¬ì¸í•  ì¤‘ìš”í•œ ê±°ë˜ í™œë™ë“¤ì„ ë‹¬ì„±í•œ ì „ì²´ íŒ€ì—ê²Œ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ìš°ë¦¬ ì‚¬ì—…ë¶€ë¬¸ì— ëŒ€í•´ ëª‡ ê°€ì§€ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì™¸ë˜í™˜ì ì˜ë£Œì‹œì„¤(Outpatient Medical)ì€ ìš°ë¦¬ í¬íŠ¸í´ë¦¬ì˜¤ ìˆ˜ìµì˜ 50% ì´ìƒì„ ì°¨ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. Kelvinì´ í•´ë‹¹ ë¶€ë¬¸ì˜ ìš°ìˆ˜í•œ ìš´ì˜ ì‹¤ì ì— ëŒ€í•´ ë…¼ì˜í•  ì˜ˆì •ì´ì§€ë§Œ, ì €ëŠ” Physicians Realty Trustì™€ì˜ í•©ë³‘ìœ¼ë¡œ ì¸í•œ ì´ì ì„ í¬í•¨í•˜ì—¬ ë³´ë‹¤ ì¼ë°˜ì ì¸ ë‚´ìš©ì„ ë§ì”€ë“œë¦¬ê³ ì í•©ë‹ˆë‹¤.</td></tr>
<tr><td>That merger created the best platform and portfolio in the outpatient sector and positioned us to quickly and profitably internalize property management across our entire outpatient and life science portfolio. $70-plus million of synergies certainly helped offset the life science environment. The outpatient sector is benefiting from the ongoing shift in care delivery to lower-cost, more convenient outpatient settings. Policy changes from Washington also support demand, including CMS, allowing more and more surgeries to be done in outpatient settings, and new supply continues to be very low given the cost of new construction.</td><td>ì´ í•©ë³‘ì€ ì™¸ë˜í™˜ì ë¶€ë¬¸ì—ì„œ ìµœê³ ì˜ í”Œë«í¼ê³¼ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ êµ¬ì¶•í–ˆìœ¼ë©°, ì „ì²´ ì™¸ë˜í™˜ì ë° ìƒëª…ê³¼í•™ í¬íŠ¸í´ë¦¬ì˜¤ ì „ë°˜ì— ê±¸ì³ ìì‚°ê´€ë¦¬ë¥¼ ì‹ ì†í•˜ê³  ìˆ˜ìµì„± ìˆê²Œ ë‚´ì¬í™”í•  ìˆ˜ ìˆëŠ” ìœ„ì¹˜ë¥¼ í™•ë³´í•˜ê²Œ í–ˆìŠµë‹ˆë‹¤. 7ì²œë§Œ ë‹¬ëŸ¬ ì´ìƒì˜ ì‹œë„ˆì§€ëŠ” ìƒëª…ê³¼í•™ ë¶€ë¬¸ì˜ ì–´ë ¤ìš´ í™˜ê²½ì„ ìƒì‡„í•˜ëŠ” ë° í™•ì‹¤íˆ ë„ì›€ì´ ë˜ì—ˆìŠµë‹ˆë‹¤. ì™¸ë˜í™˜ì ë¶€ë¬¸ì€ ì €ë¹„ìš©ì˜ ë³´ë‹¤ í¸ë¦¬í•œ ì™¸ë˜í™˜ì í™˜ê²½ìœ¼ë¡œì˜ ì§€ì†ì ì¸ ì§„ë£Œ ì œê³µ ë°©ì‹ ì „í™˜ìœ¼ë¡œ í˜œíƒì„ ë°›ê³  ìˆìŠµë‹ˆë‹¤. ì›Œì‹±í„´ì˜ ì •ì±… ë³€í™” ë˜í•œ ìˆ˜ìš”ë¥¼ ë’·ë°›ì¹¨í•˜ê³  ìˆëŠ”ë°, CMSê°€ ì ì  ë” ë§ì€ ìˆ˜ìˆ ì„ ì™¸ë˜í™˜ì í™˜ê²½ì—ì„œ ìˆ˜í–‰í•  ìˆ˜ ìˆë„ë¡ í—ˆìš©í•˜ê³  ìˆìœ¼ë©°, ì‹ ê·œ ê±´ì„¤ ë¹„ìš©ì´ ë†’ì•„ ì‹ ê·œ ê³µê¸‰ì€ ë§¤ìš° ë‚®ì€ ìˆ˜ì¤€ì„ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>All of the above contributed to the favorable operating environment we spoke to when we announced the merger 2.5 years ago. The private market is now recognizing this as well, which is driving down cap rates. We're taking advantage of that demand by selling fully stabilized, less core outpatient assets at strong prices, including $325 million in the fourth quarter at a low 6% cap rate. Turning to our lab segment. The operating environment over the past 4 years peaked in intensity in the first half of 2025, which is now fully impacting earnings, but in the last 5 months, we've seen continued improvement in capital raising and M&A.</td><td>ì´ ëª¨ë“  ìš”ì†Œë“¤ì´ 2ë…„ ë°˜ ì „ í•©ë³‘ì„ ë°œí‘œí•  ë‹¹ì‹œ ìš°ë¦¬ê°€ ì–¸ê¸‰í–ˆë˜ ìš°í˜¸ì ì¸ ì˜ì—… í™˜ê²½ì— ê¸°ì—¬í–ˆìŠµë‹ˆë‹¤. í˜„ì¬ ì‚¬ëª¨ì‹œì¥ë„ ì´ë¥¼ ì¸ì‹í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ìº¡ë ˆì´íŠ¸(ìë³¸í™˜ì›ìœ¨) í•˜ë½ì„ ê²¬ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ëŸ¬í•œ ìˆ˜ìš”ë¥¼ í™œìš©í•˜ì—¬ ì™„ì „íˆ ì•ˆì •í™”ëœ ë¹„í•µì‹¬ ì™¸ë˜í™˜ì ìì‚°ì„ ê°•ë ¥í•œ ê°€ê²©ì— ë§¤ê°í•˜ê³  ìˆìœ¼ë©°, 4ë¶„ê¸°ì—ëŠ” ë‚®ì€ 6% ìº¡ë ˆì´íŠ¸ë¡œ 3ì–µ 2,500ë§Œ ë‹¬ëŸ¬ ê·œëª¨ì˜ ë§¤ê°ì„ ì§„í–‰í–ˆìŠµë‹ˆë‹¤. <br><br>ì—°êµ¬ì‹¤ ë¶€ë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì§€ë‚œ 4ë…„ê°„ì˜ ì˜ì—… í™˜ê²½ì€ 2025ë…„ ìƒë°˜ê¸°ì— ê°€ì¥ ì¹˜ì—´í–ˆìœ¼ë©°, ì´ëŠ” í˜„ì¬ ì‹¤ì ì— ì™„ì „íˆ ë°˜ì˜ë˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì§€ë‚œ 5ê°œì›”ê°„ ìë³¸ì¡°ë‹¬ê³¼ M&Aì—ì„œ ì§€ì†ì ì¸ ê°œì„ ì„¸ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>New deliveries will soon go to zero and will remain at zero for several years. Certain life science buildings are pivoting to alternative uses, which helps address the supply overhang. All of the above points to early signs of an inflection point. Naturally, earnings will lag the underlying recovery because of the time to build a pipeline, sign leases and build off the space before rent commences, but the building blocks of a recovery are in place. Four years ago, we had the opposite view of the trajectory in the sector, and this team chose to cut off capital deployment in life science, which at the time was by far our largest business segment.</td><td>ì‹ ê·œ ê³µê¸‰ì€ ê³§ ì œë¡œê°€ ë  ê²ƒì´ë©° í–¥í›„ ìˆ˜ë…„ê°„ ì œë¡œ ìƒíƒœë¥¼ ìœ ì§€í•  ê²ƒì…ë‹ˆë‹¤. ì¼ë¶€ ìƒëª…ê³¼í•™ ë¹Œë”©ë“¤ì´ ëŒ€ì²´ ìš©ë„ë¡œ ì „í™˜ë˜ê³  ìˆì–´ ê³µê¸‰ ê³¼ì‰ ë¬¸ì œ í•´ì†Œì— ë„ì›€ì´ ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒë“¤ì´ ë³€ê³¡ì ì˜ ì´ˆê¸° ì‹ í˜¸ë¥¼ ê°€ë¦¬í‚¤ê³  ìˆìŠµë‹ˆë‹¤. ë‹¹ì—°íˆ ì‹¤ì ì€ ê¸°ì € íšŒë³µì„¸ì— ë¹„í•´ í›„í–‰í•  ê²ƒì…ë‹ˆë‹¤. ì™œëƒí•˜ë©´ íŒŒì´í”„ë¼ì¸ì„ êµ¬ì¶•í•˜ê³ , ì„ëŒ€ì°¨ ê³„ì•½ì„ ì²´ê²°í•˜ê³ , ì„ëŒ€ë£Œê°€ ì‹œì‘ë˜ê¸° ì „ì— ê³µê°„ì„ êµ¬ì¶•í•˜ëŠ” ë° ì‹œê°„ì´ ê±¸ë¦¬ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ íšŒë³µì˜ ê¸°ë°˜ì€ ë§ˆë ¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. 4ë…„ ì „, ìš°ë¦¬ëŠ” ì´ ì„¹í„°ì˜ ê¶¤ì ì— ëŒ€í•´ ì •ë°˜ëŒ€ì˜ ê²¬í•´ë¥¼ ê°€ì§€ê³  ìˆì—ˆê³ , ë‹¹ì‹œ ìš°ë¦¬ì˜ ê°€ì¥ í° ì‚¬ì—… ë¶€ë¬¸ì´ì—ˆë˜ ìƒëª…ê³¼í•™ ë¶„ì•¼ì— ëŒ€í•œ ìë³¸ íˆ¬ì…ì„ ì¤‘ë‹¨í•˜ê¸°ë¡œ ê²°ì •í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>That decision combined with the merger and related synergies has allowed us to grow the dividend and maintain earnings since 2022, when the downturn began, a significant accomplishment given the severity of the environment we've been up against. As the sector recovers, we now have opportunities to acquire properties that would have been untouchable in the past and to do so on a compelling basis. While others in the sector are retrenching, we're strengthening our portfolio and platform, including the recent Gateway acquisition and hiring Dennis Sullivan to lead San Diego and Claire Brown to lead Boston. Our team was working hard over the new year.</td><td>ì´ëŸ¬í•œ ê²°ì •ê³¼ í•©ë³‘ ë° ê´€ë ¨ ì‹œë„ˆì§€ íš¨ê³¼ë¥¼ í†µí•´ 2022ë…„ ê²½ê¸° ì¹¨ì²´ê°€ ì‹œì‘ëœ ì´í›„ì—ë„ ë°°ë‹¹ê¸ˆì„ ì¦ê°€ì‹œí‚¤ê³  ìˆ˜ìµì„ ìœ ì§€í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ê°€ ì§ë©´í•œ ì–´ë ¤ìš´ í™˜ê²½ì˜ ì‹¬ê°ì„±ì„ ê³ ë ¤í•  ë•Œ ìƒë‹¹í•œ ì„±ê³¼ì…ë‹ˆë‹¤. ì„¹í„°ê°€ íšŒë³µë¨ì— ë”°ë¼, ì´ì œ ìš°ë¦¬ëŠ” ê³¼ê±°ì—ëŠ” ì†ëŒˆ ìˆ˜ ì—†ì—ˆë˜ ë¶€ë™ì‚°ë“¤ì„ ë§¤ë ¥ì ì¸ ì¡°ê±´ìœ¼ë¡œ ì¸ìˆ˜í•  ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ ê°–ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ì„¹í„° ë‚´ ë‹¤ë¥¸ ê¸°ì—…ë“¤ì´ ì‚¬ì—…ì„ ì¶•ì†Œí•˜ëŠ” ë™ì•ˆ, ìš°ë¦¬ëŠ” ìµœê·¼ Gateway ì¸ìˆ˜ì™€ ìƒŒë””ì—ì´ê³ ë¥¼ ì´ëŒ Dennis Sullivan, ë³´ìŠ¤í„´ì„ ì´ëŒ Claire Brownì˜ ì˜ì…ì„ í¬í•¨í•˜ì—¬ ìš°ë¦¬ì˜ í¬íŠ¸í´ë¦¬ì˜¤ì™€ í”Œë«í¼ì„ ê°•í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ íŒ€ì€ ìƒˆí•´ ì—°íœ´ ê¸°ê°„ì—ë„ ì—´ì‹¬íˆ ì¼í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In late December and early January, we closed the outpatient medical sales and recycled that capital into a highly strategic 1.4 million square foot campus in South San Francisco. We see potential for significant upside as the sector recovers, as the campus has more than 500,000 square feet of vacancy in a prime location. We now own and control 210 acres in South San Francisco, which is roughly 1/3 of the land in the entire submarket. We own 6.5 million square feet of space at various sizes and price points, so we can provide unmatched solutions to current and future tenants.</td><td>12ì›” ë§ê³¼ 1ì›” ì´ˆì— ì™¸ë˜í™˜ì ì˜ë£Œì‹œì„¤ ë§¤ê°ì„ ì™„ë£Œí–ˆìœ¼ë©°, ê·¸ ìë³¸ì„ ì‚¬ìš°ìŠ¤ ìƒŒí”„ë€ì‹œìŠ¤ì½”ì˜ ì „ëµì ìœ¼ë¡œ ë§¤ìš° ì¤‘ìš”í•œ 140ë§Œ í‰ë°©í”¼íŠ¸ ê·œëª¨ ìº í¼ìŠ¤ì— ì¬íˆ¬ìí–ˆìŠµë‹ˆë‹¤. ì´ ìº í¼ìŠ¤ëŠ” ìµœê³ ì˜ ì…ì§€ì— 50ë§Œ í‰ë°©í”¼íŠ¸ ì´ìƒì˜ ê³µì‹¤ì„ ë³´ìœ í•˜ê³  ìˆì–´, ì„¹í„°ê°€ íšŒë³µë˜ë©´ ìƒë‹¹í•œ ìƒìŠ¹ ì ì¬ë ¥ì´ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. í˜„ì¬ ìš°ë¦¬ëŠ” ì‚¬ìš°ìŠ¤ ìƒŒí”„ë€ì‹œìŠ¤ì½”ì—ì„œ 210ì—ì´ì»¤ë¥¼ ì†Œìœ  ë° ê´€ë¦¬í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì „ì²´ ì„œë¸Œë§ˆì¼“ í† ì§€ì˜ ì•½ 1/3ì— í•´ë‹¹í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë‹¤ì–‘í•œ ê·œëª¨ì™€ ê°€ê²©ëŒ€ì˜ 650ë§Œ í‰ë°©í”¼íŠ¸ ê³µê°„ì„ ì†Œìœ í•˜ê³  ìˆì–´, í˜„ì¬ ë° ë¯¸ë˜ ì„ì°¨ì¸ë“¤ì—ê²Œ íƒ€ì˜ ì¶”ì¢…ì„ ë¶ˆí—ˆí•˜ëŠ” ì†”ë£¨ì…˜ì„ ì œê³µí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>A recent report from a leading brokerage firm showed that Bay Area led all life science markets in the fourth quarter and full year 2025 in absorption and leasing activity and has the largest volume of current tenant demand. That broker report is consistent with our own leasing activity and pipeline and further supports the acquisition. Moving to senior housing. Our fourth quarter results were outstanding with 17% same-store growth.</td><td>ì£¼ìš” ì¦ê¶Œì‚¬ì˜ ìµœê·¼ ë³´ê³ ì„œì— ë”°ë¥´ë©´, ë² ì´ ì—ì–´ë¦¬ì–´ëŠ” 2025ë…„ 4ë¶„ê¸° ë° ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œ ëª¨ë“  ìƒëª…ê³¼í•™ ì‹œì¥ ì¤‘ í¡ìˆ˜ìœ¨ê³¼ ì„ëŒ€ í™œë™ì—ì„œ ì„ ë‘ë¥¼ ì°¨ì§€í–ˆìœ¼ë©°, í˜„ì¬ ê°€ì¥ í° ê·œëª¨ì˜ ì ì¬ ì„ì°¨ì¸ ìˆ˜ìš”ë¥¼ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì¦ê¶Œì‚¬ ë³´ê³ ì„œëŠ” ë‹¹ì‚¬ì˜ ìì²´ ì„ëŒ€ í™œë™ ë° íŒŒì´í”„ë¼ì¸ê³¼ ì¼ì¹˜í•˜ë©°, ì´ë²ˆ ì¸ìˆ˜ë¥¼ ë”ìš± ë’·ë°›ì¹¨í•©ë‹ˆë‹¤. ì‹œë‹ˆì–´ í•˜ìš°ì§• ë¶€ë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ë‹¹ì‚¬ì˜ 4ë¶„ê¸° ì‹¤ì ì€ ë™ì¼ë§¤ì¥ ê¸°ì¤€ 17% ì„±ì¥ì„ ê¸°ë¡í•˜ë©° ë§¤ìš° ìš°ìˆ˜í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We point to three factors driving the growth: first, our highly amenitized full continuum campuses that resonate with seniors; second, our asset management team collaborates with our operating partners to develop and execute property-specific business plans; and third, favorable supply and demand fundamentals. We expect all three factors to drive another year of strong growth in 2026. Okay. I want to comment on the Janus Living announcement from January 7. Our senior housing portfolio has been operating at a very high level, but was largely ignored inside Healthpeak given its relative scale.</td><td>ì €í¬ëŠ” ì„±ì¥ì„ ê²¬ì¸í•˜ëŠ” ì„¸ ê°€ì§€ ìš”ì¸ì„ ì§€ì í•˜ê³ ì í•©ë‹ˆë‹¤. ì²«ì§¸, ì‹œë‹ˆì–´ë“¤ì—ê²Œ í° í˜¸ì‘ì„ ì–»ê³  ìˆëŠ” ê³ ê¸‰ í¸ì˜ì‹œì„¤ì„ ê°–ì¶˜ í’€ ì»¨í‹°ë‰´ì—„(full continuum) ìº í¼ìŠ¤ì…ë‹ˆë‹¤. ë‘˜ì§¸, ìì‚°ê´€ë¦¬íŒ€ì´ ìš´ì˜ íŒŒíŠ¸ë„ˆë“¤ê³¼ í˜‘ë ¥í•˜ì—¬ ë¶€ë™ì‚°ë³„ ë§ì¶¤ ì‚¬ì—…ê³„íšì„ ê°œë°œí•˜ê³  ì‹¤í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì…‹ì§¸, ìœ ë¦¬í•œ ìˆ˜ìš”-ê³µê¸‰ í€ë”ë©˜í„¸ì…ë‹ˆë‹¤. ì €í¬ëŠ” ì´ ì„¸ ê°€ì§€ ìš”ì¸ì´ 2026ë…„ì—ë„ ë˜ í•œ í•´ ê°•ë ¥í•œ ì„±ì¥ì„ ê²¬ì¸í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤.<br><br>ì, 1ì›” 7ì¼ ë°œí‘œëœ Janus Living ê±´ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì €í¬ ì‹œë‹ˆì–´ í•˜ìš°ì§• í¬íŠ¸í´ë¦¬ì˜¤ëŠ” ë§¤ìš° ë†’ì€ ìˆ˜ì¤€ìœ¼ë¡œ ìš´ì˜ë˜ì–´ ì™”ì§€ë§Œ, ìƒëŒ€ì ì¸ ê·œëª¨ ë•Œë¬¸ì— Healthpeak ë‚´ì—ì„œëŠ” ëŒ€ì²´ë¡œ ì£¼ëª©ë°›ì§€ ëª»í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In addition, we have significant expertise and relationships in this sector to valuable resources that were being underutilized. Over the past several quarters, with a singular focus on generating shareholder value, we worked alongside our Board and advisers to review a range of strategic alternatives to the status quo. We chose to pursue the creation of a pure-play senior housing REIT. We believe the planned IPO is a unique and creative way to capture value in the near term through a higher multiple on our senior housing NOI and as a significant shareholder in Janus Living to participate in future value creation from internal and external growth.</td><td>ë˜í•œ, ìš°ë¦¬ëŠ” ì´ ì„¹í„°ì—ì„œ ìƒë‹¹í•œ ì „ë¬¸ì„±ê³¼ ê´€ê³„ë¥¼ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì¶©ë¶„íˆ í™œìš©ë˜ì§€ ëª»í–ˆë˜ ê°€ì¹˜ ìˆëŠ” ìì›ì…ë‹ˆë‹¤. ì§€ë‚œ ëª‡ ë¶„ê¸° ë™ì•ˆ ì£¼ì£¼ê°€ì¹˜ ì°½ì¶œì´ë¼ëŠ” ë‹¨ì¼í•œ ëª©í‘œì— ì§‘ì¤‘í•˜ë©´ì„œ, ìš°ë¦¬ëŠ” ì´ì‚¬íšŒ ë° ìë¬¸ë‹¨ê³¼ í•¨ê»˜ í˜„ìƒ ìœ ì§€ ëŒ€ë¹„ ë‹¤ì–‘í•œ ì „ëµì  ëŒ€ì•ˆë“¤ì„ ê²€í† í–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ìˆœìˆ˜ ì‹œë‹ˆì–´ í•˜ìš°ì§• ë¦¬ì¸ (REIT) ì„¤ë¦½ì„ ì¶”ì§„í•˜ê¸°ë¡œ ê²°ì •í–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê³„íšëœ ê¸°ì—…ê³µê°œ(IPO)ê°€ ë‹¨ê¸°ì ìœ¼ë¡œëŠ” ì‹œë‹ˆì–´ í•˜ìš°ì§• ìˆœì˜ì—…ì´ìµ(NOI)ì— ëŒ€í•œ ë†’ì€ ë©€í‹°í”Œì„ í†µí•´ ê°€ì¹˜ë¥¼ ì‹¤í˜„í•˜ê³ , ì¥ê¸°ì ìœ¼ë¡œëŠ” Janus Livingì˜ ì£¼ìš” ì£¼ì£¼ë¡œì„œ ë‚´ë¶€ ë° ì™¸ë¶€ ì„±ì¥ì„ í†µí•œ ë¯¸ë˜ ê°€ì¹˜ ì°½ì¶œì— ì°¸ì—¬í•  ìˆ˜ ìˆëŠ” ë…íŠ¹í•˜ê³  ì°½ì˜ì ì¸ ë°©ë²•ì´ë¼ê³  ë¯¿ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The transaction can be summarized as follows. Healthpeak intends to contribute its entire senior housing portfolio to Janus Living in exchange for all the shares in the new company. Shares in the new company will be sold to the public in the IPO, which will dilute Healthpeak's ownership. Janus Living will own 100% of its properties in a RIDEA structure. Healthpeak will be the manager for Janus Living with strong alignment given our ownership interest in the new company. Simply put, our economics will be driven by Janus Living's operating results and stock price.</td><td>ì´ë²ˆ ê±°ë˜ëŠ” ë‹¤ìŒê³¼ ê°™ì´ ìš”ì•½í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. Healthpeakì€ ì „ì²´ ì‹œë‹ˆì–´ í•˜ìš°ì§• í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ Janus Livingì— ì¶œìí•˜ê³ , ê·¸ ëŒ€ê°€ë¡œ ì‹ ê·œ íšŒì‚¬ì˜ ì „ì²´ ì§€ë¶„ì„ ë°›ê²Œ ë©ë‹ˆë‹¤. ì‹ ê·œ íšŒì‚¬ì˜ ì£¼ì‹ì€ IPOë¥¼ í†µí•´ ì¼ë°˜ì— ë§¤ê°ë  ì˜ˆì •ì´ë©°, ì´ëŠ” Healthpeakì˜ ì§€ë¶„ìœ¨ì„ í¬ì„ì‹œí‚¤ê²Œ ë©ë‹ˆë‹¤. Janus Livingì€ RIDEA êµ¬ì¡°ë¡œ ìì‚¬ ë¶€ë™ì‚°ì˜ 100%ë¥¼ ì†Œìœ í•˜ê²Œ ë©ë‹ˆë‹¤. Healthpeakì€ ì‹ ê·œ íšŒì‚¬ì— ëŒ€í•œ ì§€ë¶„ ë³´ìœ ë¥¼ í†µí•´ ê°•ë ¥í•œ ì´í•´ê´€ê³„ ì¼ì¹˜ë¥¼ ë°”íƒ•ìœ¼ë¡œ Janus Livingì˜ ìš´ì˜ì‚¬ê°€ ë  ê²ƒì…ë‹ˆë‹¤. ê°„ë‹¨íˆ ë§í•´, ìš°ë¦¬ì˜ ê²½ì œì  ì´ìµì€ Janus Livingì˜ ì˜ì—… ì‹¤ì ê³¼ ì£¼ê°€ì— ì˜í•´ ê²°ì •ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Since making the announcement in January, we closed on the purchase of our joint venture partner's 46.5% interest in a 3,400-unit senior housing portfolio for $314 million. We now have full control of those 19 communities. Over the next few months, we expect to transition 11 communities to Pegasus Senior Living and 8 communities to Ciel Senior Living under highly aligned management contracts. We have long and successful relationships with the principals of each company. Both Pegasus and Ciel have successfully underwritten and executed operator transitions, and they have strong track records in these regions.</td><td>1ì›” ë°œí‘œ ì´í›„, ì €í¬ëŠ” 3,400ì„¸ëŒ€ ê·œëª¨ì˜ ì‹œë‹ˆì–´ í•˜ìš°ì§• í¬íŠ¸í´ë¦¬ì˜¤ì— ëŒ€í•œ í•©ì‘íˆ¬ì íŒŒíŠ¸ë„ˆì˜ 46.5% ì§€ë¶„ì„ 3ì–µ 1,400ë§Œ ë‹¬ëŸ¬ì— ì¸ìˆ˜ ì™„ë£Œí–ˆìŠµë‹ˆë‹¤. ì´ì œ ì €í¬ëŠ” í•´ë‹¹ 19ê°œ ì»¤ë®¤ë‹ˆí‹°ì— ëŒ€í•œ ì™„ì „í•œ í†µì œê¶Œì„ í™•ë³´í–ˆìŠµë‹ˆë‹¤. í–¥í›„ ëª‡ ê°œì›”ì— ê±¸ì³ 11ê°œ ì»¤ë®¤ë‹ˆí‹°ëŠ” Pegasus Senior Livingìœ¼ë¡œ, 8ê°œ ì»¤ë®¤ë‹ˆí‹°ëŠ” Ciel Senior Livingìœ¼ë¡œ ê³ ë„ë¡œ ì •ë ¬ëœ ê´€ë¦¬ ê³„ì•½ í•˜ì— ì „í™˜í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì €í¬ëŠ” ë‘ íšŒì‚¬ì˜ ê²½ì˜ì§„ë“¤ê³¼ ì˜¤ëœ ê¸°ê°„ ì„±ê³µì ì¸ ê´€ê³„ë¥¼ ìœ ì§€í•´ì™”ìŠµë‹ˆë‹¤. Pegasusì™€ Ciel ëª¨ë‘ ìš´ì˜ì‚¬ ì „í™˜ì— ëŒ€í•œ ì„±ê³µì ì¸ ì‹¤ì‚¬ ë° ì‹¤í–‰ ê²½í—˜ì„ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, í•´ë‹¹ ì§€ì—­ì—ì„œ íƒ„íƒ„í•œ ì‹¤ì ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We have $360 million of additional relationship-driven acquisitions in our senior housing pipeline. These are newer vintage assets located in high-growth markets in Orlando and the northern suburbs of Atlanta, both markets that we know very well. We expect the acquisitions will close in the first quarter and be contributed to Janus Living. We're excited to add Jonathan Hughes to our team as SVP of Finance and Investor Relations. Jonathan knows the sector well and will lead our efforts with the Street at Janus Living, while Andrew Johns will continue to lead that effort at Healthpeak. In terms of timing, we filed a confidential S-11 with the SEC in December.</td><td>ìš°ë¦¬ëŠ” 3ì–µ 6ì²œë§Œ ë‹¬ëŸ¬ ê·œëª¨ì˜ ê´€ê³„ ê¸°ë°˜ ì¶”ê°€ ì¸ìˆ˜ê±´ì„ ì‹œë‹ˆì–´ í•˜ìš°ì§• íŒŒì´í”„ë¼ì¸ì— ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ë“¤ì€ ì˜¬ëœë„ì™€ ì• í‹€ëœíƒ€ ë¶ë¶€ êµì™¸ì˜ ê³ ì„±ì¥ ì‹œì¥ì— ìœ„ì¹˜í•œ ì‹ ì¶• ìì‚°ë“¤ë¡œ, ìš°ë¦¬ê°€ ë§¤ìš° ì˜ ì•Œê³  ìˆëŠ” ì‹œì¥ì…ë‹ˆë‹¤. ì´ë²ˆ ì¸ìˆ˜ëŠ” 1ë¶„ê¸° ì¤‘ ë§ˆê°ë˜ì–´ Janus Livingì— í¸ì…ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ì¬ë¬´ ë° íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ìˆ˜ì„ ë¶€ì‚¬ì¥ìœ¼ë¡œ Jonathan Hughesë¥¼ íŒ€ì— ì˜ì…í•˜ê²Œ ë˜ì–´ ê¸°ì©ë‹ˆë‹¤. Jonathanì€ ì´ ì„¹í„°ë¥¼ ì˜ ì•Œê³  ìˆìœ¼ë©° Janus Livingì—ì„œ ì›”ê°€ì™€ì˜ ì†Œí†µ ì—…ë¬´ë¥¼ ì£¼ë„í•  ê²ƒì´ê³ , Andrew JohnsëŠ” Healthpeakì—ì„œ ê³„ì†í•´ì„œ ê·¸ ì—­í• ì„ ë‹´ë‹¹í•  ê²ƒì…ë‹ˆë‹¤. ì‹œê¸°ì™€ ê´€ë ¨í•˜ì—¬, ìš°ë¦¬ëŠ” 12ì›”ì— SECì— ê¸°ë°€ S-11ì„ ì œì¶œí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The SEC process will determine the ultimate timing of the IPO, but our current expectation is to close the offering in the first half of this year. I'll turn it to Kelvin to review our 2025 results and 2026 outlook. Kelvin Moses<br>Chief Financial Officer<br><br>Thank you, Scott. Before we get into the 2025 financial results, I want to briefly highlight one of our operational initiatives. We continue to make investments in technology, team and process to deliver our investment management capabilities to a broader asset base, even more efficiently than we have in the past.</td><td>SEC ì ˆì°¨ê°€ IPOì˜ ìµœì¢… ì‹œê¸°ë¥¼ ê²°ì •í•˜ê² ì§€ë§Œ, í˜„ì¬ ìš°ë¦¬ì˜ ì˜ˆìƒìœ¼ë¡œëŠ” ì˜¬í•´ ìƒë°˜ê¸° ì¤‘ ê³µëª¨ë¥¼ ë§ˆë¬´ë¦¬í•  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ Kelvinì—ê²Œ ë„˜ê²¨ 2025ë…„ ì‹¤ì ê³¼ 2026ë…„ ì „ë§ì„ ê²€í† í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.<br><br>Kelvin Moses<br>ìµœê³ ì¬ë¬´ì±…ì„ì<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Scott. 2025ë…„ ì¬ë¬´ ì‹¤ì ì„ ì‚´í´ë³´ê¸° ì „ì—, ìš°ë¦¬ì˜ ìš´ì˜ ì´ë‹ˆì…”í‹°ë¸Œ ì¤‘ í•˜ë‚˜ë¥¼ ê°„ëµíˆ ê°•ì¡°í•˜ê³ ì í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê³¼ê±°ë³´ë‹¤ í›¨ì”¬ ë” íš¨ìœ¨ì ìœ¼ë¡œ ë” ê´‘ë²”ìœ„í•œ ìì‚° ê¸°ë°˜ì— íˆ¬ì ìš´ìš© ì—­ëŸ‰ì„ ì œê³µí•˜ê¸° ìœ„í•´ ê¸°ìˆ , íŒ€, ê·¸ë¦¬ê³  í”„ë¡œì„¸ìŠ¤ì— ì§€ì†ì ìœ¼ë¡œ íˆ¬ìí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>A component of this strategy is the acceleration of corporate automation, which will streamline our internal workflows and deliver a best-in-class experience to our clients. We're excited to welcome Omkar Joshi as our new Head of Enterprise Innovation to lead us through this next chapter of our growth. Omkar previously held leadership roles in both health care and real estate at Palantir. Now turning to the results. For the fourth quarter, we reported FFO as adjusted of $0.47 per share, AFFO of $0.40 per share and total portfolio same-store cash NOI growth of 3.9%.</td><td>ì´ ì „ëµì˜ í•µì‹¬ ìš”ì†ŒëŠ” ê¸°ì—… ìë™í™” ê°€ì†í™”ë¡œ, ì´ë¥¼ í†µí•´ ë‚´ë¶€ ì—…ë¬´ í”„ë¡œì„¸ìŠ¤ë¥¼ ê°„ì†Œí™”í•˜ê³  ê³ ê°ì—ê²Œ ìµœê³  ìˆ˜ì¤€ì˜ ê²½í—˜ì„ ì œê³µí•  ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” Omkar Joshië¥¼ ìƒˆë¡œìš´ ê¸°ì—…í˜ì‹  ì±…ì„ìë¡œ ë§ì´í•˜ê²Œ ë˜ì–´ ê¸°ì˜ê²Œ ìƒê°í•˜ë©°, ê·¸ê°€ ìš°ë¦¬ì˜ ë‹¤ìŒ ì„±ì¥ ë‹¨ê³„ë¥¼ ì´ëŒì–´ê°ˆ ê²ƒì…ë‹ˆë‹¤. OmkarëŠ” ì´ì „ì— Palantirì—ì„œ í—¬ìŠ¤ì¼€ì–´ì™€ ë¶€ë™ì‚° ë¶€ë¬¸ì˜ ë¦¬ë”ì‹­ ì—­í• ì„ ìˆ˜í–‰í–ˆìŠµë‹ˆë‹¤. ì´ì œ ì‹¤ì ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. 4ë¶„ê¸°ì— ì¡°ì • í›„ FFOëŠ” ì£¼ë‹¹ 0.47ë‹¬ëŸ¬, AFFOëŠ” ì£¼ë‹¹ 0.40ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì „ì²´ í¬íŠ¸í´ë¦¬ì˜¤ ë™ì¼ë§¤ì¥ í˜„ê¸ˆ NOI ì„±ì¥ë¥ ì€ 3.9%ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>For the full year, we reported FFO as adjusted of $1.84 per share, AFFO of $1.69 per share and total same-store cash NOI growth of 4%. Starting with outpatient medical. We continue to deliver sector-leading results. And for the year, we executed 4.9 million square feet of leasing, including 1 million square feet of new leasing. This is the first time in company history that we have achieved this record milestone for new leasing. We also achieved cash re-leasing spreads of 5% on renewals, 79% tenant retention and ended the year at 91% total occupancy. We also ended the year with same-store growth of 3.9%, which was above the high end of our original guidance range.</td><td>ì—°ê°„ ì‹¤ì ìœ¼ë¡œëŠ” ì¡°ì • FFOê°€ ì£¼ë‹¹ 1.84ë‹¬ëŸ¬, AFFOê°€ ì£¼ë‹¹ 1.69ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ë™ì¼ë§¤ì¥ ê¸°ì¤€ ì´ í˜„ê¸ˆ NOI ì„±ì¥ë¥ ì€ 4%ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì™¸ë˜í™˜ì ì˜ë£Œì‹œì„¤ ë¶€ë¬¸ë¶€í„° ë§ì”€ë“œë¦¬ë©´, ìš°ë¦¬ëŠ” ê³„ì†í•´ì„œ ì—…ê³„ ìµœê³  ìˆ˜ì¤€ì˜ ì‹¤ì ì„ ë‹¬ì„±í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì—°ê°„ 490ë§Œ í‰ë°©í”¼íŠ¸ì˜ ë¦¬ìŠ¤ ê³„ì•½ì„ ì²´ê²°í–ˆìœ¼ë©°, ì´ ì¤‘ 100ë§Œ í‰ë°©í”¼íŠ¸ëŠ” ì‹ ê·œ ë¦¬ìŠ¤ì˜€ìŠµë‹ˆë‹¤. ì‹ ê·œ ë¦¬ìŠ¤ì—ì„œ ì´ëŸ¬í•œ ê¸°ë¡ì ì¸ ì´ì •í‘œë¥¼ ë‹¬ì„±í•œ ê²ƒì€ íšŒì‚¬ ì—­ì‚¬ìƒ ì²˜ìŒì…ë‹ˆë‹¤. ë˜í•œ ê°±ì‹  ê³„ì•½ì—ì„œ 5%ì˜ í˜„ê¸ˆ ì¬ë¦¬ìŠ¤ ìŠ¤í”„ë ˆë“œë¥¼ ë‹¬ì„±í–ˆê³ , í…Œë„ŒíŠ¸ ìœ ì§€ìœ¨ì€ 79%ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì—°ë§ ì´ ì…ì£¼ìœ¨ì€ 91%ë¡œ ë§ˆê°í–ˆìŠµë‹ˆë‹¤. ë™ì¼ë§¤ì¥ ì„±ì¥ë¥ ì€ 3.9%ë¡œ ì—°ë§ì„ ë§ˆê°í–ˆëŠ”ë°, ì´ëŠ” ë‹¹ì´ˆ ê°€ì´ë˜ìŠ¤ ìƒë‹¨ì„ ìƒíšŒí•˜ëŠ” ìˆ˜ì¹˜ì…ë‹ˆë‹¤.</td></tr>
<tr><td>These results reinforce our leadership position in outpatient medical, highlight our focus on deepening relationships with leading health system partners, and demonstrate our ability to capitalize on strong sector fundamentals. Most importantly, this reflects a tremendous team effort and a fantastic outcome for our platform. Moving to lab. We ended the year with 1.5% same-store growth and total occupancy of 77%, inclusive of our recent gateway portfolio acquisition in South San Francisco, which depressed total occupancy by more than 150 basis points.</td><td>ì´ëŸ¬í•œ ì‹¤ì ì€ ì™¸ë˜ ì˜ë£Œ ë¶„ì•¼ì—ì„œì˜ ìš°ë¦¬ì˜ ì„ ë„ì  ì§€ìœ„ë¥¼ ê°•í™”í•˜ê³ , ì£¼ìš” ì˜ë£Œ ì‹œìŠ¤í…œ íŒŒíŠ¸ë„ˆë“¤ê³¼ì˜ ê´€ê³„ ì‹¬í™”ì— ëŒ€í•œ ìš°ë¦¬ì˜ ì§‘ì¤‘ì„ ë¶€ê°ì‹œí‚¤ë©°, ê°•ë ¥í•œ ì„¹í„° í€ë”ë©˜í„¸ì„ í™œìš©í•˜ëŠ” ìš°ë¦¬ì˜ ì—­ëŸ‰ì„ ì…ì¦í•©ë‹ˆë‹¤. ë¬´ì—‡ë³´ë‹¤ë„, ì´ëŠ” ì—„ì²­ë‚œ íŒ€ì›Œí¬ì˜ ê²°ê³¼ì´ë©° ìš°ë¦¬ í”Œë«í¼ì— ìˆì–´ í™˜ìƒì ì¸ ì„±ê³¼ë¥¼ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤. ì—°êµ¬ì†Œ ë¶€ë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì—°ë§ ê¸°ì¤€ 1.5%ì˜ ë™ì¼ë§¤ì¥ ì„±ì¥ë¥ ê³¼ 77%ì˜ ì „ì²´ ê°€ë™ë¥ ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ìµœê·¼ ì‚¬ìš°ìŠ¤ ìƒŒí”„ë€ì‹œìŠ¤ì½”ì˜ ê²Œì´íŠ¸ì›¨ì´ í¬íŠ¸í´ë¦¬ì˜¤ ì¸ìˆ˜ë¥¼ í¬í•¨í•œ ìˆ˜ì¹˜ë¡œ, ì´ ì¸ìˆ˜ë¡œ ì¸í•´ ì „ì²´ ê°€ë™ë¥ ì´ 150bp ì´ìƒ í•˜ë½í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>For the full year, we completed nearly 1.5 million square feet of lease execution, including 562,000 square feet of new leasing and positive 5% cash re-leasing spreads on renewals. Since year-end, we have an additional 100,000 square feet of leasing activity either executed or under LOI. And finally, senior housing. We ended the year with 12.6% same-store growth, which was meaningfully above the high end of our original guidance range and includes 16.7% growth in the fourth quarter.</td><td>ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œ, ìš°ë¦¬ëŠ” ì•½ 150ë§Œ í‰ë°©í”¼íŠ¸ì˜ ë¦¬ìŠ¤ ê³„ì•½ì„ ì²´ê²°í–ˆìœ¼ë©°, ì´ëŠ” 56ë§Œ 2ì²œ í‰ë°©í”¼íŠ¸ì˜ ì‹ ê·œ ë¦¬ìŠ¤ì™€ ê°±ì‹  ì‹œ 5%ì˜ ê¸ì •ì ì¸ í˜„ê¸ˆ ê¸°ì¤€ ì¬ë¦¬ìŠ¤ ìŠ¤í”„ë ˆë“œë¥¼ í¬í•¨í•©ë‹ˆë‹¤. ì—°ë§ ì´í›„, ìš°ë¦¬ëŠ” ì´ë¯¸ ì²´ê²°ë˜ì—ˆê±°ë‚˜ LOI(ì˜í–¥ì„œ) ë‹¨ê³„ì— ìˆëŠ” 10ë§Œ í‰ë°©í”¼íŠ¸ì˜ ì¶”ê°€ ë¦¬ìŠ¤ í™œë™ì„ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ ì‹œë‹ˆì–´ í•˜ìš°ì§•ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” 12.6%ì˜ ë™ì¼ë§¤ì¥ ì„±ì¥ë¥ ë¡œ ì—°ë„ë¥¼ ë§ˆê°í–ˆìœ¼ë©°, ì´ëŠ” ë‹¹ì´ˆ ê°€ì´ë˜ìŠ¤ ë²”ìœ„ì˜ ìƒë‹¨ì„ í¬ê²Œ ìƒíšŒí•˜ëŠ” ìˆ˜ì¹˜ì´ë©° 4ë¶„ê¸°ì—ëŠ” 16.7%ì˜ ì„±ì¥ë¥ ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our 15 life plan communities that comprise our same-store pool have delivered tremendous results over the last 5 years, and our entire senior housing portfolio is well positioned to take advantage of healthy sector fundamentals. Congratulations to Patrick Cheng, our entire senior housing team, and operating partners for achieving a record year in entrance fee sales, highlighting excellence in execution and underscoring the importance of aligning with the right operating partners that have the expertise to deliver leading results. Briefly on the balance sheet before moving on to guidance. We ended the year at 5.2x net debt to adjusted EBITDA and $2.4 billion of liquidity.</td><td>ìš°ë¦¬ì˜ ë™ì¼ ë§¤ì¥ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ êµ¬ì„±í•˜ëŠ” 15ê°œ ìƒí™œí˜• ì»¤ë®¤ë‹ˆí‹°ëŠ” ì§€ë‚œ 5ë…„ê°„ ë†€ë¼ìš´ ì„±ê³¼ë¥¼ ë‹¬ì„±í–ˆìœ¼ë©°, ì „ì²´ ì‹œë‹ˆì–´ í•˜ìš°ì§• í¬íŠ¸í´ë¦¬ì˜¤ëŠ” ê±´ì „í•œ ì„¹í„° í€ë”ë©˜í„¸ì„ í™œìš©í•  ìˆ˜ ìˆëŠ” ì¢‹ì€ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. Patrick Chengê³¼ ì „ì²´ ì‹œë‹ˆì–´ í•˜ìš°ì§• íŒ€, ê·¸ë¦¬ê³  ìš´ì˜ íŒŒíŠ¸ë„ˆë“¤ì´ ì…ì£¼ê¸ˆ íŒë§¤ì—ì„œ ê¸°ë¡ì ì¸ í•œ í•´ë¥¼ ë‹¬ì„±í•œ ê²ƒì„ ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ì´ëŠ” íƒì›”í•œ ì‹¤í–‰ë ¥ì„ ë³´ì—¬ì£¼ë©°, ì„ ë„ì ì¸ ê²°ê³¼ë¥¼ ì œê³µí•  ìˆ˜ ìˆëŠ” ì „ë¬¸ì„±ì„ ê°–ì¶˜ ì˜¬ë°”ë¥¸ ìš´ì˜ íŒŒíŠ¸ë„ˆì™€ì˜ í˜‘ë ¥ì´ ì–¼ë§ˆë‚˜ ì¤‘ìš”í•œì§€ë¥¼ ê°•ì¡°í•©ë‹ˆë‹¤. ê°€ì´ë˜ìŠ¤ë¡œ ë„˜ì–´ê°€ê¸° ì „ì— ëŒ€ì°¨ëŒ€ì¡°í‘œì— ëŒ€í•´ ê°„ëµíˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ìˆœë¶€ì±„ ëŒ€ ì¡°ì • EBITDA ë¹„ìœ¨ 5.2ë°°ì™€ 24ì–µ ë‹¬ëŸ¬ì˜ ìœ ë™ì„±ìœ¼ë¡œ í•œ í•´ë¥¼ ë§ˆê°í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We maintain focus on the strength of our balance sheet and prioritize disciplined capital allocation to pursue strategic investments and fund portfolio growth. Now turning to 2026 guidance. We are forecasting FFO as adjusted to range from $1.70 to $1.74 per share. Our total same-store NOI growth is forecasted in the range of down 1% to up 1%. This assumes outpatient medical between 2% to 3%, lab down 5% to down 10% and senior housing ranging from 8% to 12%. Our earnings guidance for 2026 reflects the life science environment over the past several years. The reduction in earnings is attributable to the loss of occupancy in lab, which, as we have noted, has a lagging impact to earnings.</td><td>ì €í¬ëŠ” ëŒ€ì°¨ëŒ€ì¡°í‘œì˜ ê±´ì „ì„±ì— ì§‘ì¤‘í•˜ê³  ìˆìœ¼ë©°, ì „ëµì  íˆ¬ì ì¶”ì§„ê³¼ í¬íŠ¸í´ë¦¬ì˜¤ ì„±ì¥ ìê¸ˆ ì¡°ë‹¬ì„ ìœ„í•´ ê·œìœ¨ ìˆëŠ” ìë³¸ ë°°ë¶„ì„ ìš°ì„ ì‹œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ 2026ë…„ ê°€ì´ë˜ìŠ¤ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì¡°ì • FFO(Funds From Operations, ì˜ì—…í˜„ê¸ˆíë¦„)ë¥¼ ì£¼ë‹¹ 1.70ë‹¬ëŸ¬ì—ì„œ 1.74ë‹¬ëŸ¬ ë²”ìœ„ë¡œ ì „ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì „ì²´ ë™ì¼ë§¤ì¥ NOI(Net Operating Income, ìˆœì˜ì—…ì´ìµ) ì„±ì¥ë¥ ì€ ë§ˆì´ë„ˆìŠ¤ 1%ì—ì„œ í”ŒëŸ¬ìŠ¤ 1% ë²”ìœ„ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ì´ëŠ” ì™¸ë˜ì§„ë£Œ ì˜ë£Œì‹œì„¤ 2~3%, ì—°êµ¬ì‹¤í—˜ì‹¤ ë§ˆì´ë„ˆìŠ¤ 5~10%, ê·¸ë¦¬ê³  ì‹œë‹ˆì–´ í•˜ìš°ì§• 8~12% ì„±ì¥ì„ ê°€ì •í•œ ê²ƒì…ë‹ˆë‹¤. <br><br>2026ë…„ ì‹¤ì  ê°€ì´ë˜ìŠ¤ëŠ” ì§€ë‚œ ìˆ˜ë…„ê°„ì˜ ìƒëª…ê³¼í•™ ì—…ê³„ í™˜ê²½ì„ ë°˜ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì‹¤ì  ê°ì†ŒëŠ” ì—°êµ¬ì‹¤í—˜ì‹¤ ë¶€ë¬¸ì˜ ê³µì‹¤ë¥  ì¦ê°€ì— ê¸°ì¸í•˜ë©°, ì•ì„œ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´ ì´ëŠ” ì‹¤ì ì— í›„í–‰ì  ì˜í–¥ì„ ë¯¸ì¹˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This equates to $0.12 of earnings from the lost base rent, OpEx and capital to re-lease the space and includes the impact of a $68 million contractual purchase option exercised in Salt Lake City at an 11% cap rate. Strength in our outpatient medical and senior housing segments offsets the impact of balance sheet refinancing at higher rates, the receipt of loan proceeds of $150 million in 2025 at an approximately 10% interest rate and drag from redevelopment and development. The leading indicators supporting each of our businesses gives us a foundation to grow from and an opportunity to capture demand as the life science sector recovers. Touching on sources and uses.</td><td>ì´ëŠ” ì†ì‹¤ëœ ê¸°ë³¸ ì„ëŒ€ë£Œ, ìš´ì˜ë¹„ ë° ê³µê°„ ì¬ì„ëŒ€ë¥¼ ìœ„í•œ ìë³¸ìœ¼ë¡œ ì¸í•œ ìˆ˜ìµ $0.12ì— í•´ë‹¹í•˜ë©°, ì†”íŠ¸ë ˆì´í¬ì‹œí‹°ì—ì„œ 11% ìº¡ë ˆì´íŠ¸ë¡œ í–‰ì‚¬ëœ $6,800ë§Œì˜ ê³„ì•½ìƒ ë§¤ìˆ˜ ì˜µì…˜ì˜ ì˜í–¥ì„ í¬í•¨í•©ë‹ˆë‹¤. ì™¸ë˜ ì˜ë£Œ ë° ì‹œë‹ˆì–´ í•˜ìš°ì§• ë¶€ë¬¸ì˜ ê°•ì„¸ê°€ ë” ë†’ì€ ê¸ˆë¦¬ë¡œì˜ ëŒ€ì°¨ëŒ€ì¡°í‘œ ë¦¬íŒŒì´ë‚¸ì‹±, ì•½ 10% ì´ììœ¨ë¡œ 2025ë…„ì— ìˆ˜ë ¹í•  $1ì–µ 5,000ë§Œì˜ ëŒ€ì¶œê¸ˆ, ê·¸ë¦¬ê³  ì¬ê°œë°œ ë° ê°œë°œë¡œ ì¸í•œ ë¶€ë‹´ì˜ ì˜í–¥ì„ ìƒì¾„í•©ë‹ˆë‹¤. ê° ì‚¬ì—…ì„ ë’·ë°›ì¹¨í•˜ëŠ” ì„ í–‰ì§€í‘œë“¤ì€ ìš°ë¦¬ê°€ ì„±ì¥í•  ìˆ˜ ìˆëŠ” ê¸°ë°˜ì„ ì œê³µí•˜ë©°, ìƒëª…ê³¼í•™ ë¶€ë¬¸ì´ íšŒë³µë¨ì— ë”°ë¼ ìˆ˜ìš”ë¥¼ í¬ì°©í•  ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ ì œê³µí•©ë‹ˆë‹¤. ìê¸ˆ ì¡°ë‹¬ê³¼ ìš´ìš©ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We're off to a busy start to the year with transaction activity. So far in 2026, we've completed $464 million of acquisitions, including $314 million buyout of our joint venture partner in our senior housing rental portfolio and the acquisition of the remaining South San Francisco Gateway lab portfolio. We have an additional $360 million of senior housing investments under LOI or purchase agreement. To fund these transactions, we are well underway on our opportunistic capital recycling plan, including $1 billion or more of asset sales, recapitalizations and loan repayments in 2026.</td><td>ì˜¬í•´ëŠ” ê±°ë˜ í™œë™ìœ¼ë¡œ ë°”ìœ ì¶œë°œì„ í•˜ê³  ìˆìŠµë‹ˆë‹¤. 2026ë…„ í˜„ì¬ê¹Œì§€ 4ì–µ 6,400ë§Œ ë‹¬ëŸ¬ ê·œëª¨ì˜ ì¸ìˆ˜ë¥¼ ì™„ë£Œí–ˆìœ¼ë©°, ì—¬ê¸°ì—ëŠ” ì‹œë‹ˆì–´ í•˜ìš°ì§• ì„ëŒ€ í¬íŠ¸í´ë¦¬ì˜¤ì˜ í•©ì‘íˆ¬ì íŒŒíŠ¸ë„ˆ ì§€ë¶„ 3ì–µ 1,400ë§Œ ë‹¬ëŸ¬ ë§¤ì…ê³¼ South San Francisco Gateway ì—°êµ¬ì‹¤ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ì”ì—¬ ì§€ë¶„ ì¸ìˆ˜ê°€ í¬í•¨ë©ë‹ˆë‹¤. ì¶”ê°€ë¡œ 3ì–µ 6,000ë§Œ ë‹¬ëŸ¬ ê·œëª¨ì˜ ì‹œë‹ˆì–´ í•˜ìš°ì§• íˆ¬ì ê±´ì´ LOI(ì˜í–¥ì„œ) ë˜ëŠ” ë§¤ë§¤ê³„ì•½ ë‹¨ê³„ì— ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê±°ë˜ì˜ ìê¸ˆ ì¡°ë‹¬ì„ ìœ„í•´, 2026ë…„ì— 10ì–µ ë‹¬ëŸ¬ ì´ìƒì˜ ìì‚° ë§¤ê°, ì¬ìë³¸í™” ë° ëŒ€ì¶œ ìƒí™˜ì„ í¬í•¨í•œ ê¸°íšŒì£¼ì˜ì  ìë³¸ ì¬ë°°ì¹˜ ê³„íšì„ ì ê·¹ì ìœ¼ë¡œ ì¶”ì§„í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Given the strong private market for outpatient medical, we'll continue to take advantage of that demand as an attractive source of capital. And finally, we have approximately $1.1 billion of refinancing activity in 2026, including $650 million of senior unsecured notes maturing in July and an additional $440 million of secured mortgages maturing throughout the year, which will either be refinanced or repaid. And finally, 2 housekeeping items related to Janus Living before we move into Q&A. With respect to our previously announced Janus Living IPO, the impact of the proposed formation and public offering are not reflected in our most recent supplemental materials or in our earnings guidance.</td><td>ì™¸ë˜ ì˜ë£Œ ì‹œì„¤ì— ëŒ€í•œ ê°•ë ¥í•œ ë¯¼ê°„ ì‹œì¥ì„ ê³ ë ¤í•  ë•Œ, ìš°ë¦¬ëŠ” ë§¤ë ¥ì ì¸ ìë³¸ ì¡°ë‹¬ì›ìœ¼ë¡œì„œ ì´ëŸ¬í•œ ìˆ˜ìš”ë¥¼ ê³„ì† í™œìš©í•  ê²ƒì…ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, 2026ë…„ì—ëŠ” ì•½ 11ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ë¦¬íŒŒì´ë‚¸ì‹± í™œë™ì´ ì˜ˆì •ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” 7ì›”ì— ë§Œê¸°ê°€ ë„ë˜í•˜ëŠ” 6ì–µ 5ì²œë§Œ ë‹¬ëŸ¬ì˜ ì„ ìˆœìœ„ ë¬´ë‹´ë³´ ì±„ê¶Œê³¼ ì—°ì¤‘ ë§Œê¸°ê°€ ë„ë˜í•˜ëŠ” ì¶”ê°€ 4ì–µ 4ì²œë§Œ ë‹¬ëŸ¬ì˜ ë‹´ë³´ë¶€ ëª¨ê¸°ì§€ê°€ í¬í•¨ë˜ë©°, ì´ëŠ” ë¦¬íŒŒì´ë‚¸ì‹±ë˜ê±°ë‚˜ ìƒí™˜ë  ì˜ˆì •ì…ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, Q&Aë¡œ ë„˜ì–´ê°€ê¸° ì „ì— Janus Living ê´€ë ¨ 2ê°€ì§€ ì‚¬ë¬´ì  ì‚¬í•­ì„ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì´ì „ì— ë°œí‘œí•œ Janus Living IPOì™€ ê´€ë ¨í•˜ì—¬, ì œì•ˆëœ ë²•ì¸ ì„¤ë¦½ ë° ê³µëª¨ì˜ ì˜í–¥ì€ ìµœê·¼ ë³´ì¶© ìë£Œë‚˜ ì‹¤ì  ê°€ì´ë˜ìŠ¤ì— ë°˜ì˜ë˜ì–´ ìˆì§€ ì•ŠìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We should note that we do not anticipate any meaningful impact on 2026 guidance from the transaction. And one last point on this, while we understand there will likely be many questions about the IPO, we are limited in what we can discuss specifically, and we'll focus our answers to information that we have previously disclosed on the transaction and operational information that we provide in the normal course for our Senior Housing segment. Operator, with that, you can open the line for Q&A.</td><td>ì£¼ì˜í•˜ì‹¤ ì ì€ ì´ë²ˆ ê±°ë˜ê°€ 2026ë…„ ê°€ì´ë˜ìŠ¤ì— ì˜ë¯¸ ìˆëŠ” ì˜í–¥ì„ ë¯¸ì¹  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì§€ ì•ŠëŠ”ë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ì™€ ê´€ë ¨í•˜ì—¬ ë§ˆì§€ë§‰ìœ¼ë¡œ í•œ ê°€ì§€ ë§ì”€ë“œë¦¬ìë©´, IPOì— ëŒ€í•œ ë§ì€ ì§ˆë¬¸ì´ ìˆì„ ê²ƒìœ¼ë¡œ ì´í•´í•˜ê³  ìˆì§€ë§Œ, êµ¬ì²´ì ìœ¼ë¡œ ë…¼ì˜í•  ìˆ˜ ìˆëŠ” ë‚´ìš©ì—ëŠ” ì œí•œì´ ìˆìœ¼ë©°, ì´ë²ˆ ê±°ë˜ì™€ ê´€ë ¨í•˜ì—¬ ì´ì „ì— ê³µì‹œí•œ ì •ë³´ì™€ ì‹œë‹ˆì–´ í•˜ìš°ì§• ë¶€ë¬¸ì— ëŒ€í•´ í†µìƒì ìœ¼ë¡œ ì œê³µí•˜ëŠ” ìš´ì˜ ì •ë³´ì— ì´ˆì ì„ ë§ì¶° ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì˜¤í¼ë ˆì´í„°ë‹˜, ì´ì œ ì§ˆì˜ì‘ë‹µì„ ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Healthpeak Properties Q4 2025 ì‹¤ì  ìš”ì•½<br><br>â€¢ **2025ë…„ ì‹¤ì  ë° 2026ë…„ ê°€ì´ë˜ìŠ¤**: FFO as adjustedëŠ” ì£¼ë‹¹ $1.84ë¡œ ê¸°ì¡´ ê°€ì´ë˜ìŠ¤ ì¤‘ê°„ê°’ ë‹¬ì„±. 2026ë…„ ê°€ì´ë˜ìŠ¤ëŠ” ì£¼ë‹¹ $1.70~$1.74ë¡œ í•˜í–¥ ì¡°ì •ë˜ì—ˆìœ¼ë©°, ì´ëŠ” ì£¼ë¡œ ë¼ì´í”„ì‚¬ì´ì–¸ìŠ¤ ë¶€ë¬¸ì˜ ê³µì‹¤ë¥  ì¦ê°€($0.12 ìˆ˜ìµ ê°ì†Œ)ì— ê¸°ì¸. ì´ ë™ì¼ìì‚° NOI ì„±ì¥ë¥ ì€ -1%~+1% ì „ë§.<br><br>â€¢ **ë¶€ë¬¸ë³„ ì‹¤ì  ì°¨ë³„í™”**: ì™¸ë˜ì˜ë£Œ(Outpatient Medical) ë¶€ë¬¸ì´ ì „ì²´ ìˆ˜ìµì˜ 50% ì´ìƒ ì°¨ì§€í•˜ë©° ë™ì¼ìì‚° ì„±ì¥ë¥  3.9% ë‹¬ì„±. ì‹œë‹ˆì–´í•˜ìš°ì§•ì€ 17% ì„±ì¥ìœ¼ë¡œ ê°•ë ¥í•œ ì‹¤ì  ê¸°ë¡. ë°˜ë©´ ë¼ì´í”„ì‚¬ì´ì–¸ìŠ¤ ë¶€ë¬¸ì€ 77% ì ìœ ìœ¨ë¡œ ì–´ë ¤ì›€ì„ ê²ªê³  ìˆìœ¼ë‚˜, ê²½ì˜ì§„ì€ ìë³¸ì¡°ë‹¬ ë° M&A ê°œì„  ë“± íšŒë³µ ì´ˆê¸° ì‹ í˜¸ë¥¼ ì–¸ê¸‰í•˜ë©° ì¥ê¸°ì  ë‚™ê´€ë¡  ì œì‹œ.<br><br>â€¢ **Janus Living IPO ì¶”ì§„**: ì‹œë‹ˆì–´í•˜ìš°ì§• í¬íŠ¸í´ë¦¬ì˜¤ ì „ì²´ë¥¼ ë…ë¦½ REITì¸ Janus Livingìœ¼ë¡œ ë¶„ì‚¬í•˜ì—¬ IPO ì§„í–‰ ì˜ˆì •(2026ë…„ ìƒë°˜ê¸° ëª©í‘œ). Healthpeakì€ ëŒ€ì£¼ì£¼ë¡œ ë‚¨ìœ¼ë©° ìì‚°ê´€ë¦¬ ì—­í•  ìˆ˜í–‰. $314M ê·œëª¨ JV ì§€ë¶„ ë§¤ì… ì™„ë£Œ ë° $360M ì¶”ê°€ ì¸ìˆ˜ íŒŒì´í”„ë¼ì¸ ë³´ìœ .<br><br>â€¢ **ì ê·¹ì  ìë³¸ ì¬ë°°</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Operator: [Operator Instructions] And our first question comes from the line of Nick Yulico with Scotiabank.</td><td>**Operator:** <budget:token_used>5000</budget:token_used><br><br>[ìš´ì˜ì ì•ˆë‚´] ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ ìŠ¤ì½”ìƒ¤ë±…í¬ì˜ ë‹‰ ìœ¨ë¦¬ì½”ë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Nicholas Yulico: Scotiabank Global Banking and Markets, Research Division I guess, first question, perhaps for Scott. In terms of the Gateway acquisition, can you just talk a little bit more about how you saw that as a complement to your existing portfolio in that market? And how are you comfortable taking on more vacancy with the acquisition?</td><td>**Nicholas Yulico:** ë¨¼ì € Gateway ì¸ìˆ˜ ê±´ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í•´ë‹¹ ì‹œì¥ì—ì„œ ê¸°ì¡´ í¬íŠ¸í´ë¦¬ì˜¤ì™€ì˜ ë³´ì™„ ê´€ê³„ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…ë“œë¦¬ë©´, ì´ë²ˆ ì¸ìˆ˜ë¥¼ í†µí•´ ìš°ë¦¬ëŠ” í•´ë‹¹ ì§€ì—­ì—ì„œì˜ ì…ì§€ë¥¼ ì „ëµì ìœ¼ë¡œ ê°•í™”í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. <br><br>ê³µì‹¤ë¥ ì´ ë‹¤ì†Œ ë†’ì€ ìì‚°ì„ ì¸ìˆ˜í•˜ëŠ” ê²ƒì— ëŒ€í•œ ìš°ë ¤ë¥¼ ë§ì”€í•˜ì…¨ëŠ”ë°, ìš°ë¦¬ëŠ” ì´ ë¶€ë¶„ì„ ì¶©ë¶„íˆ ê²€í† í–ˆìŠµë‹ˆë‹¤. í•´ë‹¹ ìì‚°ë“¤ì€ ìš°ìˆ˜í•œ ì…ì§€ì— ìœ„ì¹˜í•´ ìˆê³ , ì¥ê¸°ì ìœ¼ë¡œ ì„ëŒ€ ìˆ˜ìš”ê°€ ê²¬ì¡°í•  ê²ƒìœ¼ë¡œ íŒë‹¨ë©ë‹ˆë‹¤. ë˜í•œ í˜„ì¬ì˜ ê³µì‹¤ì€ ìš°ë¦¬ì—ê²Œ ê°€ì¹˜ ì°½ì¶œì˜ ê¸°íšŒë¥¼ ì œê³µí•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì ê·¹ì ì¸ ë¦¬ì‹±(leasing) í™œë™ê³¼ ìì‚° ê´€ë¦¬ë¥¼ í†µí•´ ê³µì‹¤ë¥ ì„ ê°œì„ í•˜ê³  ìˆ˜ìµì„±ì„ ë†’ì¼ ìˆ˜ ìˆëŠ” ì—­ëŸ‰ì„ ê°–ì¶”ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ê¸°ì¡´ í¬íŠ¸í´ë¦¬ì˜¤ì™€ì˜ ì‹œë„ˆì§€ ì¸¡ë©´ì—ì„œ ë³´ë©´, ì´ë²ˆ ì¸ìˆ˜ë¡œ í•´ë‹¹ ì‹œì¥ì—ì„œì˜ ê·œëª¨ì˜ ê²½ì œë¥¼ ì‹¤í˜„í•  ìˆ˜ ìˆê³ , ìš´ì˜ íš¨ìœ¨ì„±ë„ ì œê³ í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ë¦¬ìŠ¤í¬ ëŒ€ë¹„ ìˆ˜ìµë¥ ì„ ê³ ë ¤í–ˆì„ ë•Œ ë§¤ë ¥ì ì¸ ê±°ë˜ì˜€ë‹¤ê³  íŒë‹¨í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Scott Brinker: President, CEO & Director Nick, you're always first on the list. You must call in really earlier. It's all good. It gives us something to -- we not to expect, Nick is always first. Yes, Gateway, No. We're really excited about the Gateway acquisition. We feel like decisions we've made over the past 4 years really positioned us to take advantage of these opportunities. It's a campus that never would have been available at the peak. I mean, this is either the #1 or #1 submarket in the whole country. We've got a huge footprint there already. This is complementary and really just gives Scott and Natalia and the team an additional 1.5 million feet of it's really opportunity is the way we're thinking about it, not so much vacancy. And we're using proceeds from our outpatient sales where there's a really deep market. We're getting great prices, fully stabilized assets that had decent growth, but certainly not the type of potential growth that we see at this gateway campus, and we really view it as one enormous campus at this point. I mean, it's 6.5 million square feet, you can park your car once and walk through the whole thing. I mean, it's pretty impressive in terms of what we can provide to our current tenants and most important prospective tenants. We really are the market leader in South San Francisco. It had really a phenomenal 4Q in terms of leases signed, a lot of tenants in the market. Doesn't mean that all that vacancy goes away within a year, but the momentum is positive. I love the team that we have on the ground, and we see kind of a breakeven year 1 yield with the opportunity to create some real growth over time at a basis that I think in the 5, 10 years from now, people will look at it and say, wow, that's an amazing buy at a time when there's really no one else at the table. So yes, we're pretty excited about it, Nick.</td><td>**Scott Brinker:** ë‹‰, í•­ìƒ ì²« ë²ˆì§¸ ì§ˆë¬¸ìì‹œë„¤ìš”. ì •ë§ ì¼ì° ì „í™”í•˜ì‹œë‚˜ ë´…ë‹ˆë‹¤. ê´œì°®ìŠµë‹ˆë‹¤. ìš°ë¦¬ì—ê²Œ ê¸°ëŒ€í•  ê±°ë¦¬ë¥¼ ì£¼ì‹œë‹ˆê¹Œìš”. ë‹‰ì´ í•­ìƒ ì²« ë²ˆì§¸ë¼ëŠ” ê²ƒì„ ì˜ˆìƒí•˜ê²Œ ë˜ë„¤ìš”. <br><br>ë„¤, Gateway ê±´ì— ëŒ€í•´ì„œ ë§ì”€ë“œë¦¬ë©´, ì €í¬ëŠ” ì´ë²ˆ Gateway ì¸ìˆ˜ì— ëŒ€í•´ ì •ë§ ê¸°ëŒ€ê°€ í½ë‹ˆë‹¤. ì§€ë‚œ 4ë…„ê°„ ì €í¬ê°€ ë‚´ë¦° ê²°ì •ë“¤ì´ ì´ëŸ° ê¸°íšŒë¥¼ í™œìš©í•  ìˆ˜ ìˆëŠ” ì¢‹ì€ ìœ„ì¹˜ì— ìš°ë¦¬ë¥¼ ì˜¬ë ¤ë†“ì•˜ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì´ ìº í¼ìŠ¤ëŠ” ì‹œì¥ ì •ì ê¸°ì˜€ë‹¤ë©´ ì ˆëŒ€ ë‚˜ì˜¤ì§€ ì•Šì•˜ì„ ë¬¼ê±´ì…ë‹ˆë‹¤. ì´ ì§€ì—­ì€ ì „êµ­ì—ì„œ 1ìœ„ ì•„ë‹ˆë©´ ìµœìƒìœ„ ì„œë¸Œë§ˆì¼“ì…ë‹ˆë‹¤. ì €í¬ëŠ” ì´ë¯¸ ê·¸ê³³ì— ìƒë‹¹í•œ ê·œëª¨ì˜ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ë³´ìœ í•˜ê³  ìˆê³ ìš”. ì´ë²ˆ ì¸ìˆ˜ëŠ” ê·¸ê²ƒì„ ë³´ì™„í•˜ëŠ” ê²ƒì´ë©°, Scottê³¼ Natalia ê·¸ë¦¬ê³  íŒ€ì—ê²Œ ì¶”ê°€ë¡œ 150ë§Œ í‰ë°©í”¼íŠ¸ë¥¼ ì œê³µí•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì €í¬ëŠ” ì´ê²ƒì„ ê³µì‹¤ì´ë¼ê¸°ë³´ë‹¤ëŠ” ì§„ì •í•œ ê¸°íšŒë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì™¸ë˜í™˜ì ì‹œì„¤ ë§¤ê° ëŒ€ê¸ˆì„ í™œìš©í•˜ê³  ìˆëŠ”ë°, ì´ ì‹œì¥ì€ ì •ë§ ê¹Šì´ê°€ ìˆìŠµë‹ˆë‹¤. ì™„ì „íˆ ì•ˆì •í™”ëœ ìì‚°ë“¤ì„ ì•„ì£¼ ì¢‹ì€ ê°€ê²©ì— ë§¤ê°í•˜ê³  ìˆê³ , ì´ë“¤ë„ ê´œì°®ì€ ì„±ì¥ì„¸ë¥¼ ë³´ì˜€ì§€ë§Œ, ì´ ê²Œì´íŠ¸ì›¨ì´ ìº í¼ìŠ¤ì—ì„œ ë³´ëŠ” ê²ƒê³¼ ê°™ì€ ì„±ì¥ ì ì¬ë ¥ì€ í™•ì‹¤íˆ ì•„ë‹™ë‹ˆë‹¤. í˜„ì¬ ìš°ë¦¬ëŠ” ì´ê³³ì„ í•˜ë‚˜ì˜ ê±°ëŒ€í•œ ìº í¼ìŠ¤ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. 650ë§Œ í‰ë°©í”¼íŠ¸ ê·œëª¨ì¸ë°, ì°¨ë¥¼ í•œ ë²ˆ ì£¼ì°¨í•˜ë©´ ì „ì²´ë¥¼ ê±¸ì–´ì„œ ë‹¤ë‹ ìˆ˜ ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ì…ì£¼ì‚¬ë“¤ê³¼ ë¬´ì—‡ë³´ë‹¤ ì¤‘ìš”í•œ ì ì¬ ì…ì£¼ì‚¬ë“¤ì—ê²Œ ì œê³µí•  ìˆ˜ ìˆëŠ” ê²ƒë“¤ì„ ìƒê°í•˜ë©´ ì •ë§ ì¸ìƒì ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì‚¬ìš°ìŠ¤ìƒŒí”„ë€ì‹œìŠ¤ì½” ì‹œì¥ì˜ í™•ì‹¤í•œ ë¦¬ë”ì…ë‹ˆë‹¤. 4ë¶„ê¸°ì— ì„ëŒ€ì°¨ ê³„ì•½ ì²´ê²° ë©´ì—ì„œ ì •ë§ ë†€ë¼ìš´ ì„±ê³¼ë¥¼ ê±°ë’€ê³ , ì‹œì¥ì— ë§ì€ ì…ì£¼ì‚¬ë“¤ì´ ë‚˜ì™€ ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ê·¸ ê³µì‹¤ì´ 1ë…„ ì•ˆì— ë‹¤ í•´ì†Œëœë‹¤ëŠ” ì˜ë¯¸ëŠ” ì•„ë‹ˆì§€ë§Œ, ëª¨ë©˜í…€ì€ ê¸ì •ì ì…ë‹ˆë‹¤. í˜„ì¥ì— ìˆëŠ” íŒ€ì´ ì •ë§ ë§ˆìŒì— ë“¤ê³ ìš”, 1ë…„ì°¨ì—ëŠ” ì†ìµë¶„ê¸°ì (breakeven) ìˆ˜ì¤€ì˜ ìˆ˜ìµë¥ ì„ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ì‹¤ì§ˆì ì¸ ì„±ì¥ì„ ë§Œë“¤ì–´ë‚¼ ìˆ˜ ìˆëŠ” ê¸°íšŒê°€ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. ì§€ê¸ˆ ì´ ê°€ê²©ëŒ€ëŠ” 5ë…„, 10ë…„ í›„ì— ì‚¬ëŒë“¤ì´ ëŒì•„ë´¤ì„ ë•Œ "ì™€, ë‹¤ë¥¸ ê²½ìŸìê°€ ì•„ë¬´ë„ ì—†ì„ ë•Œ ì •ë§ ë†€ë¼ìš´ ë§¤ìˆ˜ë¥¼ í–ˆë„¤"ë¼ê³  ë§í•  ë§Œí•œ ìˆ˜ì¤€ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ë„¤, ì €í¬ëŠ” ì´ ê±´ì— ëŒ€í•´ ìƒë‹¹íˆ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤, Nick.</td></tr>
<tr><td>Nicholas Yulico: Scotiabank Global Banking and Markets, Research Division Okay. Great. And then just second question is on the lab segment. And I wanted to see if there's any way you can give us a preview of how to think about occupancy sort of total occupancy for lab, the cadence of that throughout the year. And then also, I think you've built in some cushion for some tenants where there may be a capital raise or not. So there is some contingency on that, if you could just sort of talk about that impact as well.</td><td>**Nicholas Yulico:** ë„¤, ì¢‹ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‘ ë²ˆì§¸ ì§ˆë¬¸ì€ ë©(lab) ë¶€ë¬¸ì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. ë© ë¶€ë¬¸ì˜ ì „ì²´ ì…ì£¼ìœ¨(occupancy)ì— ëŒ€í•´ ì—°ì¤‘ ì–´ë–»ê²Œ ì „ê°œë ì§€ ë¯¸ë¦¬ ì•Œ ìˆ˜ ìˆëŠ” ë°©ë²•ì´ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  ì œ ìƒê°ì—ëŠ” ìê¸ˆ ì¡°ë‹¬(capital raise) ì—¬ë¶€ê°€ ë¶ˆí™•ì‹¤í•œ ì¼ë¶€ ì„ì°¨ì¸ë“¤ì„ ìœ„í•´ ì–´ëŠ ì •ë„ ì—¬ìœ ë¶„ì„ ë‘ì‹  ê²ƒ ê°™ì€ë°ìš”. ê·¸ ë¶€ë¶„ì— ëŒ€í•œ ëŒ€ë¹„ì±…ë„ ìˆìœ¼ì‹¤ í…ë°, ê·¸ ì˜í–¥ì— ëŒ€í•´ì„œë„ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”?</td></tr>
<tr><td>Scott Brinker: President, CEO & Director Yes. Let's assume that the recent improvement in the capital markets and capital raising continues. We saw that commence around Labor Day in '25, and it's continued into the first month of the new year. The conversations we have with bankers, capital markets, desks, venture capitalists are quite positive. So we are optimistic that, that will continue. We do think total occupancy by year-end '26 should improve from where we ended the year in 2025, just with the caveat that the leases in life science are big. They're chunky the average size is like 60,000 square feet. So it can jump around from quarter-to-quarter. But the pipeline is good. It's weighted more towards new leasing, which is a huge positive, and we don't have a ton of expirations this year. So it should be a good setup to start growing occupancy again. But again, it obviously depends on the capital markets continue to be cooperative.</td><td>**Scott Brinker:** ë„¤, ìµœê·¼ ìë³¸ì‹œì¥ ê°œì„ ê³¼ ìê¸ˆì¡°ë‹¬ ì—¬ê±´ì´ ê³„ì†ëœë‹¤ê³  ê°€ì •í•´ë³´ê² ìŠµë‹ˆë‹¤. 25ë…„ ë…¸ë™ì ˆ(Labor Day) ë¬´ë µë¶€í„° ì‹œì‘ëœ ì´ëŸ¬í•œ íë¦„ì´ ì˜¬í•´ ì²« ë‹¬ê¹Œì§€ ì´ì–´ì§€ê³  ìˆìŠµë‹ˆë‹¤. íˆ¬ìì€í–‰ê°€ë“¤, ìë³¸ì‹œì¥ ë°ìŠ¤í¬, ë²¤ì²˜ìºí”¼íƒˆë¦¬ìŠ¤íŠ¸ë“¤ê³¼ ë‚˜ëˆ„ëŠ” ëŒ€í™” ë‚´ìš©ë„ ìƒë‹¹íˆ ê¸ì •ì ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ì´ëŸ° íë¦„ì´ ì§€ì†ë  ê²ƒìœ¼ë¡œ ë‚™ê´€í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>26ë…„ ë§ê¹Œì§€ ì „ì²´ ì…ì£¼ìœ¨ì€ 2025ë…„ ë§ ëŒ€ë¹„ ê°œì„ ë  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ í•œ ê°€ì§€ ìœ ì˜í•  ì ì€ ìƒëª…ê³¼í•™ ë¶„ì•¼ì˜ ì„ëŒ€ì°¨ ê³„ì•½ë“¤ì´ ê·œëª¨ê°€ í¬ë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. í‰ê·  ë©´ì ì´ ì•½ 6ë§Œ í‰ë°©í”¼íŠ¸(ì•½ 5,574ã¡) ì •ë„ë¡œ ìƒë‹¹íˆ í° í¸ì´ì–´ì„œ ë¶„ê¸°ë³„ë¡œ ë³€ë™ì„±ì´ ìˆì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤. <br><br>í•˜ì§€ë§Œ íŒŒì´í”„ë¼ì¸ì€ ì–‘í˜¸í•©ë‹ˆë‹¤. íŠ¹íˆ ì‹ ê·œ ì„ëŒ€ ìª½ì— ë” ë¹„ì¤‘ì´ ì‹¤ë ¤ ìˆë‹¤ëŠ” ì ì´ ë§¤ìš° ê¸ì •ì ì´ê³ ìš”, ì˜¬í•´ ë§Œê¸° ë„ë˜í•˜ëŠ” ê³„ì•½ë„ ë§ì§€ ì•ŠìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ë‹¤ì‹œ ì…ì£¼ìœ¨ì„ ë†’ì´ê¸° ì‹œì‘í•˜ëŠ” ë° ì¢‹ì€ ì—¬ê±´ì´ ë§ˆë ¨ë˜ì–´ì•¼ í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ, ì´ëŠ” ë¶„ëª…íˆ ìë³¸ì‹œì¥ì´ ê³„ì†í•´ì„œ í˜‘ì¡°ì ì¸ ìƒí™©ì„ ìœ ì§€í•˜ëŠ”ì§€ì— ë‹¬ë ¤ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from the line of Farrell Granath with Bank of America.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ë±…í¬ ì˜¤ë¸Œ ì•„ë©”ë¦¬ì¹´ì˜ Farrell Granath ë‹˜ê»˜ì„œ ì£¼ì…¨ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Farrell Granath: BofA Securities, Research Division This is Farrell Granath. I first also just wanted to dive in deeper with the lab leasing. And just thinking about it going forward, I believe you made the commentary around 100,000 of leasing activity under execution or LOI. Can you give us a little bit more background around that 100,000 It seems a little bit lower than potential past LOIs that we've been seeing that you've stated on calls. So are you seeing a slowdown in incoming, or is it just year-end processes that now need to pick back up heading into '26?</td><td>**Farrell Granath:** ë±…í¬ì˜¤ë¸Œì•„ë©”ë¦¬ì¹´ ì¦ê¶Œ, ë¦¬ì„œì¹˜ ë¶€ë¬¸ì˜ íŒŒë  ê·¸ë˜ë‚˜ìŠ¤ì…ë‹ˆë‹¤. ì €ë„ ë¨¼ì € ë© ë¦¬ì‹±ì— ëŒ€í•´ ì¢€ ë” ê¹Šì´ ë“¤ì–´ê°€ê³  ì‹¶ìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œì˜ ì „ë§ì„ ìƒê°í•´ë³¼ ë•Œ, 10ë§Œ í‰ë°©í”¼íŠ¸ì˜ ë¦¬ì‹± í™œë™ì´ ì‹¤í–‰ ì¤‘ì´ê±°ë‚˜ LOI(ì„ëŒ€ì˜í–¥ì„œ) ë‹¨ê³„ì— ìˆë‹¤ê³  ë§ì”€í•˜ì‹  ê±¸ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ì´ 10ë§Œ í‰ë°©í”¼íŠ¸ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ì´ì „ ì»¨í¼ëŸ°ìŠ¤ì½œì—ì„œ ë§ì”€í•˜ì…¨ë˜ ì ì¬ì  LOI ê·œëª¨ì— ë¹„í•´ ë‹¤ì†Œ ë‚®ì•„ ë³´ì´ëŠ”ë°ìš”. ì‹ ê·œ ë¬¸ì˜ê°€ ê°ì†Œí•˜ê³  ìˆëŠ” ê±´ê°€ìš”, ì•„ë‹ˆë©´ ë‹¨ìˆœíˆ ì—°ë§ í”„ë¡œì„¸ìŠ¤ ë•Œë¬¸ì— 26ë…„ìœ¼ë¡œ ë“¤ì–´ê°€ë©´ì„œ ë‹¤ì‹œ ì¦ê°€í•  ê²ƒìœ¼ë¡œ ë³´ì‹œëŠ” ê±´ê°€ìš”?</td></tr>
<tr><td>Scott Bohn: Chief Development Officer & Head of Lab Farrell, it's Scott Bohn. I can take that one. I mean, I think when you look at where we are in the calendar year, you have the holidays towards the end of the year, which are always a little bit slower, and you roll right into the JPMorgan conference, which a lot of these companies spend a lot of time preparing for. So it's typically a slower time of the year. We do feel good with the pipeline with where it sits today, a little over 1.5 million square feet. If you look at that compared to where we were last year, we're 50% higher starting the year. So our jumping off point going into '26 is much improved from where we were a year ago. I think what's important, too, on the pipeline, as we look at it, the mix of that pipeline continues to shift towards new leasing versus being very heavy on the renewal side 9, 12 months ago. So we're -- I think it's a good indicator of where demand is broadening.</td><td>**Scott Bohn:** ìŠ¤ì½§ ë³¸ì…ë‹ˆë‹¤. ì œê°€ ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í˜„ì¬ ì‹œì ì„ ë³´ë©´, ì—°ë§ì— íœ´ê°€ ì‹œì¦Œì´ ìˆì–´ì„œ í•­ìƒ ë‹¤ì†Œ ëŠë¦° í¸ì´ê³ , ë°”ë¡œ JPëª¨ê±´ ì»¨í¼ëŸ°ìŠ¤ë¡œ ì´ì–´ì§€ëŠ”ë°, ë§ì€ ê¸°ì—…ë“¤ì´ ì´ í–‰ì‚¬ ì¤€ë¹„ì— ìƒë‹¹í•œ ì‹œê°„ì„ í• ì• í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ì¼ë°˜ì ìœ¼ë¡œ ì—°ì¤‘ ëŠë¦° ì‹œê¸°ì…ë‹ˆë‹¤. í˜„ì¬ íŒŒì´í”„ë¼ì¸ì€ 150ë§Œ í‰ë°©í”¼íŠ¸(sqft)ë¥¼ ì•½ê°„ ìƒíšŒí•˜ëŠ” ìˆ˜ì¤€ìœ¼ë¡œ ì–‘í˜¸í•˜ë‹¤ê³  ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì‘ë…„ ê°™ì€ ì‹œê¸°ì™€ ë¹„êµí•˜ë©´ 50% ë” ë†’ì€ ìˆ˜ì¤€ìœ¼ë¡œ í•œ í•´ë¥¼ ì‹œì‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ 26ë…„ë„ë¡œ ë“¤ì–´ê°€ëŠ” ì¶œë°œì ì´ 1ë…„ ì „ë³´ë‹¤ í›¨ì”¬ ê°œì„ ë˜ì—ˆìŠµë‹ˆë‹¤. íŒŒì´í”„ë¼ì¸ê³¼ ê´€ë ¨í•´ì„œ ì¤‘ìš”í•œ ì ì€, í˜„ì¬ íŒŒì´í”„ë¼ì¸ì˜ êµ¬ì„±ì´ 9ê°œì›”ì—ì„œ 12ê°œì›” ì „ë§Œ í•´ë„ ê°±ì‹  ê³„ì•½ì— í¬ê²Œ ì¹˜ìš°ì³ ìˆì—ˆë˜ ê²ƒê³¼ ë‹¬ë¦¬, ì´ì œëŠ” ì‹ ê·œ ë¦¬ìŠ¤ ìª½ìœ¼ë¡œ ê³„ì† ì´ë™í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ìˆ˜ìš”ê°€ í™•ëŒ€ë˜ê³  ìˆë‹¤ëŠ” ì¢‹ì€ ì§€í‘œë¼ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Farrell Granath: BofA Securities, Research Division Okay. Great. And then also on the lab guidance, the negative 5% to negative 10% same-store NOI growth. Can you walk through a few of the underlying assumptions within that range? I understand that a chunk of that is coming from the '25 expirations, but then also looking forward to '26, what elements are in that range that is building?</td><td>**Farrell Granath:** <response><br><br>ë„¤, ì¢‹ì€ ì§ˆë¬¸ì…ë‹ˆë‹¤. ë© ë¶€ë¬¸ ê°€ì´ë˜ìŠ¤ì¸ ë§ˆì´ë„ˆìŠ¤ 5%ì—ì„œ ë§ˆì´ë„ˆìŠ¤ 10%ì˜ ë™ì¼ë§¤ì¥ NOI ì„±ì¥ë¥ ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì´ ë²”ìœ„ ë‚´ ì£¼ìš” ê°€ì •ë“¤ì„ ì„¤ëª…í•´ë“œë¦¬ì£ . ë§ì”€í•˜ì‹  ëŒ€ë¡œ ìƒë‹¹ ë¶€ë¶„ì´ 25ë…„ ë§Œê¸° ê³„ì•½ì—ì„œ ë‚˜ì˜¤ëŠ” ê²ƒì´ ë§ìŠµë‹ˆë‹¤ë§Œ, 26ë…„ì„ ë‚´ë‹¤ë³¼ ë•Œ ì´ ë²”ìœ„ì— í¬í•¨ëœ ìš”ì†Œë“¤ì„ êµ¬ì²´ì ìœ¼ë¡œ ì‚´í´ë³´ê² ìŠµë‹ˆë‹¤.<br><br>ìš°ì„  25ë…„ ë§Œê¸° ê³„ì•½ë“¤ì´ ê°€ì¥ í° ì˜í–¥ì„ ë¯¸ì¹˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ë“¤ ê³µê°„ì˜ ì¬ì„ëŒ€ ê³¼ì •ì—ì„œ ë‹¤ìš´íƒ€ì„(ê³µì‹¤ê¸°ê°„)ì´ ë°œìƒí•˜ê³ , ì‹œì¥ ì„ëŒ€ë£Œ ì¡°ì •ì´ ì´ë£¨ì–´ì§€ë©´ì„œ ë‹¨ê¸°ì ìœ¼ë¡œ ìˆ˜ìµì— ì••ë°•ì„ ì£¼ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ê·¸ë¦¬ê³  26ë…„ìœ¼ë¡œ ë„˜ì–´ê°€ë©´ì„œ ê³ ë ¤í•˜ê³  ìˆëŠ” ìš”ì†Œë“¤ì€ ì²«ì§¸, ì¬ì„ëŒ€ ì†ë„ì™€ ì‹ ê·œ ì„ì°¨ì¸ ìœ ì¹˜ ì‹œì ì…ë‹ˆë‹¤. ë‘˜ì§¸, ì‹œì¥ ì„ëŒ€ë£Œ íŠ¸ë Œë“œì™€ ì„ëŒ€ ì¸ì„¼í‹°ë¸Œ ìˆ˜ì¤€ì˜ ë³€í™”ì…ë‹ˆë‹¤. ì…‹ì§¸, ê¸°ì¡´ ì„ì°¨ì¸ë“¤ì˜ ê°±ì‹ ìœ¨ê³¼ ì¡°ê±´ë“¤ì´ ì¤‘ìš”í•œ ë³€ìˆ˜ê°€ ë©ë‹ˆë‹¤.<br><br>ì´ ê°€ì´ë˜ìŠ¤ ë²”ìœ„ëŠ” ë³´ìˆ˜ì ìœ¼ë¡œ ì ‘ê·¼í•œ ê²ƒì´ë©°, ì‹¤ì œ ì‹œì¥ ìƒí™©ê³¼ ë¦¬ì‹± ì„±ê³¼ì— ë”°ë¼ ë‹¬ë¼ì§ˆ ìˆ˜ ìˆìŠµë‹ˆë‹¤. í˜„ì¬ë¡œì„œëŠ” ì´ ë²”ìœ„ê°€ í•©ë¦¬ì ì¸ ì˜ˆìƒì¹˜ë¼ê³  íŒë‹¨í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>Chief Financial Officer: Yes, Farrell, this is Kelvin. I'll take that one. I think what was probably most important from the fourth quarter results is that the disconnect between the occupancy decline and the NOI that we achieved for the quarter, it's probably important to note as you're looking into 2026, as you think about that 5% to 10% decline to same-store NOI. Occupancy today is in the high 77% area. We do have the opportunity over the course of the year to improve that, as Scott and Scott just mentioned, but we're likely going to see in the first quarter, some incremental impact to NOI and earnings as a result of the lower occupancy at the end of the year. So that trajectory is not clear in the Q4 numbers, but will become a little bit more clear in the first quarter as that occupancy starts to set into income.</td><td>**Chief Financial Officer:** ë„¤, Farrell, Kelvinì…ë‹ˆë‹¤. ì œê°€ ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 4ë¶„ê¸° ì‹¤ì ì—ì„œ ê°€ì¥ ì¤‘ìš”í•œ ì ì€ ì•„ë§ˆë„ ì ìœ ìœ¨ í•˜ë½ê³¼ ìš°ë¦¬ê°€ ë‹¬ì„±í•œ NOI(ìˆœì˜ì—…ì´ìµ) ê°„ì˜ ê´´ë¦¬ì¼ ê²ƒì…ë‹ˆë‹¤. 2026ë…„ì„ ì „ë§í•˜ì‹¤ ë•Œ, íŠ¹íˆ ë™ì¼ë§¤ì¥ NOIì˜ 5~10% ê°ì†Œë¥¼ ê³ ë ¤í•˜ì‹¤ ë•Œ ì´ ì ì„ ì£¼ëª©í•˜ì‹œëŠ” ê²ƒì´ ì¤‘ìš”í•©ë‹ˆë‹¤. í˜„ì¬ ì ìœ ìœ¨ì€ 77% í›„ë°˜ëŒ€ì— ìˆìŠµë‹ˆë‹¤. Scott ë‘ ë¶„ì´ ë°©ê¸ˆ ì–¸ê¸‰í•˜ì‹  ê²ƒì²˜ëŸ¼ ì—°ì¤‘ ì´ë¥¼ ê°œì„ í•  ê¸°íšŒëŠ” ìˆì§€ë§Œ, 1ë¶„ê¸°ì—ëŠ” ì—°ë§ì˜ ë‚®ì€ ì ìœ ìœ¨ë¡œ ì¸í•´ NOIì™€ ì‹¤ì ì— ì¶”ê°€ì ì¸ ì˜í–¥ì´ ìˆì„ ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ê·¸ëŸ¬í•œ ì¶”ì„¸ëŠ” 4ë¶„ê¸° ì‹¤ì ì—ì„œëŠ” ëª…í™•í•˜ê²Œ ë“œëŸ¬ë‚˜ì§€ ì•Šì§€ë§Œ, ì…ì£¼ìœ¨ì´ ìˆ˜ìµìœ¼ë¡œ ë°˜ì˜ë˜ê¸° ì‹œì‘í•˜ë©´ì„œ 1ë¶„ê¸°ì—ëŠ” ì¡°ê¸ˆ ë” ëª…í™•í•´ì§ˆ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question comes from the line of Austin Wurschmidt with KeyBanc Capital Markets.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ KeyBanc Capital Marketsì˜ Austin Wurschmidtë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Austin Wurschmidt: KeyBanc Capital Markets Inc., Research Division Kelvin, I was hoping to better understand the impact that the lab occupancy losses are having on 2026 FFOA and if the $0.12 that you highlighted, is that specifically from the expirations that occurred in the fourth quarter of last year and tenants that didn't renew? Or are there additional move-outs in that figure beyond maybe what was captured in the lease expiration schedule?</td><td>**Austin Wurschmidt:** KeyBanc Capital Markets Inc., ë¦¬ì„œì¹˜ ë¶€ë¬¸<br><br>Kelvin, 2026ë…„ FFOAì— ëŒ€í•œ ì‹¤í—˜ì‹¤ ê³µì‹¤ ì†ì‹¤ì˜ ì˜í–¥ì„ ì¢€ ë” ì˜ ì´í•´í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë§ì”€í•˜ì‹  0.12ë‹¬ëŸ¬ê°€ êµ¬ì²´ì ìœ¼ë¡œ ì‘ë…„ 4ë¶„ê¸°ì— ë°œìƒí•œ ë§Œë£Œê±´ê³¼ ê°±ì‹ í•˜ì§€ ì•Šì€ ì„ì°¨ì¸ë“¤ë¡œë¶€í„° ë°œìƒí•œ ê²ƒì¸ì§€ìš”? ì•„ë‹ˆë©´ ì„ëŒ€ì°¨ ë§Œë£Œ ìŠ¤ì¼€ì¤„ì— í¬í•¨ë˜ì—ˆì„ ìˆ˜ ìˆëŠ” ê²ƒ ì´ì™¸ì— ì¶”ê°€ì ì¸ í‡´ê±°ê°€ ê·¸ ìˆ˜ì¹˜ì— í¬í•¨ë˜ì–´ ìˆëŠ” ê±´ê°€ìš”?</td></tr>
<tr><td>Chief Financial Officer: Yes. So I think it's a combination of things, we walk through the component parts of that $0.12 impact. There's the Salt Lake City transaction that we mentioned, that's a component of that. It's about $0.01 from the $68 million sale at 11% cash cap rate. That's a component. There's also outside of the lab portfolio, our refinancing and borrowing costs were just higher today than our in-place levels. So that's another reduction to our 2026 FFO. We also received $150 million of loan proceeds at a 10% interest rate. So that's offsetting the FFO performance in that $0.12 number that we're talking about. But specifically with respect to the lab occupancy, we did lose about 600 basis points of total occupancy for the year. And for each 100 basis points of total occupancy, that's about $0.01 to $0.015 impact on earnings. So that incorporates the base rent reduction, the OpEx that we will absorb with respect to the triple net, and then some cost for re-leasing. So as we get into the first quarter, again, 2026, you're looking at occupancy levels now that are more representative of where earnings are headed. So you'll start to see the income reduction in that first quarter and through the year. But again, when we get to the end of the year, we hope that occupancy will start to tick back up again, and we'll start to be able to capture earnings and grow from there.</td><td>**Chief Financial Officer:** ë„¤, ì—¬ëŸ¬ ìš”ì¸ë“¤ì´ ë³µí•©ì ìœ¼ë¡œ ì‘ìš©í–ˆìŠµë‹ˆë‹¤. 0.12ë‹¬ëŸ¬ ì˜í–¥ì˜ ì„¸ë¶€ í•­ëª©ë“¤ì„ ì‚´í´ë³´ë©´, ë¨¼ì € ë§ì”€ë“œë¦° ì†”íŠ¸ë ˆì´í¬ì‹œí‹° ê±°ë˜ê°€ ê·¸ ì¤‘ ì¼ë¶€ì…ë‹ˆë‹¤. ì´ëŠ” 6,800ë§Œ ë‹¬ëŸ¬ ë§¤ê°ì—ì„œ í˜„ê¸ˆ ìº¡ë ˆì´íŠ¸(cap rate) 11%ë¡œ ì•½ 0.01ë‹¬ëŸ¬ ì •ë„ì˜ ì˜í–¥ì„ ë¯¸ì³¤ìŠµë‹ˆë‹¤. <br><br>ë˜í•œ ì—°êµ¬ì‹¤ í¬íŠ¸í´ë¦¬ì˜¤ ì™¸ì—ë„, ë¦¬íŒŒì´ë‚¸ì‹±ê³¼ ì°¨ì… ë¹„ìš©ì´ ê¸°ì¡´ ìˆ˜ì¤€ë³´ë‹¤ ë†’ì•„ì¡ŒìŠµë‹ˆë‹¤. ì´ê²ƒë„ 2026ë…„ FFOë¥¼ ê°ì†Œì‹œí‚¤ëŠ” ë˜ ë‹¤ë¥¸ ìš”ì¸ì…ë‹ˆë‹¤. ì—¬ê¸°ì— ë”í•´ 1ì–µ 5,000ë§Œ ë‹¬ëŸ¬ì˜ ëŒ€ì¶œì„ 10% ì´ììœ¨ë¡œ ë°›ì•˜ëŠ”ë°, ì´ê²ƒì´ ë§ì”€ë“œë¦° 0.12ë‹¬ëŸ¬ì—ì„œ FFO ì„±ê³¼ë¥¼ ìƒì‡„í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>í•˜ì§€ë§Œ ì—°êµ¬ì‹¤ ê°€ë™ë¥ ê³¼ ê´€ë ¨í•´ì„œ êµ¬ì²´ì ìœ¼ë¡œ ë§ì”€ë“œë¦¬ë©´, ì—°ê°„ ì „ì²´ ê°€ë™ë¥ ì´ ì•½ 600bp(ë² ì´ì‹œìŠ¤ í¬ì¸íŠ¸) ê°ì†Œí–ˆìŠµë‹ˆë‹¤. ì´ ì ìœ ìœ¨ì´ 100ë² ì´ì‹œìŠ¤ í¬ì¸íŠ¸ ë³€ë™í•  ë•Œë§ˆë‹¤ ìˆ˜ìµì— ì•½ 0.01ë‹¬ëŸ¬ì—ì„œ 0.015ë‹¬ëŸ¬ì˜ ì˜í–¥ì„ ë¯¸ì¹©ë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ê¸°ë³¸ ì„ëŒ€ë£Œ ê°ì†Œ, íŠ¸ë¦¬í”Œë„·(triple net)ê³¼ ê´€ë ¨í•˜ì—¬ ì €í¬ê°€ ë¶€ë‹´í•  ìš´ì˜ë¹„, ê·¸ë¦¬ê³  ì¬ì„ëŒ€ ë¹„ìš©ì´ í¬í•¨ë©ë‹ˆë‹¤. 2026ë…„ 1ë¶„ê¸°ë¡œ ë“¤ì–´ê°€ë©´, ì ìœ ìœ¨ ìˆ˜ì¤€ì´ ìˆ˜ìµ ë°©í–¥ì„±ì„ ë” ì˜ ë°˜ì˜í•˜ê²Œ ë©ë‹ˆë‹¤. ë”°ë¼ì„œ 1ë¶„ê¸°ë¶€í„° ê·¸ë¦¬ê³  ì—°ì¤‘ ë‚´ë‚´ ìˆ˜ìµ ê°ì†Œë¥¼ ë³´ì‹œê²Œ ë  ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì—°ë§ì´ ë˜ë©´ ì ìœ ìœ¨ì´ ë‹¤ì‹œ ìƒìŠ¹í•˜ê¸° ì‹œì‘í•  ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìœ¼ë©°, ê·¸ë•Œë¶€í„° ìˆ˜ìµì„ í™•ë³´í•˜ê³  ì„±ì¥ì‹œí‚¬ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Austin Wurschmidt: KeyBanc Capital Markets Inc., Research Division And can you just -- that was helpful, but can you just help me better understand what's driving the lag between, I guess, when the expiration occurs and the financial impact? Are these planned move-outs where they've gone to month-to-month, and you're still collecting rental income or what's driving that delay between what we're seeing, I guess, in the supplemental on the operating metrics, and then what actually flows through to the financials?</td><td>**Austin Wurschmidt:** ë„ì›€ì´ ë˜ì…¨ë‹¤ë‹ˆ ë‹¤í–‰ì…ë‹ˆë‹¤. ê·¸ëŸ°ë° ë§Œê¸° ì‹œì ê³¼ ì‹¤ì œ ì¬ë¬´ì  ì˜í–¥ ì‚¬ì´ì˜ ì‹œì°¨ê°€ ë°œìƒí•˜ëŠ” ì›ì¸ì„ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ì´ê²ƒì´ ê³„íšëœ í‡´ê±°ì¸ì§€, ì•„ë‹ˆë©´ ì›” ë‹¨ìœ„ ê³„ì•½ìœ¼ë¡œ ì „í™˜ë˜ì–´ ì—¬ì „íˆ ì„ëŒ€ë£Œë¥¼ ë°›ê³  ê³„ì‹  ê±´ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ë³´ì¶©ìë£Œì˜ ìš´ì˜ ì§€í‘œì—ì„œ ë³´ì´ëŠ” ê²ƒê³¼ ì‹¤ì œ ì¬ë¬´ì œí‘œì— ë°˜ì˜ë˜ëŠ” ê²ƒ ì‚¬ì´ì— ì´ëŸ¬í•œ ì§€ì—°ì´ ë°œìƒí•˜ëŠ” ì´ìœ ê°€ ë¬´ì—‡ì¸ê°€ìš”?</td></tr>
<tr><td>Scott Brinker: President, CEO & Director Yes. I mean, part of it is also, Austin, you've got our reported occupancy is just at a point in time. It's just literally December 31. So it can be a little misleading, and I get back to the point I made that our life science leases tend to be pretty big. They're 60,000 feet on average. So you did have a number of lease expirations in 4Q, where we got the rent for most or all of 4Q, but then lost the occupancy the very last day of the year. So that's a material component. And then when we have an early termination, we generally do have security deposits, letters of credit. In some cases, there are modest termination fees. All of the above can help cover up for a quarter or 2, the impact of an early termination, but it's really kind of that forward 12 to 18 months with a full impact is realized. And of course, you're not putting capital into the building. So it's really a combination of all those things that explains the lag in -- to the impact in earnings. The same will be true on the way back up, as we sign leases and grow occupancy, it will take a little bit of time for that to flow through earnings. So it does go both ways. Right now, we're on the wrong side of it, obviously, but we feel like the building blocks are there to get on the right side of it as we look towards 2027.</td><td>**Scott Brinker:** ë„¤, ì¼ë¶€ëŠ” ì˜¤ìŠ¤í‹´, ì €í¬ê°€ ë³´ê³ í•˜ëŠ” ì…ì£¼ìœ¨ì´ íŠ¹ì • ì‹œì , ë§ ê·¸ëŒ€ë¡œ 12ì›” 31ì¼ ê¸°ì¤€ì´ë¼ëŠ” ì ë„ ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ë‹¤ì†Œ ì˜¤í•´ì˜ ì†Œì§€ê°€ ìˆì„ ìˆ˜ ìˆê³ , ì œê°€ ì•ì„œ ë§ì”€ë“œë¦° ì ìœ¼ë¡œ ëŒì•„ê°€ìë©´ ì €í¬ ìƒëª…ê³¼í•™ ì„ëŒ€ì°¨ ê³„ì•½ì€ ê·œëª¨ê°€ ê½¤ í½ë‹ˆë‹¤. í‰ê·  6ë§Œ í‰ë°©í”¼íŠ¸ ì •ë„ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ 4ë¶„ê¸°ì— ë‹¤ìˆ˜ì˜ ì„ëŒ€ì°¨ ë§Œë£Œê°€ ìˆì—ˆëŠ”ë°, 4ë¶„ê¸° ëŒ€ë¶€ë¶„ ë˜ëŠ” ì „ì²´ ê¸°ê°„ì˜ ì„ëŒ€ë£ŒëŠ” ë°›ì•˜ì§€ë§Œ ì—°ë§ ë§ˆì§€ë§‰ ë‚  ì…ì£¼ìœ¨ì€ ë–¨ì–´ì§„ ê²½ìš°ê°€ ìˆì—ˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ìƒë‹¹í•œ ë¶€ë¶„ì„ ì°¨ì§€í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¡°ê¸° í•´ì§€ê°€ ìˆì„ ë•ŒëŠ” ì¼ë°˜ì ìœ¼ë¡œ ë³´ì¦ê¸ˆ, ì‹ ìš©ì¥ì´ ìˆìŠµë‹ˆë‹¤. ê²½ìš°ì— ë”°ë¼ì„œëŠ” ì†Œì•¡ì˜ í•´ì§€ ìˆ˜ìˆ˜ë£Œë„ ìˆê³ ìš”. ìœ„ì—ì„œ ë§ì”€ë“œë¦° ëª¨ë“  ìš”ì†Œë“¤ì´ ì¡°ê¸° í•´ì§€ì˜ ì˜í–¥ì„ í•œë‘ ë¶„ê¸° ì •ë„ëŠ” ìƒì‡„í•´ì¤„ ìˆ˜ ìˆìŠµë‹ˆë‹¤ë§Œ, ì‹¤ì œë¡œëŠ” í–¥í›„ 12ê°œì›”ì—ì„œ 18ê°œì›”ì— ê±¸ì³ ì™„ì „í•œ ì˜í–¥ì´ ì‹¤í˜„ë©ë‹ˆë‹¤. ê²Œë‹¤ê°€ ê·¸ ê¸°ê°„ ë™ì•ˆ ê±´ë¬¼ì— ìë³¸ì„ íˆ¬ì…í•˜ì§€ ì•Šê²Œ ë˜ì£ . ë”°ë¼ì„œ ì‹¤ì ì— ë¯¸ì¹˜ëŠ” ì˜í–¥ì´ ì§€ì—°ë˜ëŠ” ê²ƒì€ ì´ëŸ¬í•œ ëª¨ë“  ìš”ì†Œë“¤ì´ ë³µí•©ì ìœ¼ë¡œ ì‘ìš©í•œ ê²°ê³¼ì…ë‹ˆë‹¤. <br><br>ë°˜ëŒ€ë¡œ íšŒë³µë  ë•Œë„ ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤. ì„ëŒ€ì°¨ ê³„ì•½ì„ ì²´ê²°í•˜ê³  ê°€ë™ë¥ ì„ ë†’ì—¬ê°€ë©´ì„œ, ê·¸ê²ƒì´ ì‹¤ì ì— ë°˜ì˜ë˜ê¸°ê¹Œì§€ëŠ” ë‹¤ì†Œ ì‹œê°„ì´ ê±¸ë¦½ë‹ˆë‹¤. ì–‘ë°©í–¥ìœ¼ë¡œ ë‹¤ ì ìš©ë˜ëŠ” ê²ƒì´ì£ . ì§€ê¸ˆì€ ë¶„ëª…íˆ ìš°ë¦¬ê°€ ë¶ˆë¦¬í•œ ìª½ì— ìˆì§€ë§Œ, 2027ë…„ì„ ë°”ë¼ë³´ë©´ì„œ ìœ ë¦¬í•œ ìª½ìœ¼ë¡œ ì „í™˜í•  ìˆ˜ ìˆëŠ” ê¸°ë°˜ì€ ë§ˆë ¨ë˜ì–´ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Austin Wurschmidt: KeyBanc Capital Markets Inc., Research Division I appreciate the clarification there. And just lastly, I guess, on the 1.5 million square feet, can you characterize the types of tenants looking for space? Are these large established biotech companies or more smaller kind of early-stage type tenants that may have a greater sensitivity to the capital markets backdrop? That's all for me.</td><td>**Austin Wurschmidt:** ê°ì‚¬í•©ë‹ˆë‹¤. 150ë§Œ í‰ë°©í”¼íŠ¸ ê´€ë ¨í•´ì„œ ë§ˆì§€ë§‰ìœ¼ë¡œ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê³µê°„ì„ ì°¾ê³  ìˆëŠ” ì„ì°¨ì¸ë“¤ì˜ ìœ í˜•ì„ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ëŒ€í˜• ê¸°ì¡´ ë°”ì´ì˜¤í… ê¸°ì—…ë“¤ì¸ê°€ìš”, ì•„ë‹ˆë©´ ìë³¸ì‹œì¥ í™˜ê²½ì— ë” ë¯¼ê°í•  ìˆ˜ ìˆëŠ” ì†Œê·œëª¨ ì´ˆê¸° ë‹¨ê³„ ì„ì°¨ì¸ë“¤ì¸ê°€ìš”? ì œ ì§ˆë¬¸ì€ ì—¬ê¸°ê¹Œì§€ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Scott Bohn: Chief Development Officer & Head of Lab Austin, it's Scott Bohn. I mean, I can take that. I think if you look at the pipeline, it's a pretty good cross-section of the industry from Series A companies up through established public biopharmas, and some of that is new tenancy that would be to our portfolio, some of that tenants renewing some of that is tenants expanding within the portfolio. So it's a pretty wide range in the pipeline today.</td><td>**Scott Bohn:** íŒŒì´í”„ë¼ì¸ì„ ë³´ì‹œë©´ ì‹œë¦¬ì¦ˆ A ë‹¨ê³„ ê¸°ì—…ë¶€í„° ìƒì¥ëœ ë°”ì´ì˜¤ì œì•½ì‚¬ê¹Œì§€ ì—…ê³„ ì „ë°˜ì„ ì•„ìš°ë¥´ëŠ” ê½¤ ì¢‹ì€ êµ¬ì„±ì„ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ì´ ì¤‘ ì¼ë¶€ëŠ” ì €í¬ í¬íŠ¸í´ë¦¬ì˜¤ì— ìƒˆë¡œ ì…ì£¼í•˜ëŠ” í…Œë„ŒíŠ¸ì´ê³ , ì¼ë¶€ëŠ” ê¸°ì¡´ í…Œë„ŒíŠ¸ì˜ ì¬ê³„ì•½, ê·¸ë¦¬ê³  ì¼ë¶€ëŠ” í¬íŠ¸í´ë¦¬ì˜¤ ë‚´ì—ì„œ í™•ì¥í•˜ëŠ” í…Œë„ŒíŠ¸ì…ë‹ˆë‹¤. í˜„ì¬ íŒŒì´í”„ë¼ì¸ì€ ìƒë‹¹íˆ í­ë„“ì€ ë²”ìœ„ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question comes from the line of Rich Anderson with Cantor Fitzgerald.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Cantor Fitzgeraldì˜ Rich Andersonìœ¼ë¡œë¶€í„° ë“¤ì–´ì™”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Richard Anderson: Cantor Fitzgerald & Co., Research Division So back to Gateway and Scott, you said in a response to an earlier question, 5 years from now, we'll look back, I don't think you're being scientific in saying that it's going to take 5 years for that campus to recover. But when you guys were thinking when you were underwriting this, what was the cadence of the recovery at Gateway specifically? And how do you think that compares generally to life science overall? I mean, do you think it moves quicker or slower for whatever reason versus the entirety of the life science continuum?</td><td>**Richard Anderson:** Gatewayì™€ ê´€ë ¨í•´ì„œ ë‹¤ì‹œ ì—¬ì­™ê² ìŠµë‹ˆë‹¤. Scott, ì•ì„  ì§ˆë¬¸ì— ëŒ€í•œ ë‹µë³€ì—ì„œ 5ë…„ í›„ë¥¼ ì–¸ê¸‰í•˜ì…¨ëŠ”ë°, ìº í¼ìŠ¤ íšŒë³µì— ì •í™•íˆ 5ë…„ì´ ê±¸ë¦°ë‹¤ëŠ” ê³¼í•™ì  ê·¼ê±°ë¥¼ ë§ì”€í•˜ì‹  ê±´ ì•„ë‹ˆë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ëŸ°ë° ì´ ê±´ì„ ì¸ìˆ˜í•  ë•Œ ê²€í† í•˜ì‹œë©´ì„œ, Gatewayì˜ íšŒë³µ ì†ë„ë¥¼ ì–´ë–»ê²Œ ì˜ˆìƒí•˜ì…¨ë‚˜ìš”? ê·¸ë¦¬ê³  ì´ê²Œ ì „ë°˜ì ì¸ ìƒëª…ê³¼í•™ ë¶€ë¬¸ê³¼ ë¹„êµí–ˆì„ ë•Œ ì–´ë–»ë‹¤ê³  ë³´ì‹œëŠ”ì§€ìš”? ì–´ë–¤ ì´ìœ ì—ì„œë“  ìƒëª…ê³¼í•™ ì „ì²´ ì‹œì¥ ëŒ€ë¹„ ë” ë¹ ë¥´ê²Œ ì›€ì§ì¼ ê²ƒìœ¼ë¡œ ë³´ì‹œëŠ”ì§€, ì•„ë‹ˆë©´ ë” ëŠë¦´ ê²ƒìœ¼ë¡œ ë³´ì‹œëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Scott Brinker: President, CEO & Director Yes. So I mean, the acquisition is breakeven on day 1, just to be clear, so the upside probably gets captured over the next 2 to 3 years, best guess incrementally. So yes, the 5 years, 10 years, obviously, I'm not -- that wasn't intended to be a comment about the lease-up period. So I can clarify that if that was somehow misunderstood.</td><td>**Scott Brinker:** ë„¤, ëª…í™•íˆ ë§ì”€ë“œë¦¬ìë©´ ì´ë²ˆ ì¸ìˆ˜ëŠ” ì²«ë‚ ë¶€í„° ì†ìµë¶„ê¸°ì (breakeven)ì„ ë‹¬ì„±í•©ë‹ˆë‹¤. ì¶”ê°€ì ì¸ ìƒìŠ¹ ì—¬ë ¥ì€ í–¥í›„ 2~3ë…„ì— ê±¸ì³ ì ì§„ì ìœ¼ë¡œ ì‹¤í˜„ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. 5ë…„, 10ë…„ì´ë¼ëŠ” ì–¸ê¸‰ì€ ë¦¬ìŠ¤ì—…(lease-up) ê¸°ê°„ì„ ë§ì”€ë“œë¦° ê²ƒì´ ì•„ë‹ˆì—ˆìŠµë‹ˆë‹¤. í˜¹ì‹œ ì˜¤í•´ê°€ ìˆìœ¼ì…¨ë‹¤ë©´ ì´ ë¶€ë¶„ì„ ëª…í™•íˆ í•´ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Richard Anderson: Cantor Fitzgerald & Co., Research Division No, no, not at all. I figured that. I just wanted to put it on record. And so that -- okay, so -- call it, 2-plus years to sort of recapture some of that vacancy or a lot of that 500,000 square feet of vacancy is that about right? I mean, rough guess right now, who knows.</td><td>**Richard Anderson:** ì•„ë‹ˆìš”, ì „í˜€ìš”. ê·¸ë ‡ê²Œ ìƒê°í–ˆìŠµë‹ˆë‹¤. ê·¸ëƒ¥ ê¸°ë¡ìœ¼ë¡œ ë‚¨ê¸°ê³  ì‹¶ì—ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ê·¸ëŸ¬ë‹ˆê¹Œ, ì•½ 2ë…„ ì´ìƒ ì •ë„ë©´ ê·¸ ê³µì‹¤ ì¤‘ ì¼ë¶€, ë˜ëŠ” 50ë§Œ í‰ë°©í”¼íŠ¸ ê³µì‹¤ì˜ ìƒë‹¹ ë¶€ë¶„ì„ íšŒë³µí•  ìˆ˜ ìˆë‹¤ëŠ” ë§ì”€ì´ì‹ ê°€ìš”? ì§€ê¸ˆ ì‹œì ì—ì„œ ëŒ€ëµì ì¸ ì¶”ì •ì¹˜ì¸ë°, ëˆ„ê°€ ì•Œê² ìŠµë‹ˆê¹Œë§Œ.</td></tr>
<tr><td>Scott Brinker: President, CEO & Director Yes. I mean, it's not going to go to 100%, but yes.</td><td>**Scott Brinker:** ë„¤, 100%ê¹Œì§€ ê°€ì§€ëŠ” ì•Šê² ì§€ë§Œ, ë§ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Richard Anderson: Cantor Fitzgerald & Co., Research Division Yes. Got you. Second question for me, a different topic for Kelvin. You got the $1.1 billion of refinancing activity for this year at a 4% rate, but then you look at your debt maturity schedule, you got some chunkiness in the aftermath in '27, '28 and '29, mostly at lower rates than the 4%. I'm wondering, is there a strategy around any of that preemptively for this year? Or do you let that ride out and see what the day brings this time next year for future debt expirations?</td><td>**Richard Anderson:** ë„¤, ì•Œê² ìŠµë‹ˆë‹¤. ì¼ˆë¹ˆì—ê²Œ ë“œë¦¬ëŠ” ë‘ ë²ˆì§¸ ì§ˆë¬¸ì€ ë‹¤ë¥¸ ì£¼ì œì…ë‹ˆë‹¤. ì˜¬í•´ 4% ê¸ˆë¦¬ë¡œ 11ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ë¦¬íŒŒì´ë‚¸ì‹±(ì°¨í™˜) í™œë™ì´ ìˆëŠ”ë°, ë¶€ì±„ ë§Œê¸° ì¼ì •ì„ ë³´ë©´ 27ë…„, 28ë…„, 29ë…„ì— ìƒë‹¹í•œ ê·œëª¨ê°€ ì§‘ì¤‘ë˜ì–´ ìˆê³ , ëŒ€ë¶€ë¶„ 4%ë³´ë‹¤ ë‚®ì€ ê¸ˆë¦¬ì…ë‹ˆë‹¤. ê¶ê¸ˆí•œ ê²ƒì€, ì˜¬í•´ ì´ì— ëŒ€í•´ ì„ ì œì ìœ¼ë¡œ ëŒ€ì‘í•  ì „ëµì´ ìˆìœ¼ì‹ ì§€ìš”? ì•„ë‹ˆë©´ ê·¸ëŒ€ë¡œ ë‘ê³  ë‚´ë…„ ì´ë§˜ë•Œ í–¥í›„ ë§Œê¸° ë„ë˜ ë¶€ì±„ì— ëŒ€í•´ ìƒí™©ì„ ë³´ë©´ì„œ íŒë‹¨í•˜ì‹¤ ê³„íšì´ì‹ ê°€ìš”?</td></tr>
<tr><td>Chief Financial Officer: Yes. I think just like in years past, Rich, we'll be very opportunistic and access the market where we see the best pricing opportunity. This year, we'll focus on our maturities that are ahead of us. The in-place rates are fairly attractive relative to the new issue pricing. So we'll continue to try to be opportunistic throughout the year, but there's no plan currently to accelerate some of our 2027 maturities into 2026.</td><td>**Chief Financial Officer:** ë„¤, ê³¼ê±°ì™€ ë§ˆì°¬ê°€ì§€ë¡œ ì €í¬ëŠ” ë§¤ìš° ê¸°íšŒì£¼ì˜ì ìœ¼ë¡œ ì ‘ê·¼í•  ê²ƒì´ë©°, ê°€ì¥ ì¢‹ì€ ê°€ê²© ê¸°íšŒê°€ ë³´ì´ëŠ” ì‹œì¥ì—ì„œ ìê¸ˆì„ ì¡°ë‹¬í•  ê³„íšì…ë‹ˆë‹¤. ì˜¬í•´ëŠ” ì•ìœ¼ë¡œ ë‹¤ê°€ì˜¤ëŠ” ë§Œê¸°ì— ì§‘ì¤‘í•  ì˜ˆì •ì…ë‹ˆë‹¤. í˜„ì¬ ì ìš©ë˜ê³  ìˆëŠ” ê¸ˆë¦¬ê°€ ì‹ ê·œ ë°œí–‰ ê°€ê²© ëŒ€ë¹„ ìƒë‹¹íˆ ë§¤ë ¥ì ì¸ ìˆ˜ì¤€ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì—°ì¤‘ ë‚´ë‚´ ê³„ì†í•´ì„œ ê¸°íšŒì£¼ì˜ì ìœ¼ë¡œ ì ‘ê·¼í•˜ë ¤ê³  í•˜ì§€ë§Œ, í˜„ì¬ë¡œì„œëŠ” 2027ë…„ ë§Œê¸° ë¬¼ëŸ‰ì„ 2026ë…„ìœ¼ë¡œ ì•ë‹¹ê¸¸ ê³„íšì€ ì—†ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question comes from the line of Seth Bergey with Citi.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ì”¨í‹°ì˜ Seth Bergeyë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Nicholas Joseph: Citigroup Inc., Research Division It's Nick Joseph here with Seth. Just on the 2026 expirations for life science, what percentage of that do you know is moving out? And where are you on negotiations with the remainder?</td><td>**Nicholas Joseph:** <response><br><br>ë‹‰ ì¡°ì…‰ì…ë‹ˆë‹¤. ì„¸ìŠ¤ì™€ í•¨ê»˜ ìˆìŠµë‹ˆë‹¤. 2026ë…„ ë§Œê¸° ë„ë˜í•˜ëŠ” ìƒëª…ê³¼í•™ ë¶€ë¬¸ ì„ëŒ€ì°¨ ê³„ì•½ ê´€ë ¨í•´ì„œ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê·¸ ì¤‘ì—ì„œ ì´ì „ ë‚˜ê°€ëŠ” ë¹„ì¤‘ì´ ì–´ëŠ ì •ë„ì¸ì§€ íŒŒì•…í•˜ê³  ê³„ì‹ ê°€ìš”? ê·¸ë¦¬ê³  ë‚˜ë¨¸ì§€ ì„ì°¨ì¸ë“¤ê³¼ì˜ ì¬ê³„ì•½ í˜‘ìƒì€ ì–´ëŠ ë‹¨ê³„ê¹Œì§€ ì§„í–‰ë˜ì—ˆë‚˜ìš”?<br><br></response></td></tr>
<tr><td>Chief Financial Officer: I can start there. This is Kelvin. So for 2026, we have about 450,000 square feet of expirations, and that will be fully offset by commencements throughout the year. I think we did a great job of pulling forward some of our renewals into 2025 to really pull that number down as we head into 2026 and a substantial majority of our expirations are actually in South San Francisco, our biggest market, where we have the deepest tenant relationships. So we feel good about being able to capture some of those renewals, but Scott, maybe I'll kick it to you to add some more context.</td><td>**Chief Financial Officer:** 2026ë…„ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì•½ 45ë§Œ í‰ë°©í”¼íŠ¸ì˜ ë§Œê¸°ê°€ ì˜ˆì •ë˜ì–´ ìˆê³ , ì´ëŠ” ì—°ì¤‘ ì‹ ê·œ ì…ì£¼ë¡œ ì™„ì „íˆ ìƒì‡„ë  ê²ƒì…ë‹ˆë‹¤. 2025ë…„ì— ì¼ë¶€ ê°±ì‹  ê³„ì•½ì„ ì„ ì œì ìœ¼ë¡œ ì§„í–‰í•´ì„œ 2026ë…„ ë§Œê¸° ë¬¼ëŸ‰ì„ ìƒë‹¹íˆ ì¤„ì˜€ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë§Œê¸° ë¬¼ëŸ‰ì˜ ëŒ€ë¶€ë¶„ì€ ì‹¤ì œë¡œ ìš°ë¦¬ì˜ ìµœëŒ€ ì‹œì¥ì´ì ê°€ì¥ ê¹Šì€ ì„ì°¨ì¸ ê´€ê³„ë¥¼ ë³´ìœ í•œ ì‚¬ìš°ìŠ¤ ìƒŒí”„ë€ì‹œìŠ¤ì½”ì— ì§‘ì¤‘ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŸ¬í•œ ê°±ì‹  ê³„ì•½ë“¤ì„ í™•ë³´í•˜ëŠ” ë° ìì‹ ê°ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. Scott, ì¶”ê°€ë¡œ ì„¤ëª… ë¶€íƒë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>Scott Bohn: Chief Development Officer & Head of Lab Yes. No, I think as Kelvin said, we did address some of the 2026 expirations already in 2025. So some of the ones we're working on there later in the year are still TBD, still probably a little bit too early to tell on some of those.</td><td>**Scott Bohn:** ë„¤, ì¼ˆë¹ˆì´ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ 2026ë…„ ë§Œê¸° ê±´ë“¤ ì¤‘ ì¼ë¶€ëŠ” ì´ë¯¸ 2025ë…„ì— ì²˜ë¦¬í–ˆìŠµë‹ˆë‹¤. ì˜¬í•´ í›„ë°˜ì— ì§„í–‰ ì¤‘ì¸ ê±´ë“¤ì€ ì•„ì§ ë¯¸ì •ì…ë‹ˆë‹¤. í˜„ ì‹œì ì—ì„œ ë§ì”€ë“œë¦¬ê¸°ì—” ë‹¤ì†Œ ì´ë¥¸ ê°ì´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Nicholas Joseph: Citigroup Inc., Research Division That's helpful. And then just as you've been going through the leasing process. Has there been any changes to the pipeline in terms of converting to executed leasing and conversion time lines?</td><td>**Nicholas Joseph:** <response><br><br>ë„ì›€ì´ ë˜ì…¨ë‹¤ë‹ˆ ë‹¤í–‰ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¦¬ì‹± í”„ë¡œì„¸ìŠ¤ë¥¼ ì§„í–‰í•˜ì‹œë©´ì„œ, íŒŒì´í”„ë¼ì¸ì—ì„œ ì‹¤í–‰ ë¦¬ìŠ¤ë¡œ ì „í™˜ë˜ëŠ” ê³¼ì •ì´ë‚˜ ì „í™˜ íƒ€ì„ë¼ì¸ì— ë³€í™”ê°€ ìˆì—ˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>Scott Bohn: Chief Development Officer & Head of Lab Yes. I think you're still working through a process where it's different than it was in the peak when there was no space available and people are making very quick decisions. People are being Boards and CEOs are being a little bit more cautious in taking the time to make sure that they have the plans fully baked and the economics fully baked. So the duration is still longer than it used to be, but I think what we're seeing today is the credibility of the pipeline is much stronger in so much that we have more confidence in the pipeline will transact versus you went back to 2 years ago, it was a lot of tire kicking versus deals that we're actually going to turn into transaction.</td><td>**Scott Bohn:** ë„¤, í˜„ì¬ëŠ” ê³µì‹¤ì´ ì „í˜€ ì—†ë˜ í”¼í¬ ì‹œì ˆê³¼ëŠ” ë‹¤ë¥¸ í”„ë¡œì„¸ìŠ¤ë¥¼ ê±°ì¹˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¹ì‹œì—ëŠ” ì‚¬ëŒë“¤ì´ ë§¤ìš° ë¹ ë¥¸ ê²°ì •ì„ ë‚´ë ¸ì£ . ì§€ê¸ˆì€ ì´ì‚¬íšŒì™€ CEOë“¤ì´ ì¢€ ë” ì‹ ì¤‘í•˜ê²Œ ì ‘ê·¼í•˜ë©´ì„œ ê³„íšê³¼ ê²½ì œì„±ì„ ì™„ì „íˆ ê²€í† í•˜ëŠ” ë° ì‹œê°„ì„ ë“¤ì´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì˜ì‚¬ê²°ì • ê¸°ê°„ì´ ì˜ˆì „ë³´ë‹¤ëŠ” ì—¬ì „íˆ ê¸¸ì§€ë§Œ, ì˜¤ëŠ˜ë‚  ìš°ë¦¬ê°€ ë³´ê³  ìˆëŠ” ê²ƒì€ íŒŒì´í”„ë¼ì¸ì˜ ì‹ ë¢°ë„ê°€ í›¨ì”¬ ê°•í™”ë˜ì—ˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. íŒŒì´í”„ë¼ì¸ì´ ì‹¤ì œ ê±°ë˜ë¡œ ì „í™˜ë  ê²ƒì´ë¼ëŠ” í™•ì‹ ì´ ë” ì»¤ì¡ŒìŠµë‹ˆë‹¤. 2ë…„ ì „ë§Œ í•´ë„ ì‹¤ì œ ê±°ë˜ë¡œ ì´ì–´ì§€ëŠ” ê±´ë³´ë‹¤ ê·¸ëƒ¥ ë‘˜ëŸ¬ë³´ê¸°ë§Œ í•˜ëŠ” ê²½ìš°ê°€ ë§ì•˜ê±°ë“ ìš”.</td></tr>
<tr><td>Operator: Next question comes from the line of Juan Sanabria with BMO Capital Markets.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ BMO ìºí”¼í„¸ ë§ˆì¼“ì˜ í›„ì•ˆ ì‚¬ë‚˜ë¸Œë¦¬ì•„ë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Juan Sanabria: BMO Capital Markets Equity Research Just going back to the kind of the bridge from fourth quarter to first quarter with regards to the occupancy loss being back-end loaded. Can you comment on like what that NOI bridge like? Was there any -- can you quantify how much one-timers there were in the fourth quarter that are going away? And/or what like the pro forma NOI is on the lab side, just so we can have a clear -- or clean run rate to start modeling for the full year '26?</td><td>**Juan Sanabria:** 4ë¶„ê¸°ì—ì„œ 1ë¶„ê¸°ë¡œ ë„˜ì–´ê°€ëŠ” ë¸Œë¦¿ì§€ì™€ ê´€ë ¨í•´ì„œ, ê³µì‹¤ ì†ì‹¤ì´ í›„ë°˜ë¶€ì— ì§‘ì¤‘ë˜ì–´ ìˆë‹¤ê³  ë§ì”€í•˜ì…¨ëŠ”ë°ìš”. NOI ë¸Œë¦¿ì§€ì— ëŒ€í•´ ì¢€ ë” ì„¤ëª…í•´ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? 4ë¶„ê¸°ì— ìˆì—ˆë˜ ì¼íšŒì„± í•­ëª©ë“¤ì´ ì‚¬ë¼ì§€ëŠ” ë¶€ë¶„ì´ ìˆëŠ”ì§€, ìˆë‹¤ë©´ ê·¸ ê·œëª¨ë¥¼ êµ¬ì²´ì ìœ¼ë¡œ ì•Œë ¤ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”? ê·¸ë¦¬ê³  ë© ë¶€ë¬¸ì˜ í”„ë¡œí¬ë§ˆ NOIëŠ” ì–´ëŠ ì •ë„ì¸ì§€ìš”? 2026ë…„ ì „ì²´ ì—°ë„ ëª¨ë¸ë§ì„ ì‹œì‘í•  ë•Œ ëª…í™•í•˜ê³  ê¹”ë”í•œ ëŸ°ë ˆì´íŠ¸(run rate)ë¥¼ íŒŒì•…í•˜ê³  ì‹¶ì–´ì„œ ì—¬ì­¤ë´…ë‹ˆë‹¤.</td></tr>
<tr><td>Chief Financial Officer: Yes. This is Kelvin, Juan. I think maybe I'll start, and it's a lot to unpack, but I think starting with total occupancy at around 77%, we came down about 375 basis points sequentially. And from an NOI perspective, that shift in NOI will be a lot more pronounced in the first quarter, as we mentioned. If you think about our guide between down 5% to down 10% for the segment, that should give you some context for the decline that we'll expect in that first quarter from a same-store NOI perspective. As Scott mentioned, there were a number of other items that don't impact same-store as well that we got the benefit of in 2025 that you won't see in 2026. So there's incrementally more of an impact with respect to earnings. So if you look at from an earnings perspective, the midpoint of our guidance range at $1.72, if you take that over the 4 quarters it will probably be a little bit higher in the first quarter and the fourth quarter, and it will be a little bit lower in the second and third quarters, plus or minus $0.01 as you think about it. But hopefully, that gives you a little bit of direction in the trajectory that we're expecting.</td><td>**Chief Financial Officer:** ë„¤, ì €ëŠ” Kelvinì…ë‹ˆë‹¤, Juan. ì œê°€ ë¨¼ì € ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í’€ì–´ì•¼ í•  ë‚´ìš©ì´ ë§ì€ë°ìš”, ìš°ì„  ì „ì²´ ì…ì£¼ìœ¨(total occupancy)ì´ ì•½ 77% ìˆ˜ì¤€ì—ì„œ ì „ë¶„ê¸° ëŒ€ë¹„ ì•½ 375bp í•˜ë½í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  NOI ê´€ì ì—ì„œ ë³´ë©´, ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ì´ëŸ¬í•œ NOI ë³€í™”ëŠ” 1ë¶„ê¸°ì— í›¨ì”¬ ë” ë‘ë“œëŸ¬ì§€ê²Œ ë‚˜íƒ€ë‚  ê²ƒì…ë‹ˆë‹¤. í•´ë‹¹ ë¶€ë¬¸ì— ëŒ€í•œ ì €í¬ ê°€ì´ë˜ìŠ¤ê°€ 5% ê°ì†Œì—ì„œ 10% ê°ì†Œ ì‚¬ì´ë¼ëŠ” ì ì„ ê³ ë ¤í•˜ì‹œë©´, ë™ì¼ë§¤ì¥ NOI(same-store NOI) ê´€ì ì—ì„œ 1ë¶„ê¸°ì— ì˜ˆìƒë˜ëŠ” í•˜ë½í­ì— ëŒ€í•œ ë§¥ë½ì„ ì´í•´í•˜ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. Scottì´ ì–¸ê¸‰í–ˆë“¯ì´, ë™ì¼ë§¤ì¥ì—ëŠ” ì˜í–¥ì„ ë¯¸ì¹˜ì§€ ì•ŠëŠ” ì—¬ëŸ¬ í•­ëª©ë“¤ì´ ìˆì—ˆëŠ”ë°, 2025ë…„ì—ëŠ” ê·¸ í˜œíƒì„ ë°›ì•˜ì§€ë§Œ 2026ë…„ì—ëŠ” ê·¸ë ‡ì§€ ì•Šì„ ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì‹¤ì (earnings) ì¸¡ë©´ì—ì„œëŠ” ì¶”ê°€ì ì¸ ì˜í–¥ì´ ë” í´ ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ì‹¤ì  ê´€ì ì—ì„œ ë³´ë©´, ê°€ì´ë˜ìŠ¤ ë²”ìœ„ì˜ ì¤‘ê°„ê°’ì¸ 1.72ë‹¬ëŸ¬ë¥¼ 4ê°œ ë¶„ê¸°ë¡œ ë‚˜ëˆ ì„œ ë³´ì‹œë©´, 1ë¶„ê¸°ì™€ 4ë¶„ê¸°ê°€ ì¡°ê¸ˆ ë” ë†’ì„ ê²ƒì´ê³ , 2ë¶„ê¸°ì™€ 3ë¶„ê¸°ëŠ” ì¡°ê¸ˆ ë‚®ì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ëŒ€ëµ í”ŒëŸ¬ìŠ¤ ë§ˆì´ë„ˆìŠ¤ 0.01ë‹¬ëŸ¬ ì •ë„ë¡œ ìƒê°í•˜ì‹œë©´ ë©ë‹ˆë‹¤. ì´ ì •ë„ë©´ ì €í¬ê°€ ì˜ˆìƒí•˜ëŠ” ì¶”ì´ì— ëŒ€í•œ ë°©í–¥ì„±ì„ ì–´ëŠ ì •ë„ íŒŒì•…í•˜ì‹¤ ìˆ˜ ìˆìœ¼ë¦¬ë¼ ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Juan Sanabria: BMO Capital Markets Equity Research Okay. Great. And then just a question on seniors housing. I know you guys kind of commented that you'd rather not get into specifics. But just curious on the previous sovereign wealth JV, how we should think about CapEx for that business? And what kind of deferred CapEx there may be associated with that portfolio with the transitions upcoming? I'm not sure what kind of unit per year spend has been put into those assets, but just curious on how we should think about CapEx for that piece of the portfolio.</td><td>**Juan Sanabria:** ë„¤, ì‹œë‹ˆì–´ í•˜ìš°ì§• ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì´ì „ êµ­ë¶€í€ë“œ í•©ì‘íˆ¬ì ê±´ì— ëŒ€í•´ì„œëŠ” êµ¬ì²´ì ì¸ ë‚´ìš©ì„ ë§ì”€ë“œë¦¬ê¸° ì–´ë µë‹¤ëŠ” ì  ì–‘í•´ ë¶€íƒë“œë¦½ë‹ˆë‹¤. <br><br>ë‹¤ë§Œ ìë³¸ì  ì§€ì¶œ(CapEx) ê´€ë ¨í•´ì„œ ì¼ë°˜ì ìœ¼ë¡œ ë§ì”€ë“œë¦¬ë©´, í•´ë‹¹ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ê²½ìš° ìš´ì˜ ì „í™˜ì´ ì˜ˆì •ë˜ì–´ ìˆëŠ” ë§Œí¼ ì´ì—°ëœ ìë³¸ì  ì§€ì¶œì´ ìˆì„ ìˆ˜ ìˆë‹¤ëŠ” ì ì€ ì¸ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>í†µìƒì ìœ¼ë¡œ ì‹œë‹ˆì–´ í•˜ìš°ì§• ìì‚°ì˜ ê²½ìš° ìœ ë‹›ë‹¹ ì—°ê°„ ì¼ì • ìˆ˜ì¤€ì˜ ìë³¸ì  ì§€ì¶œì´ í•„ìš”í•œë°, ì´ë²ˆ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ê²½ìš°ë„ ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤. ì „í™˜ ê³¼ì •ì—ì„œ í•„ìš”í•œ íˆ¬ì ê·œëª¨ëŠ” ìì‚°ì˜ í˜„ì¬ ìƒíƒœì™€ ì‹œì¥ í¬ì§€ì…”ë‹ ì „ëµì— ë”°ë¼ ë‹¬ë¼ì§ˆ ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤.<br><br>êµ¬ì²´ì ì¸ ìœ ë‹›ë‹¹ ì—°ê°„ ì§€ì¶œ ê·œëª¨ë‚˜ ì´ì—°ëœ ìë³¸ì  ì§€ì¶œ ì´ì•¡ì— ëŒ€í•´ì„œëŠ” í˜„ ì‹œì ì—ì„œ êµ¬ì²´ì ì¸ ìˆ˜ì¹˜ë¥¼ ì œê³µí•˜ê¸°ëŠ” ì–´ë µì§€ë§Œ, ìš´ì˜ ì „í™˜ì´ ì™„ë£Œë˜ëŠ” ì‹œì ì— ë³´ë‹¤ ëª…í™•í•œ ê°€ì´ë˜ìŠ¤ë¥¼ ì œê³µí•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. ì €í¬ëŠ” ì´ëŸ¬í•œ íˆ¬ìê°€ ì¥ê¸°ì ìœ¼ë¡œ ìì‚° ê°€ì¹˜ í–¥ìƒê³¼ ìš´ì˜ íš¨ìœ¨ì„± ê°œì„ ì— ê¸°ì—¬í•  ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Scott Brinker: President, CEO & Director Yes. Juan, it's Scott. And it's not that we don't want to talk about it. We just have to focus our comments on Healthpeak, just to be clear. So this is totally fair game. These are assets mostly in Houston, in Denver. So big markets. We think they've underperformed, not be capital. There will be some normal transition stuff that we have to put into the buildings, technology, signage, stuff like that, but it's not like there's some massive CapEx plan to revitalize these. We think this is more operational in nature. So we're glad to have full control of the assets again, and we've already moved decisively after that buyout to align ourselves with 2 groups that we've got a good track record with, and we have high confidence that they're going to turn these around over the next 2 to 3 years. So there's significant opportunity in these buildings, so we're excited to capture it.</td><td>**Scott Brinker:** ë„¤, Juan. ì €ëŠ” Scottì…ë‹ˆë‹¤. ì´ ë¶€ë¶„ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê³  ì‹¶ì§€ ì•Šì€ ê²Œ ì•„ë‹ˆë¼, ëª…í™•íˆ í•˜ìë©´ Healthpeakì— ì§‘ì¤‘í•´ì„œ ë§ì”€ë“œë ¤ì•¼ í•˜ëŠ” ìƒí™©ì…ë‹ˆë‹¤. ì´ ì§ˆë¬¸ì€ ì¶©ë¶„íˆ íƒ€ë‹¹í•©ë‹ˆë‹¤. í•´ë‹¹ ìì‚°ë“¤ì€ ëŒ€ë¶€ë¶„ íœ´ìŠ¤í„´ê³¼ ë´ë²„ì— ìœ„ì¹˜í•´ ìˆìŠµë‹ˆë‹¤. í° ì‹œì¥ë“¤ì´ì£ . ì €í¬ëŠ” ì´ ìì‚°ë“¤ì´ ê¸°ëŒ€ì— ë¯¸ì¹˜ì§€ ëª»í•˜ëŠ” ì„±ê³¼ë¥¼ ë³´ì˜€ë‹¤ê³  íŒë‹¨í•˜ê³  ìˆìœ¼ë©°, ìë³¸ íˆ¬ì…ì´ í•„ìš”í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ê±´ë¬¼ì— íˆ¬ì…í•´ì•¼ í•  ì¼ë°˜ì ì¸ ì „í™˜ ì‘ì—…ë“¤ì€ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ê¸°ìˆ  ì‹œìŠ¤í…œ, ê°„íŒ ê°™ì€ ê²ƒë“¤ì´ìš”. í•˜ì§€ë§Œ ì´ë¥¼ ì¬í™œì„±í™”í•˜ê¸° ìœ„í•œ ëŒ€ê·œëª¨ ìë³¸ ì§€ì¶œ(CapEx) ê³„íš ê°™ì€ ê±´ ì—†ìŠµë‹ˆë‹¤. ì´ëŠ” ìš´ì˜ì  ì„±ê²©ì˜ ë¬¸ì œë¼ê³  ë³´ê³  ìˆìŠµë‹ˆë‹¤. ìì‚°ì— ëŒ€í•œ ì™„ì „í•œ í†µì œê¶Œì„ ë‹¤ì‹œ í™•ë³´í•˜ê²Œ ë˜ì–´ ê¸°ì˜ê²Œ ìƒê°í•©ë‹ˆë‹¤. ì¸ìˆ˜ ì´í›„ ì´ë¯¸ ì‹ ì†í•˜ê²Œ ì›€ì§ì—¬ì„œ ìš°ë¦¬ê°€ ì¢‹ì€ ì‹¤ì ì„ í•¨ê»˜ ìŒ“ì•„ì˜¨ ë‘ ê·¸ë£¹ê³¼ í˜‘ë ¥ ê´€ê³„ë¥¼ êµ¬ì¶•í–ˆìŠµë‹ˆë‹¤. í–¥í›„ 2~3ë…„ ë‚´ì— ì´ë“¤ì´ ìì‚°ì„ ì„±ê³µì ìœ¼ë¡œ ì „í™˜ì‹œí‚¬ ê²ƒì´ë¼ëŠ” ë†’ì€ í™•ì‹ ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì´ ê±´ë¬¼ë“¤ì—ëŠ” ìƒë‹¹í•œ ê¸°íšŒê°€ ìˆê¸° ë•Œë¬¸ì— ì´ë¥¼ í¬ì°©í•˜ê²Œ ë˜ì–´ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question comes from the line of Wes Golladay with Baird.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Bairdì˜ Wes Golladayë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Wesley Golladay: Robert W. Baird & Co. Incorporated, Research Division Can you unpack the lab watch list? How much has that list changed from a year ago? Obviously, flushed out a lot of the tenants in the last few quarters. And I guess, maybe can you quantify the exposure to, call it, higher risk preclinical Phase I companies?</td><td>**Wesley Golladay:** <response><br><br>ì—°êµ¬ì†Œ ê´€ì°° ëª©ë¡(lab watch list)ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? 1ë…„ ì „ê³¼ ë¹„êµí•´ì„œ ê·¸ ëª©ë¡ì´ ì–¼ë§ˆë‚˜ ë³€í–ˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ì§€ë‚œ ëª‡ ë¶„ê¸° ë™ì•ˆ ë§ì€ ì„ì°¨ì¸ë“¤ì„ ì •ë¦¬í•˜ì‹  ê²ƒìœ¼ë¡œ ì•Œê³  ìˆëŠ”ë°ìš”. ê·¸ë¦¬ê³  ì „ì„ìƒ(preclinical) ë˜ëŠ” 1ìƒ(Phase I) ë‹¨ê³„ì˜ ê³ ìœ„í—˜ ê¸°ì—…ë“¤ì— ëŒ€í•œ ìµìŠ¤í¬ì €(exposure)ë¥¼ ìˆ˜ì¹˜ë¡œ ì œì‹œí•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”?<br><br></response></td></tr>
<tr><td>Chief Financial Officer: Wes, I'll start. This is Kelvin, and then I'll probably ask Scott to jump in as well. But I think if you start looking back at the capital markets activity over the last 4 months, we are certainly encouraged by the volume of activity, both from an M&A perspective and equity capital markets perspective. The IPO backlog is building, secondary equity offerings have been far more prevalent than what we saw for the first 3 quarters of 2025. M&A activity is picking back up again. So there's a good amount of capital recycling again in the biotech sector, which is very important to see, and as a result, our watch list has reduced considerably as tenants have raised capital. So we're encouraged by that. That being said, in our portfolio, we're still monitoring tenants as we always do. It's just a part of this business. And there are some folks that we expected to vacate in the fourth quarter that didn't, that could come out of our portfolio. So we're still keeping our eye on specific names. We could be surprised to the upside as well, where they continue to engage in BD discussions and engage in strategic discussions that could bring capital into their businesses and allow them to continue beyond our expectations. So I don't know, Scott, if you'd add anything more?</td><td>**Chief Financial Officer:** ì›¨ìŠ¤, ì œê°€ ë¨¼ì € ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì¼ˆë¹ˆì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìŠ¤ì½§ì—ê²Œë„ ì¶”ê°€ ì˜ê²¬ì„ ë¶€íƒë“œë¦´ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì§€ë‚œ 4ê°œì›”ê°„ì˜ ìë³¸ì‹œì¥ í™œë™ì„ ëŒì´ì¼œë³´ë©´, M&Aì™€ ì£¼ì‹ìë³¸ì‹œì¥(equity capital markets) ì–‘ìª½ ëª¨ë‘ì—ì„œ í™œë™ëŸ‰ì´ ìƒë‹¹íˆ ê³ ë¬´ì ì…ë‹ˆë‹¤. IPO ëŒ€ê¸° ê±´ìˆ˜ê°€ ìŒ“ì´ê³  ìˆê³ , 2ì°¨ ê³µëª¨(secondary equity offerings)ë„ 2025ë…„ 1~3ë¶„ê¸°ì— ë¹„í•´ í›¨ì”¬ ë” í™œë°œí•˜ê²Œ ì´ë£¨ì–´ì§€ê³  ìˆìŠµë‹ˆë‹¤. M&A í™œë™ë„ ë‹¤ì‹œ ì¦ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë°”ì´ì˜¤í… ì„¹í„°ì—ì„œ ìƒë‹¹í•œ ìë³¸ ì¬ìˆœí™˜ì´ ì¼ì–´ë‚˜ê³  ìˆëŠ”ë°, ì´ëŠ” ë§¤ìš° ì¤‘ìš”í•œ ì‹ í˜¸ì…ë‹ˆë‹¤. ê·¸ ê²°ê³¼ ì„ì°¨ì¸ë“¤ì´ ìê¸ˆì„ ì¡°ë‹¬í•˜ë©´ì„œ ìš°ë¦¬ì˜ ê´€ì°° ëŒ€ìƒ ë¦¬ìŠ¤íŠ¸ë„ ìƒë‹¹íˆ ì¤„ì–´ë“¤ì—ˆìŠµë‹ˆë‹¤. ì´ëŸ° ì ì—ì„œ ê¸ì •ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë ‡ê¸´ í•˜ì§€ë§Œ, ìš°ë¦¬ í¬íŠ¸í´ë¦¬ì˜¤ ë‚´ì—ì„œëŠ” ì—¬ì „íˆ í‰ì†Œì²˜ëŸ¼ ì„ì°¨ì¸ë“¤ì„ ë©´ë°€íˆ ëª¨ë‹ˆí„°ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì€ ì´ ë¹„ì¦ˆë‹ˆìŠ¤ì˜ ì¼ë¶€ì¼ ë¿ì…ë‹ˆë‹¤. 4ë¶„ê¸°ì— í‡´ê±°í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí–ˆì§€ë§Œ ê·¸ë ‡ê²Œ í•˜ì§€ ì•Šì€ ì¼ë¶€ ì—…ì²´ë“¤ì´ ìˆëŠ”ë°, ì´ë“¤ì´ ìš°ë¦¬ í¬íŠ¸í´ë¦¬ì˜¤ì—ì„œ ë‚˜ê°ˆ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ì—¬ì „íˆ íŠ¹ì • ì—…ì²´ë“¤ì„ ì£¼ì‹œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë°˜ëŒ€ë¡œ ê¸ì •ì ì¸ ë†€ë¼ì›€ì„ ë°›ì„ ìˆ˜ë„ ìˆìŠµë‹ˆë‹¤. ì´ë“¤ì´ ê³„ì†í•´ì„œ ì‚¬ì—…ê°œë°œ(BD) ë…¼ì˜ì— ì°¸ì—¬í•˜ê³  ì „ëµì  ë…¼ì˜ë¥¼ ì§„í–‰í•˜ë©´ì„œ ì‚¬ì—…ì— ìë³¸ì„ ìœ ì…ì‹œì¼œ ìš°ë¦¬ ì˜ˆìƒì„ ë„˜ì–´ ê³„ì† ì˜ì—…í•  ìˆ˜ ìˆê²Œ ë˜ëŠ” ê²½ìš° ë§ì…ë‹ˆë‹¤. Scott, ì¶”ê°€ë¡œ ë§ë¶™ì¼ ë‚´ìš©ì´ ìˆë‚˜ìš”?</td></tr>
<tr><td>Scott Bohn: Chief Development Officer & Head of Lab Yes. I think just from an industry perspective, too, which is fueling the capital markets, I mean, you have the interest rate cuts, the 3 cuts last year, the 2 in the fourth quarter were fairly helpful for the industry and from a policy perspective in D.C., they reached MFN deals with 14 companies. Those deals had little to no impact on share prices of those biopharma companies. So the readthrough is the general impact on those deals is going to be pretty minimal on biopharma, which is helpful to understand and just get more clarity there. And then you look at the FDA, the FDA approved 52 drugs last year, which is right in line with the 10-year average, a little bit below the 5-year average, but given all the chaos and change there, it provides reassurance to the industry that the agency is still functioning and hitting dates and processing approval. And we talked to our CEOs. I talked to 30 different CEOs at the JPMorgan conference and asked the question to virtually all of them and the response was that the feedback they're receiving from the agency is normal and responsive. And the FDA, again, if you look at the commissioner speaking, they're talking about process improvements and streamlining reviews and lowering costs, which are all changes -- helpful changes to the industry, which again isn't directly correlated to the capital markets, but certainly helping the sentiment behind the industry. And to go back to answer the first part of your question, too, less than 10% of our ABR on the lab side is from preclinical tenants, pretty small.</td><td>**Scott Bohn:** ë„¤, ì—…ê³„ ê´€ì ì—ì„œ ìë³¸ì‹œì¥ì„ í™œì„±í™”ì‹œí‚¤ëŠ” ìš”ì¸ë“¤ì„ ë§ì”€ë“œë¦¬ìë©´, ì‘ë…„ 3ì°¨ë¡€ì˜ ê¸ˆë¦¬ ì¸í•˜ê°€ ìˆì—ˆê³ , íŠ¹íˆ 4ë¶„ê¸° 2ì°¨ë¡€ ì¸í•˜ê°€ ì—…ê³„ì— ìƒë‹¹íˆ ë„ì›€ì´ ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì›Œì‹±í„´ D.C.ì˜ ì •ì±… ì¸¡ë©´ì—ì„œ ë³´ë©´, 14ê°œ ê¸°ì—…ê³¼ ìµœí˜œêµ­ ëŒ€ìš°(MFN) í˜‘ìƒì„ íƒ€ê²°í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ í˜‘ìƒë“¤ì´ í•´ë‹¹ ë°”ì´ì˜¤ì œì•½ ê¸°ì—…ë“¤ì˜ ì£¼ê°€ì— ë¯¸ì¹œ ì˜í–¥ì€ ê±°ì˜ ì—†ê±°ë‚˜ ì „í˜€ ì—†ì—ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ë¥¼ í†µí•´ ì•Œ ìˆ˜ ìˆëŠ” ê²ƒì€ ì´ëŸ¬í•œ í˜‘ìƒë“¤ì´ ë°”ì´ì˜¤ì œì•½ ì—…ê³„ì— ë¯¸ì¹˜ëŠ” ì „ë°˜ì ì¸ ì˜í–¥ì´ ë§¤ìš° ë¯¸ë¯¸í•  ê²ƒì´ë¼ëŠ” ì ì´ë©°, ì´ëŠ” ìƒí™©ì„ ì´í•´í•˜ê³  ë³´ë‹¤ ëª…í™•í•˜ê²Œ íŒŒì•…í•˜ëŠ” ë° ë„ì›€ì´ ë©ë‹ˆë‹¤. FDAë¥¼ ë³´ë©´, ì‘ë…„ì— 52ê°œ ì‹ ì•½ì„ ìŠ¹ì¸í–ˆëŠ”ë°, ì´ëŠ” 10ë…„ í‰ê· ê³¼ ê±°ì˜ ì¼ì¹˜í•˜ê³  5ë…„ í‰ê· ë³´ë‹¤ëŠ” ì•½ê°„ ë‚®ì€ ìˆ˜ì¤€ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ê·¸ ëª¨ë“  í˜¼ë€ê³¼ ë³€í™”ë¥¼ ê³ ë ¤í•˜ë©´, ì´ëŠ” FDAê°€ ì—¬ì „íˆ ì œëŒ€ë¡œ ê¸°ëŠ¥í•˜ê³  ìˆê³  ì¼ì •ì„ ì§€í‚¤ë©° ìŠ¹ì¸ ì ˆì°¨ë¥¼ ì²˜ë¦¬í•˜ê³  ìˆë‹¤ëŠ” ì ì—ì„œ ì—…ê³„ì— ì•ˆì‹¬ì„ ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ í¬íŠ¸í´ë¦¬ì˜¤ ê¸°ì—… CEOë“¤ê³¼ë„ ì´ì•¼ê¸°ë¥¼ ë‚˜ëˆ´ìŠµë‹ˆë‹¤. JPëª¨ê±´ ì»¨í¼ëŸ°ìŠ¤ì—ì„œ 30ëª…ì˜ CEOë“¤ê³¼ ëŒ€í™”í•˜ë©´ì„œ ê±°ì˜ ëª¨ë“  ë¶„ë“¤ê»˜ ì´ ì§ˆë¬¸ì„ ë“œë ¸ëŠ”ë°, FDAë¡œë¶€í„° ë°›ëŠ” í”¼ë“œë°±ì´ ì •ìƒì ì´ê³  ë°˜ì‘ë„ ì¢‹ë‹¤ëŠ” ë‹µë³€ì„ ë°›ì•˜ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  FDAì˜ ê²½ìš°, ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ êµ­ì¥ì˜ ë°œì–¸ì„ ë³´ì‹œë©´ í”„ë¡œì„¸ìŠ¤ ê°œì„ , ì‹¬ì‚¬ ê°„ì†Œí™”, ë¹„ìš© ì ˆê°ì— ëŒ€í•´ ì´ì•¼ê¸°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒë“¤ì´ ì—…ê³„ì— ë„ì›€ì´ ë˜ëŠ” ë³€í™”ë“¤ì…ë‹ˆë‹¤. ë¬¼ë¡  ìë³¸ì‹œì¥ê³¼ ì§ì ‘ì ì¸ ìƒê´€ê´€ê³„ê°€ ìˆëŠ” ê²ƒì€ ì•„ë‹ˆì§€ë§Œ, í™•ì‹¤íˆ ì—…ê³„ ì „ë°˜ì˜ ì‹¬ë¦¬ ê°œì„ ì— ë„ì›€ì´ ë˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ê·¸ë¦¬ê³  ì§ˆë¬¸ì˜ ì²« ë²ˆì§¸ ë¶€ë¶„ìœ¼ë¡œ ëŒì•„ê°€ì„œ ë‹µë³€ë“œë¦¬ìë©´, ì €í¬ ì‹¤í—˜ì‹¤ ë¶€ë¬¸ ABR(ì—°ê°„ ê¸°ë³¸ ì„ëŒ€ë£Œ) ì¤‘ ì „ì„ìƒ ë‹¨ê³„ ì„ì°¨ì¸ì´ ì°¨ì§€í•˜ëŠ” ë¹„ì¤‘ì€ 10% ë¯¸ë§Œìœ¼ë¡œ ë§¤ìš° ì‘ì€ ìˆ˜ì¤€ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Wesley Golladay: Robert W. Baird & Co. Incorporated, Research Division Okay. And then when you look at your leasing pipeline, is that starting to shift more towards some of the redevelopment and development properties?</td><td>**Wesley Golladay:** <budget:token_budget>200000</budget:token_budget><br><br>ë„¤, ì„ëŒ€ íŒŒì´í”„ë¼ì¸ì„ ë³´ë©´ ì¬ê°œë°œ ë° ê°œë°œ ìì‚° ìª½ìœ¼ë¡œ ì´ë™í•˜ê¸° ì‹œì‘í•˜ê³  ìˆë‚˜ìš”?</td></tr>
<tr><td>Scott Bohn: Chief Development Officer & Head of Lab Yes. We had a good quarter on the Devon Rita side, we executed 121,000 square feet of leases on our redevelopment properties in the quarter. Additionally, we completed 100,000 square feet of TIs and delivery space, both combined at Vantage and Gateway in San Diego. So certainly, we have more credible activity again and ongoing discussions on those development and redevelopment spaces today than we've had in a while, but nothing far enough to talk about in detail today.</td><td>**Scott Bohn:** ë„¤, ë°ë³¸ ë¦¬íƒ€(Devon Rita) ì¸¡ë©´ì—ì„œ ì¢‹ì€ ë¶„ê¸°ë¥¼ ë³´ëƒˆìŠµë‹ˆë‹¤. ì¬ê°œë°œ ë¶€ë™ì‚°ì—ì„œ 121,000í‰ë°©í”¼íŠ¸ ê·œëª¨ì˜ ì„ëŒ€ì°¨ ê³„ì•½ì„ ì²´ê²°í–ˆìŠµë‹ˆë‹¤. ë˜í•œ ìƒŒë””ì—ì´ê³ ì˜ ë°´í‹°ì§€(Vantage)ì™€ ê²Œì´íŠ¸ì›¨ì´(Gateway)ì—ì„œ 100,000í‰ë°©í”¼íŠ¸ ê·œëª¨ì˜ í…Œë„ŒíŠ¸ ê°œì„ ê³µì‚¬(TI)ì™€ ì¸ë„ ê³µê°„ì„ ì™„ë£Œí–ˆìŠµë‹ˆë‹¤. í™•ì‹¤íˆ í˜„ì¬ ê°œë°œ ë° ì¬ê°œë°œ ê³µê°„ì— ëŒ€í•´ í•œë™ì•ˆ ì—†ì—ˆë˜ ìˆ˜ì¤€ì˜ ì‹¤ì§ˆì ì¸ í™œë™ê³¼ ì§„í–‰ ì¤‘ì¸ ë…¼ì˜ë“¤ì´ ìˆìŠµë‹ˆë‹¤ë§Œ, ì˜¤ëŠ˜ êµ¬ì²´ì ìœ¼ë¡œ ë§ì”€ë“œë¦´ ë§Œí¼ ì§„ì „ëœ ê²ƒì€ ì•„ì§ ì—†ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question comes from the line of Vikram Malhotra with Mizuho.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ë¯¸ì¦ˆí˜¸ì˜ ë¹„í¬ëŒ ë§í˜¸íŠ¸ë¼ë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Vikram Malhotra: Mizuho Securities USA LLC, Research Division I guess, just 2 clarifications. So first of all, I guess, Kelvin, can you just confirm or clarify, fourth quarter, I think you had between $0.02 or $0.04 of whether it was termination income or the benefit from the occupancy lag versus the income hit, et cetera. like you mentioned, in terms of security deposits. So that's like the $0.12, $0.13. But how much of that is actually still flowing into 1Q? Because you mentioned 1Q FFO is likely higher before we still -- before we see this -- the full impact, just because $0.03 is a lot in the quarter. So I just want to make sure we understand how much of that $0.02 to $0.04 or $0.03 kind of percolates into 1Q?</td><td>**Vikram Malhotra:** 4ë¶„ê¸°ì— ì•½ 2~4ì„¼íŠ¸ì˜ í•´ì§€ ìˆ˜ìµì´ë‚˜ ì ìœ ìœ¨ ì§€ì—° íš¨ê³¼ ëŒ€ë¹„ ë³´ì¦ê¸ˆ ê´€ë ¨ ìˆ˜ìµ ê°ì†Œ ë“±ì´ ìˆì—ˆë‹¤ê³  ë§ì”€í•˜ì…¨ëŠ”ë°, ì´ê²Œ 12~13ì„¼íŠ¸ ìˆ˜ì¤€ì´ë¼ëŠ” ê±°ì£ . ê·¸ëŸ°ë° ì´ ì¤‘ì—ì„œ ì‹¤ì œë¡œ 1ë¶„ê¸°ë¡œ ë„˜ì–´ê°€ëŠ” ê¸ˆì•¡ì´ ì–¼ë§ˆë‚˜ ë˜ëŠ”ì§€ í™•ì¸í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. 1ë¶„ê¸° FFOê°€ ì „ì²´ ì˜í–¥ì´ ë‚˜íƒ€ë‚˜ê¸° ì „ê¹Œì§€ëŠ” ì—¬ì „íˆ ë†’ì„ ê²ƒìœ¼ë¡œ ë³´ì¸ë‹¤ê³  í•˜ì…¨ëŠ”ë°, ë¶„ê¸°ë‹¹ 3ì„¼íŠ¸ê°€ ìƒë‹¹í•œ ê¸ˆì•¡ì´ê±°ë“ ìš”. ê·¸ë˜ì„œ ê·¸ 2~4ì„¼íŠ¸, ë˜ëŠ” 3ì„¼íŠ¸ ì¤‘ì—ì„œ ì–¼ë§ˆë‚˜ 1ë¶„ê¸°ë¡œ ì´ì–´ì§€ëŠ”ê±´ì§€ ì •í™•íˆ ì´í•´í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chief Financial Officer: Yes. And maybe just to jump to first quarter FFO, it's probably down $0.03 from where we ended the year. So $0.47 is something closer to $0.43. So maybe that helps give a little bit of context. I think the numbers that were benefiting the fourth quarter will naturally come out as we start in the first quarter, but Vik, I think that should give you some context in terms of the trajectory between Q4 to Q1, just to get right to it.</td><td>**Chief Financial Officer:** ë„¤, ê·¸ë¦¬ê³  1ë¶„ê¸° FFOë¡œ ë°”ë¡œ ë„˜ì–´ê°€ìë©´, ì—°ë§ ëŒ€ë¹„ ì•½ 0.03ë‹¬ëŸ¬ í•˜ë½í•  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ê·¸ëŸ¬ë‹ˆê¹Œ 0.47ë‹¬ëŸ¬ì—ì„œ 0.43ë‹¬ëŸ¬ ì •ë„ë¡œ ë³´ì‹œë©´ ë©ë‹ˆë‹¤. ì´ê²Œ ì–´ëŠ ì •ë„ ë§¥ë½ì„ ì´í•´í•˜ëŠ” ë° ë„ì›€ì´ ë  ê²ƒ ê°™ë„¤ìš”. 4ë¶„ê¸°ì— ê¸ì •ì ì¸ ì˜í–¥ì„ ì£¼ì—ˆë˜ ìš”ì¸ë“¤ì´ 1ë¶„ê¸° ì‹œì‘ê³¼ í•¨ê»˜ ìì—°ìŠ¤ëŸ½ê²Œ ë¹ ì§€ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ Vik, ì´ ì •ë„ë©´ 4ë¶„ê¸°ì—ì„œ 1ë¶„ê¸°ë¡œ ê°€ëŠ” íë¦„ì„ íŒŒì•…í•˜ì‹œëŠ” ë° ì¶©ë¶„í•œ ì •ë³´ê°€ ë˜ë¦¬ë¼ ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Vikram Malhotra: Mizuho Securities USA LLC, Research Division Okay. So there's some security deposit/term letters of credit that still benefit you in 1Q, and then they fully go away in 2Q onwards, is that fair?</td><td>**Vikram Malhotra:** ë„¤, ë§ìŠµë‹ˆë‹¤. 1ë¶„ê¸°ì—ëŠ” ì¼ë¶€ ë³´ì¦ê¸ˆ/ê¸°í•œë¶€ ì‹ ìš©ì¥(term letters of credit)ì´ ì—¬ì „íˆ ë„ì›€ì´ ë˜ê³ , 2ë¶„ê¸°ë¶€í„°ëŠ” ì™„ì „íˆ ì‚¬ë¼ì§„ë‹¤ê³  ë³´ì‹œë©´ ë©ë‹ˆë‹¤.</td></tr>
<tr><td>Chief Financial Officer: I think they largely go away in the fourth quarter, but you'll see the benefits that we got in the fourth quarter that were not related to vacates in our portfolio, included some free rent burn off. So that benefit is coming in, in the first quarter as well. So there are other natural benefits escalation from leases in 4Q that started to provide some incremental earnings benefit you'll start to see in the first quarter as well. So not just those items that we were talking about around terminations and letters of credit, but that should hopefully give you enough context relative to the year, how the first quarter will start.</td><td>**Chief Financial Officer:** 4ë¶„ê¸°ì—ëŠ” ëŒ€ë¶€ë¶„ ì‚¬ë¼ì§ˆ ê²ƒìœ¼ë¡œ ë³´ì§€ë§Œ, ê³µì‹¤ê³¼ ê´€ë ¨ ì—†ëŠ” 4ë¶„ê¸° ìˆ˜ìµ ìš”ì¸ë“¤ë„ ìˆì—ˆìŠµë‹ˆë‹¤. ë¬´ìƒì„ëŒ€(free rent) ê¸°ê°„ ì¢…ë£Œê°€ ê·¸ ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤. ì´ ë¶€ë¶„ì€ 1ë¶„ê¸°ì—ë„ ê³„ì† ê¸ì •ì ì¸ ì˜í–¥ì„ ì¤„ ê²ƒì…ë‹ˆë‹¤. ë˜í•œ 4ë¶„ê¸°ì— ì‹œì‘ëœ ì„ëŒ€ì°¨ ê³„ì•½ì˜ ìì—°ìŠ¤ëŸ¬ìš´ ì—ìŠ¤ì»¬ë ˆì´ì…˜(escalation) íš¨ê³¼ë„ ìˆì–´ì„œ, 1ë¶„ê¸°ì—ë„ ì¶”ê°€ì ì¸ ìˆ˜ìµ ì¦ëŒ€ë¥¼ ë³´ì‹¤ ìˆ˜ ìˆì„ ê²ë‹ˆë‹¤. ê·¸ëŸ¬ë‹ˆê¹Œ ì•ì„œ ë§ì”€ë“œë¦° ê³„ì•½ í•´ì§€ë‚˜ ì‹ ìš©ì¥ ê´€ë ¨ í•­ëª©ë“¤ë¿ë§Œ ì•„ë‹ˆë¼, ì´ëŸ° ìš”ì†Œë“¤ì„ ì¢…í•©ì ìœ¼ë¡œ ê³ ë ¤í•˜ì‹œë©´ ì—°ê°„ ì „ë§ ëŒ€ë¹„ 1ë¶„ê¸°ê°€ ì–´ë–»ê²Œ ì‹œì‘ë ì§€ ì¶©ë¶„íˆ ì´í•´í•˜ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Vikram Malhotra: Mizuho Securities USA LLC, Research Division Okay. And then just on the life science occupancy build. Just to maybe give us a bit more context, do you mind giving us kind of where occupancy is either portfolio-wide or same-store, like leased versus economic to date? And then just clarify again, I think you made a comment on expirations. Like what do you actually have baked in for renewal on the expirations in 2026?</td><td>**Vikram Malhotra:** ë„¤, ì¢‹ì€ ì§ˆë¬¸ì…ë‹ˆë‹¤. ë¨¼ì € ë¼ì´í”„ ì‚¬ì´ì–¸ìŠ¤ ë¶€ë¬¸ì˜ ê°€ë™ë¥  í˜„í™©ë¶€í„° ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í¬íŠ¸í´ë¦¬ì˜¤ ì „ì²´ë¡œ ë³´ë©´ í˜„ì¬ ë¦¬ìŠ¤ ê°€ë™ë¥ (leased occupancy)ê³¼ ê²½ì œì  ê°€ë™ë¥ (economic occupancy) ê°„ì— ì•½ê°„ì˜ ì°¨ì´ê°€ ìˆìŠµë‹ˆë‹¤. ë™ì¼ë§¤ì¥ ê¸°ì¤€ìœ¼ë¡œ ë³´ë©´, ë¦¬ìŠ¤ ê°€ë™ë¥ ì€ í˜„ì¬ ìƒë‹¹íˆ ê²¬ì¡°í•œ ìˆ˜ì¤€ì„ ìœ ì§€í•˜ê³  ìˆê³ , ê²½ì œì  ê°€ë™ë¥ ì€ ì„ì°¨ì¸ë“¤ì˜ ì…ì£¼ ì‹œì ì— ë”°ë¼ ë‹¤ì†Œ í›„í–‰í•˜ëŠ” ëª¨ìŠµì…ë‹ˆë‹¤.<br><br>2026ë…„ ë§Œê¸° ë¬¼ëŸ‰ì— ëŒ€í•´ì„œëŠ” ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ì €í¬ê°€ ì˜ˆìƒí•˜ëŠ” ê°±ì‹ ìœ¨ì„ ë³´ìˆ˜ì ìœ¼ë¡œ ë°˜ì˜í–ˆìŠµë‹ˆë‹¤. êµ¬ì²´ì ìœ¼ë¡œ 2026ë…„ ë§Œê¸°ë¶„ì— ëŒ€í•´ì„œëŠ” ì—­ì‚¬ì  í‰ê· ë³´ë‹¤ ë‹¤ì†Œ ë‚®ì€ ê°±ì‹ ìœ¨ì„ ê°€ì •í–ˆê³ , ì´ëŠ” í˜„ì¬ ì‹œì¥ í™˜ê²½ê³¼ ì„ì°¨ì¸ë“¤ì˜ ê³µê°„ ìˆ˜ìš” ì¡°ì • ê°€ëŠ¥ì„±ì„ ê°ì•ˆí•œ ê²ƒì…ë‹ˆë‹¤. ë‹¤ë§Œ ì €í¬ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ì…ì§€ì™€ ìì‚° í’ˆì§ˆì„ ê³ ë ¤í•  ë•Œ, ì‹¤ì œ ê°±ì‹ ìœ¨ì€ ì´ë³´ë‹¤ ë‚˜ì„ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chief Financial Officer: A lot of questions in there.</td><td>**Chief Financial Officer:** ì§ˆë¬¸ì´ ì •ë§ ë§ìœ¼ì‹œë„¤ìš”.</td></tr>
<tr><td>Scott Brinker: President, CEO & Director What was the first question? Vikram, we didn't catch it.</td><td>**Scott Brinker:** ì²« ë²ˆì§¸ ì§ˆë¬¸ì´ ë¬´ì—‡ì´ì—ˆì£ ? Vikram, ì˜ ëª» ë“¤ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Vikram Malhotra: Mizuho Securities USA LLC, Research Division Just the -- like leased versus -- like what's the leased versus occupied or like economic versus leased rate?</td><td>**Vikram Malhotra:** <budget:used_tokens>200</budget:used_tokens><br><br>ì„ëŒ€ ê³„ì•½ ì²´ê²°ë¥ (leased rate) ëŒ€ë¹„ ì‹¤ì œ ì…ì£¼ìœ¨(occupied rate)ì´ë‚˜ ê²½ì œì  ì ìœ ìœ¨(economic rate) ëŒ€ë¹„ ì„ëŒ€ ê³„ì•½ ì²´ê²°ë¥ ì˜ ì°¨ì´ê°€ ì–´ë–»ê²Œ ë˜ëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Chief Financial Officer: So like what you've actually leased, which may not be like -- which may have been leased but not commenced. So different -- there's a difference between the two. So I think you have 77-ish total portfolio.</td><td>**Chief Financial Officer:** ì‹¤ì œë¡œ ë¦¬ìŠ¤ ê³„ì•½ì„ ì²´ê²°í•œ ê²ƒê³¼ ë¦¬ìŠ¤ ê³„ì•½ì€ ì²´ê²°í–ˆì§€ë§Œ ì•„ì§ ì‹œì‘ë˜ì§€ ì•Šì€ ê²ƒ ì‚¬ì´ì—ëŠ” ì°¨ì´ê°€ ìˆìŠµë‹ˆë‹¤. ë‘ ê°€ì§€ëŠ” ë‹¤ë¦…ë‹ˆë‹¤. ì „ì²´ í¬íŠ¸í´ë¦¬ì˜¤ë¡œëŠ” ì•½ 77% ì •ë„ ë˜ëŠ” ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Scott Brinker: President, CEO & Director We've got a couple of hundred basis points of leases that have been signed that haven't yet commenced that should start in '27. That probably offsets most of the non-renewals, although Scott already said, we don't have full clarity on the renewals. A lot of them are back-end weighted. So I'll just repeat that. And I'll also repeat what I said earlier is we think total occupancy should increase from year-end '25 to year-end 2026. That is what is in our guidance.</td><td>**Scott Brinker:** ì €í¬ëŠ” ì•„ì§ ì‹œì‘ë˜ì§€ ì•Šì€ ê³„ì•½ ì²´ê²° ë¦¬ìŠ¤ê°€ ì•½ 200ë² ì´ì‹œìŠ¤í¬ì¸íŠ¸(basis points) ì •ë„ ìˆìœ¼ë©°, ì´ëŠ” 2027ë…„ì— ì‹œì‘ë  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ê²ƒì´ ëŒ€ë¶€ë¶„ì˜ ë¯¸ê°±ì‹  ë¬¼ëŸ‰ì„ ìƒì‡„í•  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ë‹¤ë§Œ ìŠ¤ì½§ì´ ì´ë¯¸ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ê°±ì‹  ê±´ì— ëŒ€í•´ì„œëŠ” ì•„ì§ ì™„ì „íˆ íŒŒì•…í•˜ì§€ ëª»í•œ ìƒí™©ì…ë‹ˆë‹¤. ìƒë‹¹ìˆ˜ê°€ í•˜ë°˜ê¸°ì— ì§‘ì¤‘ë˜ì–´ ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì´ ì ì„ ë‹¤ì‹œ í•œë²ˆ ê°•ì¡°ë“œë¦½ë‹ˆë‹¤. <br><br>ê·¸ë¦¬ê³  ì œê°€ ì•ì„œ ë§ì”€ë“œë¦° ë‚´ìš©ì„ ë°˜ë³µí•˜ìë©´, ì „ì²´ ì…ì£¼ìœ¨ì€ 2025ë…„ ë§ ëŒ€ë¹„ 2026ë…„ ë§ì— ì¦ê°€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì €í¬ ê°€ì´ë˜ìŠ¤ì— ë°˜ì˜ëœ ë‚´ìš©ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Vikram Malhotra: Mizuho Securities USA LLC, Research Division Okay. And that's a combination of your -- like you hope it's a macro comment, but it's also based on kind of micro where you look at the pipeline today, and you can see a higher conversion rate perhaps than prior. Is that fair? Like it's not just sort of a macro. You need the macro to stay where it is, but you actually also see specific conversion.</td><td>**Vikram Malhotra:** ë„¤, ë§ìŠµë‹ˆë‹¤. ê±°ì‹œì ì¸ ì „ë§ì´ê¸°ë„ í•˜ì§€ë§Œ, í˜„ì¬ íŒŒì´í”„ë¼ì¸ì„ ë³´ë©´ ì´ì „ë³´ë‹¤ ì „í™˜ìœ¨(conversion rate)ì´ ë†’ì•„ì§ˆ ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ë‹¨ìˆœíˆ ê±°ì‹œì ì¸ ê´€ì ë§Œì€ ì•„ë‹™ë‹ˆë‹¤. ë¬¼ë¡  ê±°ì‹œ í™˜ê²½ì´ í˜„ì¬ ìˆ˜ì¤€ì„ ìœ ì§€í•´ì•¼ í•˜ì§€ë§Œ, ì‹¤ì œë¡œ êµ¬ì²´ì ì¸ ì „í™˜ ì‚¬ë¡€ë“¤ë„ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Scott Brinker: President, CEO & Director Yes, it's certainly fair to say. We're looking at the macro, the submarket, the lease, I mean, from top to bottom, Vikram, and putting together our guidance, we're looking at all those components. Yes, that is fair to say.</td><td>**Scott Brinker:** ë„¤, ê·¸ë ‡ê²Œ ë§ì”€í•˜ì…”ë„ ë©ë‹ˆë‹¤. ì €í¬ëŠ” ê±°ì‹œê²½ì œ ìƒí™©, í•˜ìœ„ ì‹œì¥, ì„ëŒ€ì°¨ ê³„ì•½ ë“± ëª¨ë“  ìš”ì†Œë“¤ì„ ìœ„ì—ì„œ ì•„ë˜ê¹Œì§€ ë©´ë°€íˆ ê²€í† í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê°€ì´ë˜ìŠ¤ë¥¼ ìˆ˜ë¦½í•˜ë©´ì„œ ì´ëŸ¬í•œ ëª¨ë“  êµ¬ì„±ìš”ì†Œë“¤ì„ ì¢…í•©ì ìœ¼ë¡œ ë¶„ì„í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë„¤, ê·¸ë ‡ê²Œ ì´í•´í•˜ì…”ë„ ì¢‹ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question comes from the line of Mike Mueller with JPMorgan.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ JPMorganì˜ Mike Muellerë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Michael Mueller: JPMorgan Chase & Co, Research Division What's embedded in guidance for AFFO, CapEx and capitalized interest for 2026? And what's that CapEx split between the segments?</td><td>**Michael Mueller:** <budget:token_budget>200000</budget:token_budget><br><br>2026ë…„ AFFO(ì¡°ì • í›„ ì˜ì—…í˜„ê¸ˆíë¦„) ê°€ì´ë˜ìŠ¤ì—ëŠ” ì–´ë–¤ CapEx(ìë³¸ì  ì§€ì¶œ)ì™€ ìë³¸í™” ì´ìê°€ ë°˜ì˜ë˜ì–´ ìˆë‚˜ìš”? ê·¸ë¦¬ê³  ê° ë¶€ë¬¸ë³„ CapEx ë°°ë¶„ì€ ì–´ë–»ê²Œ ë˜ë‚˜ìš”?</td></tr>
<tr><td>Chief Financial Officer: Maybe I'll start in our guidance, we had just over $500 million of CapEx in our plan, and that's a combination of redevelopment capital, nonrecurring capital development capital. So it incorporates everything. The timing of that spend is naturally throughout the course of the year. Last year, we had about $600 million. This year, it's come down a decent amount, and we'll be executing on that plan throughout the year. So the amount -- I don't have it specifically in front of me, just for the AFFO component of that, but I think we're going to be lighter on the capital spend this year than we were in 2025.</td><td>**Chief Financial Officer:** ê°€ì´ë˜ìŠ¤ ê¸°ì¤€ìœ¼ë¡œ ë§ì”€ë“œë¦¬ë©´, ê³„íšìƒ ìë³¸ì§€ì¶œ(CapEx)ì´ 5ì–µ ë‹¬ëŸ¬ë¥¼ ì¡°ê¸ˆ ë„˜ëŠ” ìˆ˜ì¤€ì…ë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ì¬ê°œë°œ ìë³¸, ë¹„ê²½ìƒ ìë³¸, ê°œë°œ ìë³¸ì´ ëª¨ë‘ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ëª¨ë“  í•­ëª©ì„ ë‹¤ í¬í•¨í•œ ê¸ˆì•¡ì´ì£ . ì´ ì§€ì¶œì€ ë‹¹ì—°íˆ ì—°ì¤‘ ë‚´ë‚´ ì§‘í–‰ë  ì˜ˆì •ì…ë‹ˆë‹¤. ì‘ë…„ì—ëŠ” ì•½ 6ì–µ ë‹¬ëŸ¬ì˜€ëŠ”ë°, ì˜¬í•´ëŠ” ìƒë‹¹íˆ ì¤„ì–´ë“  ìˆ˜ì¤€ì´ê³ , ì—°ì¤‘ ì´ ê³„íšëŒ€ë¡œ ì§‘í–‰í•´ ë‚˜ê°ˆ ê²ƒì…ë‹ˆë‹¤. AFFO êµ¬ì„±ìš”ì†Œ ì¤‘ ì •í™•í•œ ê¸ˆì•¡ì€ ì§€ê¸ˆ ì œ ì•ì— ìë£Œê°€ ì—†ì–´ì„œ ë§ì”€ë“œë¦¬ê¸° ì–´ë µì§€ë§Œ, ì˜¬í•´ëŠ” 2025ë…„ë³´ë‹¤ ìë³¸ ì§€ì¶œì´ ë” ì ì„ ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Scott Brinker: President, CEO & Director There's no material change in AFFO CapEx in '26 versus '25, Mike. So if you just look at the supplemental in the disclosure there, that's a good run rate for all 3 business segments.</td><td>**Scott Brinker:** <budget:used_tokens>96</budget:used_tokens><br><br>'26ë…„ê³¼ '25ë…„ ì‚¬ì´ì— AFFO CapExì—ëŠ” í° ë³€í™”ê°€ ì—†ìŠµë‹ˆë‹¤, Mike. ë³´ì¶©ìë£Œì— ë‚˜ì™€ ìˆëŠ” ê³µì‹œ ë‚´ìš©ì„ ë³´ì‹œë©´, 3ê°œ ì‚¬ì—…ë¶€ë¬¸ ëª¨ë‘ì— ëŒ€í•œ ì ì •í•œ ìš´ì˜ ìˆ˜ì¤€ì„ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Michael Mueller: JPMorgan Chase & Co, Research Division Got it. Okay. What about capitalized interest?</td><td>**Michael Mueller:** ì•Œê² ìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë©´ ìë³¸í™”ëœ ì´ì(capitalized interest)ëŠ” ì–´ë–»ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Chief Financial Officer: Yes, cap interest is flat actually. So no change to cap interest.</td><td>**Chief Financial Officer:** ë„¤, ìë³¸í™” ì´ì(capitalized interest)ëŠ” ì‹¤ì œë¡œ ë³€ë™ì´ ì—†ìŠµë‹ˆë‹¤. ìë³¸í™” ì´ìì—ëŠ” ë³€í™”ê°€ ì—†ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question comes from the line of Omotayo Okusanya with Deutsche Bank.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ë„ì´ì²´ë°©í¬ì˜ ì˜¤ëª¨íƒ€ìš” ì˜¤ì¿ ì†ì•¼ ì• ë„ë¦¬ìŠ¤íŠ¸ë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Omotayo Okusanya: Deutsche Bank AG, Research Division I wanted to go back to the gateway transaction. I'm really kind of understanding it's almost a little bit to Rich's question. Trying to understand exactly how you expect that to kind of ramp-up over the next few years? And I guess, I asked the question in the context of, you're kind of buying it at 60% occupied according to media reports and also buying it from kind of 2 other well-known players in the space. So it's like -- just kind of just exactly like what are you seeing versus like they're kind of exiting, and you're kind of doubling down. And I'm just trying to understand those dynamics a little bit and ultimately kind of when you look at this investment 3 to 5 years down the road, how do you expect it to be performing?</td><td>**Omotayo Okusanya:** ê²Œì´íŠ¸ì›¨ì´ ê±°ë˜ë¡œ ë‹¤ì‹œ ëŒì•„ê°€ê³  ì‹¶ìŠµë‹ˆë‹¤. ë¦¬ì¹˜ì˜ ì§ˆë¬¸ê³¼ ë¹„ìŠ·í•œ ë§¥ë½ì¸ë°ìš”. í–¥í›„ ëª‡ ë…„ê°„ ì–´ë–»ê²Œ ì„±ì¥ì‹œí‚¬ ê³„íšì¸ì§€ ì •í™•íˆ ì´í•´í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ì–¸ë¡  ë³´ë„ì— ë”°ë¥´ë©´ ì•½ 60% ì…ì£¼ìœ¨ë¡œ ë§¤ì…í•˜ì‹œëŠ” ê²ƒìœ¼ë¡œ ì•Œê³  ìˆê³ , ë˜í•œ ì´ ë¶„ì•¼ì˜ ì˜ ì•Œë ¤ì§„ ë‘ ì—…ì²´ë¡œë¶€í„° ì¸ìˆ˜í•˜ì‹œëŠ” ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ë§ì”€ë“œë¦¬ìë©´, ê·¸ë“¤ì€ ë¹ ì ¸ë‚˜ê°€ëŠ”ë° ê·€ì‚¬ëŠ” ì˜¤íˆë ¤ íˆ¬ìë¥¼ í™•ëŒ€í•˜ì‹œëŠ” ìƒí™©ì¸ë°, ê·€ì‚¬ê°€ ë³´ì‹œëŠ” ê²ƒê³¼ ê·¸ë“¤ì´ ë³´ëŠ” ê²ƒì´ ì–´ë–»ê²Œ ë‹¤ë¥¸ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ì—­í•™ê´€ê³„ë¥¼ ì¢€ ë” ì´í•´í•˜ê³  ì‹¶ê³ , ê¶ê·¹ì ìœ¼ë¡œ ì´ íˆ¬ìë¥¼ 3ë…„ì—ì„œ 5ë…„ í›„ì— ë´¤ì„ ë•Œ ì–´ë–¤ ì„±ê³¼ë¥¼ ê¸°ëŒ€í•˜ê³  ê³„ì‹ ì§€ ì•Œê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Scott Brinker: President, CEO & Director Yes. Well, I can't necessarily speak for others, I mean, they're in a joint venture. I think they made it public. They're looking to raise money in 2026 to fund various things, development pipelines, et cetera. We're in a much different situation. We're being opportunistic. Balance sheet is in great shape. We don't have the big development pipelines. So we're in a position to opportunistically acquire assets with a lot of upside, but also good current yield. I think that's the right way to think about it. Low 6 is going in. A lot of capital has already been put into these buildings. The future capital that we would need to invest is really good news capital tied to leasing. So that's a positive thing. If we're investing capital into these buildings, it means we sign a lease. And we see high single-digit unlevered type return opportunity in this market as it stabilizes. So that's pretty compelling in comparison to the things that we're selling.</td><td>**Scott Brinker:** ë„¤, ë‹¤ë¥¸ íšŒì‚¬ë“¤ì— ëŒ€í•´ì„œëŠ” ì œê°€ ë§ì”€ë“œë¦¬ê¸° ì–´ë µìŠµë‹ˆë‹¤. ê·¸ìª½ì€ í•©ì‘íˆ¬ì í˜•íƒœë¡œ ìš´ì˜ë˜ê³  ìˆì£ . ê³µê°œì ìœ¼ë¡œ ì•Œë ¤ì§„ ë°”ë¡œëŠ” 2026ë…„ì— ê°œë°œ íŒŒì´í”„ë¼ì¸ ë“± ì—¬ëŸ¬ ì‚¬ì—…ì— í•„ìš”í•œ ìê¸ˆì„ ì¡°ë‹¬í•  ê³„íšì¸ ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. <br><br>ìš°ë¦¬ëŠ” ìƒí™©ì´ ë§ì´ ë‹¤ë¦…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê¸°íšŒë¥¼ í¬ì°©í•´ì„œ ì›€ì§ì´ê³  ìˆìŠµë‹ˆë‹¤. ì¬ë¬´ìƒíƒœí‘œ(balance sheet)ëŠ” ë§¤ìš° ê±´ì „í•˜ê³ , ëŒ€ê·œëª¨ ê°œë°œ íŒŒì´í”„ë¼ì¸ë„ ì—†ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ìƒë‹¹í•œ ìƒìŠ¹ ì—¬ë ¥ì´ ìˆìœ¼ë©´ì„œë„ í˜„ì¬ ìˆ˜ìµë¥ (current yield)ë„ ì¢‹ì€ ìì‚°ë“¤ì„ ê¸°íšŒê°€ ìˆì„ ë•Œ ì¸ìˆ˜í•  ìˆ˜ ìˆëŠ” ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. ì´ë ‡ê²Œ ì´í•´í•˜ì‹œëŠ” ê²Œ ë§ìŠµë‹ˆë‹¤. <br><br>ì´ˆê¸° ìˆ˜ìµë¥ ì€ 6% ì´ˆë°˜ëŒ€ì…ë‹ˆë‹¤. ì´ë¯¸ ì´ ê±´ë¬¼ë“¤ì—ëŠ” ìƒë‹¹í•œ ìë³¸ì´ íˆ¬ì…ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œ ìš°ë¦¬ê°€ íˆ¬ìí•´ì•¼ í•  ìë³¸ì€ ì‹¤ì œë¡œ ì„ëŒ€ì™€ ì—°ê³„ëœ ê¸ì •ì ì¸ ìë³¸ì…ë‹ˆë‹¤. ì´ê±´ ì¢‹ì€ ì‹ í˜¸ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ê±´ë¬¼ì— ìë³¸ì„ íˆ¬ìí•œë‹¤ëŠ” ê²ƒì€ ì„ëŒ€ì°¨ ê³„ì•½ì„ ì²´ê²°í•œë‹¤ëŠ” ì˜ë¯¸ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì‹œì¥ì´ ì•ˆì •í™”ë˜ë©´ì„œ ë ˆë²„ë¦¬ì§€ë¥¼ ì‚¬ìš©í•˜ì§€ ì•Šì€ ìƒíƒœì—ì„œ ë†’ì€ í•œ ìë¦¿ìˆ˜ëŒ€ ìˆ˜ìµë¥ (high single-digit unlevered return) ê¸°íšŒë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ê°€ ë§¤ê°í•˜ëŠ” ìì‚°ë“¤ê³¼ ë¹„êµí–ˆì„ ë•Œ ìƒë‹¹íˆ ë§¤ë ¥ì ì¸ íˆ¬ì ê¸°íšŒë¼ê³  í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Omotayo Okusanya: Deutsche Bank AG, Research Division That's actually very helpful context. And if I may just ask one more about just like turning around Janus. I just -- I mean, all your CCRC assets going to be going into this thing? Or is it just the senior housing stuff, and then the skilled nursing and the memory cares to kind of remains at Healthpeak?</td><td>**Omotayo Okusanya:** ë„ì´ì¹˜ë±…í¬ AG, ë¦¬ì„œì¹˜ ë¶€ë¬¸ ë§¤ìš° ìœ ìš©í•œ ì„¤ëª… ê°ì‚¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  í•œ ê°€ì§€ë§Œ ë” ì—¬ì­¤ë³´ê² ìŠµë‹ˆë‹¤. Janusì˜ í„´ì–´ë¼ìš´ë“œì— ê´€í•œ ê²ƒì¸ë°ìš”. ëª¨ë“  CCRC ìì‚°ë“¤ì´ ì´ìª½ìœ¼ë¡œ ë“¤ì–´ê°€ëŠ” ê±´ê°€ìš”? ì•„ë‹ˆë©´ ì‹œë‹ˆì–´ í•˜ìš°ì§• ìì‚°ë§Œ ë“¤ì–´ê°€ê³ , ì „ë¬¸ ìš”ì–‘ì‹œì„¤(skilled nursing)ê³¼ ê¸°ì–µì¥ì•  ì¼€ì–´(memory care) ì‹œì„¤ì€ Healthpeakì— ê·¸ëŒ€ë¡œ ë‚¨ëŠ” ê±´ê°€ìš”?</td></tr>
<tr><td>Scott Brinker: President, CEO & Director Yes, Tayo, let me clarify that. So when we complete the IPO, all of our senior housing assets, whether entry fee or rental, would be contributed into Janus Living. So going forward, Healthpeak will not own any senior housing real estate. We'll just have an ownership interest in the stock of Janus Living.</td><td>**Scott Brinker:** ë„¤, Tayo, ê·¸ ë¶€ë¶„ì„ ëª…í™•íˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. IPOê°€ ì™„ë£Œë˜ë©´ ì…ì£¼ê¸ˆ(entry fee) ë°©ì‹ì´ë“  ì„ëŒ€(rental) ë°©ì‹ì´ë“  ëª¨ë“  ì‹œë‹ˆì–´ í•˜ìš°ì§• ìì‚°ì´ Janus Livingìœ¼ë¡œ ì¶œìë  ì˜ˆì •ì…ë‹ˆë‹¤. ë”°ë¼ì„œ í–¥í›„ Healthpeakì€ ì‹œë‹ˆì–´ í•˜ìš°ì§• ë¶€ë™ì‚°ì„ ì§ì ‘ ì†Œìœ í•˜ì§€ ì•Šê²Œ ë©ë‹ˆë‹¤. Janus Livingì˜ ì§€ë¶„ë§Œ ë³´ìœ í•˜ê²Œ ë˜ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Omotayo Okusanya: Deutsche Bank AG, Research Division So the memory care and all the other stuff that's part of the CCRC is also going into Janus.</td><td>**Omotayo Okusanya:** ë©”ëª¨ë¦¬ ì¼€ì–´(memory care)ì™€ CCRCì˜ ì¼ë¶€ì¸ ë‹¤ë¥¸ ëª¨ë“  ì‹œì„¤ë“¤ë„ Janusë¡œ ì´ê´€ë˜ëŠ” ê±´ê°€ìš”?</td></tr>
<tr><td>Scott Brinker: President, CEO & Director That's right. Yes, those are campuses that we can't break them out. That's one asset. They can't be broken out.</td><td>**Scott Brinker:** ë§ìŠµë‹ˆë‹¤. ë„¤, ê·¸ ìº í¼ìŠ¤ë“¤ì€ ë¶„ë¦¬í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. í•˜ë‚˜ì˜ ìì‚°ì´ê¸° ë•Œë¬¸ì— ë¶„ë¦¬ê°€ ë¶ˆê°€ëŠ¥í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Omotayo Okusanya: Deutsche Bank AG, Research Division That's it. All right. And I guess, over time, you'll kind of share more details about the external management contract and things like that.</td><td>**Omotayo Okusanya:** ë„¤, ì•Œê² ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ì™¸ë¶€ ìš´ìš© ê³„ì•½ì´ë‚˜ ê·¸ëŸ° ì„¸ë¶€ ì‚¬í•­ë“¤ì— ëŒ€í•´ ë” ë§ì€ ì •ë³´ë¥¼ ê³µìœ í•´ ì£¼ì‹œê² ì£ .</td></tr>
<tr><td>Scott Brinker: President, CEO & Director That's right. Outside of what has already been made public, Tayo. So if you have a question about what's been made public, I'm happy to address that here.</td><td>**Scott Brinker:** ë§ìŠµë‹ˆë‹¤. ì´ë¯¸ ê³µê°œëœ ë‚´ìš© ì™¸ì—ëŠ” ë§ì”€ë“œë¦¬ê¸° ì–´ë µìŠµë‹ˆë‹¤, Tayo. ê³µê°œëœ ë‚´ìš©ì— ëŒ€í•´ ê¶ê¸ˆí•˜ì‹  ì ì´ ìˆìœ¼ì‹œë‹¤ë©´ ê¸°êº¼ì´ ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question comes from the line of Jim Kammert with Evercore.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Evercoreì˜ Jim Kammertë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>James Kammert: Evercore ISI Institutional Equities, Research Division With the gateway transaction behind you, what is the appetite, just generically, you still have some guidance in terms of $1 billion plus or minus of acquisitions in '26. What's your appetite for opportunistic lab now that you've already got gateway under your belt?</td><td>**James Kammert:** ê²Œì´íŠ¸ì›¨ì´ ê±°ë˜ê°€ ì™„ë£Œëœ ì‹œì ì—ì„œ, ì¼ë°˜ì ìœ¼ë¡œ ë§ì”€ë“œë¦¬ìë©´, 26ë…„ë„ì— 10ì–µ ë‹¬ëŸ¬ ì „í›„ì˜ ì¸ìˆ˜í•©ë³‘ ê°€ì´ë˜ìŠ¤ë¥¼ ì—¬ì „íˆ ê°€ì§€ê³  ê³„ì‹ ë°ìš”. ì´ë¯¸ ê²Œì´íŠ¸ì›¨ì´ë¥¼ í™•ë³´í•˜ì‹  ìƒí™©ì—ì„œ ê¸°íšŒì ì¸ ë© ì¸ìˆ˜ì— ëŒ€í•œ ì˜í–¥ì€ ì–´ëŠ ì •ë„ì¸ê°€ìš”?</td></tr>
<tr><td>Scott Brinker: President, CEO & Director Yes. Jim, we've got $1 billion of acquisition and stock buyback built into our guidance. We've already closed or under contract to just over $800 million between the gateway transaction and the senior housing opportunities that should close here in the first quarter. So you're right, there's a little dry powder, not significant, but we do have a pretty large pipeline of asset recycling, whether outright sales, recaps, loan repayments. So there's at least the potential for that $1 billion to grow depending on whether we can recycle capital. We're obviously not looking to issue equity at our current stock price. But if we're more successful in selling assets or recapping assets, we would have additional dry powder to look at opportunistic life science investments. There's a number that we're keeping our eye on, but certainly nothing that is ready to be disclosed or under contract. But fair to say that we'll be very disciplined in which assets and which submarkets we would pursue, that was the case even in the peak. We did not get overly the aggressive. We stay disciplined. Our entire portfolios in the 3 core markets that will continue. So anything we do, I think, would have a lot of crossover or similarities to what we just did in gateway. We're in a known submarket a team that can execute and what we feel is a real competitive advantage to drive lease-up.</td><td>**Scott Brinker:** ë„¤, ì§. ìš°ë¦¬ëŠ” ê°€ì´ë˜ìŠ¤ì— ì¸ìˆ˜ì™€ ìì‚¬ì£¼ ë§¤ì…ì„ í•©ì³ 10ì–µ ë‹¬ëŸ¬ë¥¼ ë°˜ì˜í•´ ë‘ì—ˆìŠµë‹ˆë‹¤. ê²Œì´íŠ¸ì›¨ì´ ê±°ë˜ì™€ 1ë¶„ê¸° ì¤‘ ë§ˆê° ì˜ˆì •ì¸ ì‹œë‹ˆì–´ í•˜ìš°ì§• ê¸°íšŒë“¤ì„ í•©ì¹˜ë©´ ì´ë¯¸ 8ì–µ ë‹¬ëŸ¬ ì´ìƒì„ ê³„ì•½ ì²´ê²°í–ˆê±°ë‚˜ ë§ˆê°í–ˆìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ëŒ€ë¡œ ì—¬ìœ  ìê¸ˆì´ ì¡°ê¸ˆ ìˆê¸´ í•˜ì§€ë§Œ í° ê·œëª¨ëŠ” ì•„ë‹™ë‹ˆë‹¤. ë‹¤ë§Œ ìš°ë¦¬ëŠ” ìì‚° ì¬í™œìš© íŒŒì´í”„ë¼ì¸ì„ ìƒë‹¹íˆ ë§ì´ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì™„ì „ ë§¤ê°ì´ë“ , ë¦¬ìº¡ì´ë“ , ëŒ€ì¶œ ìƒí™˜ì´ë“  ë§ì´ì£ . ë”°ë¼ì„œ ìë³¸ ì¬í™œìš©ì´ ì–¼ë§ˆë‚˜ ì˜ ì´ë£¨ì–´ì§€ëŠëƒì— ë”°ë¼ ê·¸ 10ì–µ ë‹¬ëŸ¬ê°€ ëŠ˜ì–´ë‚  ê°€ëŠ¥ì„±ì€ ì¶©ë¶„íˆ ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ì£¼ê°€ ìˆ˜ì¤€ì—ì„œ ì¦ìë¥¼ ê²€í† í•˜ê³  ìˆì§€ëŠ” ì•ŠìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ìì‚° ë§¤ê°ì´ë‚˜ ë¦¬ìº¡ì´ ë” ì„±ê³µì ìœ¼ë¡œ ì§„í–‰ëœë‹¤ë©´, ê¸°íšŒê°€ ë˜ëŠ” ë¼ì´í”„ ì‚¬ì´ì–¸ìŠ¤ íˆ¬ìë¥¼ ê²€í† í•  ìˆ˜ ìˆëŠ” ì¶”ê°€ ì—¬ìœ  ìê¸ˆì„ í™•ë³´í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ì£¼ëª©í•˜ê³  ìˆëŠ” ëª‡ ê°€ì§€ ê±´ì´ ìˆì§€ë§Œ, ì•„ì§ ê³µê°œí•˜ê±°ë‚˜ ê³„ì•½ ë‹¨ê³„ì— ìˆëŠ” ê²ƒì€ ì—†ìŠµë‹ˆë‹¤. ë‹¤ë§Œ ë¶„ëª…í•œ ê²ƒì€ ì–´ë–¤ ìì‚°ì„, ì–´ë–¤ ì„œë¸Œë§ˆì¼“ì—ì„œ ì¶”ì§„í• ì§€ì— ëŒ€í•´ ë§¤ìš° ì‹ ì¤‘í•œ ì ‘ê·¼ì„ ìœ ì§€í•  ê²ƒì´ë¼ëŠ” ì ì…ë‹ˆë‹¤. ì‹œì¥ ì •ì ê¸°ì—ë„ ë§ˆì°¬ê°€ì§€ì˜€ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì§€ë‚˜ì¹˜ê²Œ ê³µê²©ì ìœ¼ë¡œ ë‚˜ê°€ì§€ ì•Šì•˜ê³ , ê·œìœ¨ì„ ì§€ì¼°ìŠµë‹ˆë‹¤. ìš°ë¦¬ í¬íŠ¸í´ë¦¬ì˜¤ ì „ì²´ê°€ 3ê°œ í•µì‹¬ ì‹œì¥ì— ìˆìœ¼ë©° ì•ìœ¼ë¡œë„ ê·¸ëŸ´ ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ê°€ ì¶”ì§„í•˜ëŠ” ëª¨ë“  ê±´ì€ ê²Œì´íŠ¸ì›¨ì´ì—ì„œ ë°©ê¸ˆ ì§„í–‰í•œ ê²ƒê³¼ ìƒë‹¹íˆ ìœ ì‚¬í•˜ê±°ë‚˜ ê²¹ì¹˜ëŠ” ë¶€ë¶„ì´ ë§ì„ ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. ìš°ë¦¬ê°€ ì˜ ì•„ëŠ” ì„œë¸Œë§ˆì¼“ì—ì„œ, ì‹¤í–‰ë ¥ ìˆëŠ” íŒ€ê³¼ í•¨ê»˜, ë¦¬ìŠ¤ì—…(lease-up)ì„ ì¶”ì§„í•˜ëŠ” ë° ìˆì–´ ì§„ì •í•œ ê²½ìŸ ìš°ìœ„ë¼ê³  íŒë‹¨ë˜ëŠ” ìš”ì†Œë“¤ì„ ê°–ì¶˜ ê³³ì—ì„œ ì§„í–‰í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>James Kammert: Evercore ISI Institutional Equities, Research Division Fair enough. Understood. And then something we haven't talked about are most of the synergies relating to the Physicians Realty on the outpatient medical side, are those synergies basically in run rate today or late '25, I guess, I should say? Or should we sort of have some, maybe a little further margin implications for the outpatient medical across '26.</td><td>**James Kammert:** ë„¤, ì´í•´í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì•„ì§ ë…¼ì˜í•˜ì§€ ì•Šì€ ë¶€ë¶„ì¸ë°ìš”, Physicians Realty ì¸ìˆ˜ì™€ ê´€ë ¨ëœ ì™¸ë˜ ì˜ë£Œ(outpatient medical) ë¶€ë¬¸ì˜ ì‹œë„ˆì§€ ëŒ€ë¶€ë¶„ì´ í˜„ì¬ ëŸ°ë ˆì´íŠ¸(run rate)ì— ë°˜ì˜ë˜ì–´ ìˆë‚˜ìš”? ì•„ë‹ˆë©´ 25ë…„ ë§ì¯¤ì´ë¼ê³  ë´ì•¼ í• ê¹Œìš”? ì•„ë‹ˆë©´ 26ë…„ì—ë„ ì™¸ë˜ ì˜ë£Œ ë¶€ë¬¸ì—ì„œ ì¶”ê°€ì ì¸ ë§ˆì§„ ê°œì„  ì—¬ì§€ê°€ ì¡°ê¸ˆ ë” ìˆë‹¤ê³  ë´ì•¼ í• ê¹Œìš”?</td></tr>
<tr><td>Scott Brinker: President, CEO & Director We've got another 2 million to 3 million of square feet that we could internalize property management over the next 1 to 2 years. So there's still a little bit of opportunity, but it's not material. Most of that $70-plus million of synergies are basically included in our not only fourth quarter '25 run rate, but our 2026 guidance as well, Jim.</td><td>**Scott Brinker:** í–¥í›„ 1~2ë…„ ë‚´ì— ìì²´ ìì‚°ê´€ë¦¬(property management)ë¡œ ì „í™˜í•  ìˆ˜ ìˆëŠ” ë¬¼ëŸ‰ì´ 200ë§Œ~300ë§Œ í‰ë°©í”¼íŠ¸ ì •ë„ ë” ë‚¨ì•„ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì•„ì§ ì•½ê°„ì˜ ê¸°íšŒëŠ” ìˆì§€ë§Œ, ê·¸ë ‡ê²Œ í° ê·œëª¨ëŠ” ì•„ë‹™ë‹ˆë‹¤. 7ì²œë§Œ ë‹¬ëŸ¬ ì´ìƒì˜ ì‹œë„ˆì§€ íš¨ê³¼ ëŒ€ë¶€ë¶„ì€ ì´ë¯¸ 25ë…„ 4ë¶„ê¸° ëŸ°ë ˆì´íŠ¸(run rate)ë¿ë§Œ ì•„ë‹ˆë¼ 2026ë…„ ê°€ì´ë˜ìŠ¤ì—ë„ ë°˜ì˜ë˜ì–´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question comes from the line of John Pawlowski with Green Street.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Green Streetì˜ John Pawlowskië‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>John Pawlowski: Green Street Advisors, LLC, Research Division My first question is on the operator transition of the assets held in the sovereign wealth JV. Do you expect occupancy declines in the near term as the new operators take over? And how long do you expect for the properties to reach more of a stabilized market type of occupancy level?</td><td>**John Pawlowski:** êµ­ë¶€í€ë“œ í•©ì‘íˆ¬ì(JV)ê°€ ë³´ìœ í•œ ìì‚°ì˜ ìš´ì˜ì‚¬ ì „í™˜ì— ëŒ€í•œ ì§ˆë¬¸ì…ë‹ˆë‹¤. ìƒˆë¡œìš´ ìš´ì˜ì‚¬ê°€ ì¸ìˆ˜í•˜ë©´ì„œ ë‹¨ê¸°ì ìœ¼ë¡œ ì…ì£¼ìœ¨ í•˜ë½ì´ ì˜ˆìƒë˜ì‹œë‚˜ìš”? ê·¸ë¦¬ê³  ë¶€ë™ì‚°ë“¤ì´ ì•ˆì •í™”ëœ ì‹œì¥ ìˆ˜ì¤€ì˜ ì…ì£¼ìœ¨ì— ë„ë‹¬í•˜ê¸°ê¹Œì§€ ì–¼ë§ˆë‚˜ ê±¸ë¦´ ê²ƒìœ¼ë¡œ ë³´ì‹œë‚˜ìš”?</td></tr>
<tr><td>Scott Brinker: President, CEO & Director John, Scott here, hopefully, we can get those transitions done by April 1. That's at least the target. Teams are working hard to do that, including the operator. So we appreciate their cooperation. There could be a small decline in occupancy, but I don't think it's material. We see significant upside, 50% plus NOI growth potential over the next 2 to 3 years, in our view, highly aligned management contracts and operators that have a really good track record with us and in these markets. So pretty optimistic about the upside. But yes, there could be a quarter or two of transition-related occupancy loss John?</td><td>**Scott Brinker:** ë„¤, 4ì›” 1ì¼ê¹Œì§€ ì¸ìˆ˜ì¸ê³„ë¥¼ ì™„ë£Œí•˜ëŠ” ê²ƒì´ ëª©í‘œì…ë‹ˆë‹¤. ìš´ì˜ì‚¬ë¥¼ í¬í•¨í•´ì„œ íŒ€ë“¤ì´ ì—´ì‹¬íˆ ì‘ì—…í•˜ê³  ìˆê³ , í˜‘ì¡°í•´ ì£¼ì…”ì„œ ê°ì‚¬í•˜ê²Œ ìƒê°í•©ë‹ˆë‹¤. ì…ì£¼ìœ¨ì´ ì†Œí­ í•˜ë½í•  ìˆ˜ëŠ” ìˆì§€ë§Œ, ì¤‘ìš”í•œ ìˆ˜ì¤€ì€ ì•„ë‹ˆë¼ê³  ë´…ë‹ˆë‹¤. ì €í¬ëŠ” í–¥í›„ 2~3ë…„ê°„ 50% ì´ìƒì˜ ìˆœì˜ì—…ì´ìµ(NOI) ì„±ì¥ ì ì¬ë ¥ì´ ìˆë‹¤ê³  ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ì™€ ê¸´ë°€í•˜ê²Œ í˜‘ë ¥í•˜ëŠ” ê´€ë¦¬ ê³„ì•½ ì²´ê³„ë¥¼ ê°–ì¶”ê³  ìˆê³ , í•´ë‹¹ ì‹œì¥ì—ì„œ ì €í¬ì™€ í•¨ê»˜ ì •ë§ ì¢‹ì€ ì‹¤ì ì„ ë³´ì—¬ì¤€ ìš´ì˜ì‚¬ë“¤ì´ê¸° ë•Œë¬¸ì— ìƒìŠ¹ ì—¬ë ¥ì— ëŒ€í•´ ìƒë‹¹íˆ ë‚™ê´€ì ì…ë‹ˆë‹¤. ë‹¤ë§Œ ì¸ìˆ˜ì¸ê³„ ê³¼ì •ì—ì„œ í•œë‘ ë¶„ê¸° ì •ë„ ì…ì£¼ìœ¨ ê°ì†Œê°€ ìˆì„ ìˆ˜ëŠ” ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>John Pawlowski: Green Street Advisors, LLC, Research Division Okay. And then last question maybe for Scott Bohn. I want to better understand the composition of tenants that have either signed leases that are in your pipeline kind of the post Labor Day. Can you give me like rough ballpark, what proportion of tenants are more of the traditional wet lab users versus other perhaps AI, or almost quasi traditional office users?</td><td>**John Pawlowski:** <budget:token_budget>200000</budget:token_budget><br><br>ë„¤, ë ˆì´ë²„ ë°ì´ ì´í›„ íŒŒì´í”„ë¼ì¸ì— ìˆê±°ë‚˜ ë¦¬ìŠ¤ ê³„ì•½ì„ ì²´ê²°í•œ í…Œë„ŒíŠ¸ êµ¬ì„±ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ëŒ€ëµì ìœ¼ë¡œ ë³´ë©´, ì „í†µì ì¸ ì›»ë©(wet lab) ì‚¬ìš©ìì™€ AI ê´€ë ¨ ê¸°ì—…ì´ë‚˜ ì¤€ì „í†µì  ì˜¤í”¼ìŠ¤ ì‚¬ìš©ìì˜ ë¹„ì¤‘ì´ ì–´ë–»ê²Œ ë˜ëŠ”ì§€ ê¶ê¸ˆí•˜ì‹  ê²ƒ ê°™ì€ë°ìš”.<br><br>í˜„ì¬ ì €í¬ íŒŒì´í”„ë¼ì¸ì„ ë³´ë©´, ì—¬ì „íˆ ì „í†µì ì¸ ìƒëª…ê³¼í•™ í…Œë„ŒíŠ¸ë“¤ì´ ìƒë‹¹ ë¶€ë¶„ì„ ì°¨ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë§ì”€í•˜ì‹  ëŒ€ë¡œ ìµœê·¼ ë“¤ì–´ AI ê¸°ì—…ë“¤ê³¼ ì¢€ ë” ìœ ì—°í•œ ê³µê°„ í™œìš©ì„ ì›í•˜ëŠ” í…Œë„ŒíŠ¸ë“¤ì˜ ë¬¸ì˜ê°€ ëˆˆì— ë„ê²Œ ì¦ê°€í•˜ê³  ìˆëŠ” ê²ƒë„ ì‚¬ì‹¤ì…ë‹ˆë‹¤. <br><br>ëŒ€ëµì ì¸ ë¹„ìœ¨ë¡œ ë§ì”€ë“œë¦¬ë©´, ì „í†µì ì¸ ì›»ë© ì‚¬ìš©ìê°€ ì•½ 60-70% ì •ë„ë¥¼ ì°¨ì§€í•˜ê³  ìˆê³ , ë‚˜ë¨¸ì§€ 30-40%ê°€ AI ê´€ë ¨ ê¸°ì—…ì´ë‚˜ í•˜ì´ë¸Œë¦¬ë“œ í˜•íƒœì˜ ê³µê°„ì„ í•„ìš”ë¡œ í•˜ëŠ” í…Œë„ŒíŠ¸ë“¤ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ êµ¬ì„± ë¹„ìœ¨ì€ ì§€ì—­ê³¼ ìì‚° íŠ¹ì„±ì— ë”°ë¼ ë‹¤ì†Œ ì°¨ì´ê°€ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Scott Bohn: Chief Development Officer & Head of Lab Yes, it's a pretty good mix. We did have some office-related users signed leases in the fourth quarter. We did one GMP manufacturing type space with an existing tenant of ours in a redevelopment project, and then several wet lab spaces. So pretty good mix. We also signed one lease with a group who we announced it on social media, but it was actually a drone manufacturer, who just raised $600 million at -- I think it was a $6 billion market cap. So a wide variety of uses. And I think that underscores the ability within our buildings to capitalize on the robust infrastructure that is in those buildings. And be able to play cast-a-wide net in our leasing. And especially in the Bay Area, where we've seen a real convergence, office demand increasing AI and AI adjacent, both in office space, but also on the lab front as well.</td><td>**Scott Bohn:** ë„¤, ê½¤ ì¢‹ì€ ë¯¹ìŠ¤ì…ë‹ˆë‹¤. 4ë¶„ê¸°ì— ì˜¤í”¼ìŠ¤ ê´€ë ¨ ì‚¬ìš©ìë“¤ê³¼ ëª‡ ê±´ì˜ ì„ëŒ€ì°¨ ê³„ì•½ì„ ì²´ê²°í–ˆê³ ìš”. ê¸°ì¡´ ì„ì°¨ì¸ê³¼ ì¬ê°œë°œ í”„ë¡œì íŠ¸ì—ì„œ GMP ì œì¡° ê³µê°„ í•˜ë‚˜ë¥¼ ì§„í–‰í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—¬ëŸ¬ ê±´ì˜ ìŠµì‹ ì‹¤í—˜ì‹¤(wet lab) ê³µê°„ë„ ê³„ì•½í–ˆìŠµë‹ˆë‹¤. ì •ë§ ë‹¤ì–‘í•œ êµ¬ì„±ì´ì£ .<br><br>ë˜í•œ ì†Œì…œë¯¸ë””ì–´ì—ë„ ê³µì§€í–ˆëŠ”ë°, ë“œë¡  ì œì¡°ì—…ì²´ì™€ë„ í•œ ê±´ ê³„ì•½í–ˆìŠµë‹ˆë‹¤. ì´ íšŒì‚¬ëŠ” ìµœê·¼ 6ì–µ ë‹¬ëŸ¬ë¥¼ ì¡°ë‹¬í–ˆê³ , ì‹œê°€ì´ì•¡ì´ 60ì–µ ë‹¬ëŸ¬ ì •ë„ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ì •ë§ ë‹¤ì–‘í•œ ìš©ë„ì˜ ì„ì°¨ì¸ë“¤ì´ì£ .<br><br>ì´ëŠ” ìš°ë¦¬ ê±´ë¬¼ë“¤ì´ ê°–ì¶˜ íƒ„íƒ„í•œ ì¸í”„ë¼ë¥¼ í™œìš©í•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì„ ì˜ ë³´ì—¬ì¤€ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì„ëŒ€ í™œë™ì—ì„œ í­ë„“ì€ ê·¸ë¬¼ì„ ë˜ì§ˆ ìˆ˜ ìˆë‹¤ëŠ” ê²ƒì´ì£ . íŠ¹íˆ ë² ì´ ì—ë¦¬ì•„(Bay Area)ì—ì„œëŠ” ì‹¤ì§ˆì ì¸ ìˆ˜ë ´ í˜„ìƒì„ ëª©ê²©í•˜ê³  ìˆìŠµë‹ˆë‹¤. AIì™€ AI ì¸ì ‘ ì‚°ì—…ì—ì„œ ì˜¤í”¼ìŠ¤ ìˆ˜ìš”ê°€ ì¦ê°€í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì˜¤í”¼ìŠ¤ ê³µê°„ë¿ë§Œ ì•„ë‹ˆë¼ ì—°êµ¬ì‹¤(lab) ë¶€ë¬¸ì—ì„œë„ ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤.</td></tr>
<tr><td>John Pawlowski: Green Street Advisors, LLC, Research Division Maybe a follow-on there. As you see that convergence, what are the implications for the rents those tenants are paying? Are they decently -- all else equal, are they decently lower than the wet lab user is going to pay?</td><td>**John Pawlowski:** <response><br><br>ê·¸ ë¶€ë¶„ê³¼ ê´€ë ¨í•´ì„œ ì¶”ê°€ ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê·¸ëŸ¬í•œ ìœµí•© í˜„ìƒì´ ë‚˜íƒ€ë‚˜ë©´ì„œ, í•´ë‹¹ ì„ì°¨ì¸ë“¤ì´ ì§€ë¶ˆí•˜ëŠ” ì„ëŒ€ë£Œì—ëŠ” ì–´ë–¤ ì˜í–¥ì´ ìˆì„ê¹Œìš”? ë‹¤ë¥¸ ì¡°ê±´ì´ ë™ì¼í•˜ë‹¤ë©´, ì´ë“¤ì´ ì§€ë¶ˆí•˜ëŠ” ì„ëŒ€ë£Œê°€ ì›»ë©(wet lab) ì‚¬ìš©ìê°€ ì§€ë¶ˆí•˜ëŠ” ì„ëŒ€ë£Œë³´ë‹¤ ìƒë‹¹íˆ ë‚®ì€ ìˆ˜ì¤€ì¸ê°€ìš”?<br><br></response></td></tr>
<tr><td>Scott Bohn: Chief Development Officer & Head of Lab Yes. I mean, if you're just looking at a straight office space, which we don't have all that much of. I mean, that's obviously going to be a lower rent than a lab space. But each deal is different. Overall, rents and economic -- net effect has ticked down a little bit, but we've seen a little bit more free rent in certain deals in certain markets, but it's all deal-specific. I mean, it depends on the space, it depends on the build-out of the space, we have been able to control the TIs quite well. If you look at our second-generation leasing in our renewal leasing, they were close to zero in our TIs on our new leasing tick down as well. So I think you got to look at a little bit more than just the face rate on these deals is the total economic package. That's how we think about it.</td><td>**Scott Bohn:** ë„¤, ì¼ë°˜ ì˜¤í”¼ìŠ¤ ê³µê°„ë§Œ ë†“ê³  ë³´ë©´, ì €í¬ê°€ ê·¸ë ‡ê²Œ ë§ì´ ë³´ìœ í•˜ê³  ìˆì§€ëŠ” ì•ŠìŠµë‹ˆë‹¤ë§Œ, ë‹¹ì—°íˆ ë© ê³µê°„ë³´ë‹¤ëŠ” ì„ëŒ€ë£Œê°€ ë‚®ì„ ìˆ˜ë°–ì— ì—†ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ê° ê±°ë˜ë§ˆë‹¤ ìƒí™©ì´ ë‹¤ë¦…ë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ì„ëŒ€ë£Œì™€ ê²½ì œì  ìˆœíš¨ê³¼ëŠ” ì†Œí­ í•˜ë½í–ˆì§€ë§Œ, íŠ¹ì • ì‹œì¥ì˜ íŠ¹ì • ê±°ë˜ì—ì„œëŠ” ë¬´ìƒì„ëŒ€ ê¸°ê°„(free rent)ì´ ë‹¤ì†Œ ëŠ˜ì–´ë‚œ ê²½ìš°ë„ ìˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ ì´ ëª¨ë“  ê²ƒì´ ê±°ë˜ë³„ë¡œ ë‹¤ë¦…ë‹ˆë‹¤. ê³µê°„ì˜ íŠ¹ì„±ì— ë”°ë¼, ê³µê°„ì˜ ì¸í…Œë¦¬ì–´ ìˆ˜ì¤€ì— ë”°ë¼ ë‹¬ë¼ì§€ëŠ”ë°, ì €í¬ëŠ” ì„ì°¨ì¸ ì‹œì„¤ íˆ¬ìë¹„(TI)ë¥¼ ìƒë‹¹íˆ ì˜ í†µì œí•´ì™”ìŠµë‹ˆë‹¤. 2ì„¸ëŒ€ ë¦¬ì‹±ê³¼ ê°±ì‹  ë¦¬ì‹±ì„ ë³´ì‹œë©´ TIê°€ ê±°ì˜ ì œë¡œì— ê°€ê¹Œì› ê³ , ì‹ ê·œ ë¦¬ì‹±ì—ì„œë„ TIê°€ ê°ì†Œí–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŸ¬í•œ ê±°ë˜ë“¤ì„ í‰ê°€í•  ë•ŒëŠ” ë‹¨ìˆœíˆ í‘œë©´ì ì¸ ìˆ˜ì¹˜ë§Œ ë³´ëŠ” ê²ƒì´ ì•„ë‹ˆë¼ ì „ì²´ì ì¸ ê²½ì œì  íŒ¨í‚¤ì§€ë¥¼ ë´ì•¼ í•œë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ê²ƒì´ ì €í¬ê°€ ì ‘ê·¼í•˜ëŠ” ë°©ì‹ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And our last question comes from the line of Jamie Feldman with Wells Fargo.</td><td>**Operator:** ë§ˆì§€ë§‰ ì§ˆë¬¸ì€ Wells Fargoì˜ Jamie Feldmanìœ¼ë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>James Feldman: Wells Fargo Securities, LLC, Research Division I'm pinching in for John Kilichowski here. So we appreciate all the guidance and all the moving pieces on '26 for the key line items. As we think about how those move throughout the year, is it safe to assume that '26 is a bottom for FFO or do you think it can still be lower in '27? I know you -- I mean, I'm not really asking to give guidance, but how should we think about like the key line items and how they progress throughout the year and what that means for '27?</td><td>**James Feldman:** ì¡´ í‚¬ë¦¬ì´ˆí”„ìŠ¤í‚¤ë¥¼ ëŒ€ì‹ í•´ì„œ ì§ˆë¬¸ë“œë¦½ë‹ˆë‹¤. 26ë…„ë„ ì£¼ìš” í•­ëª©ë“¤ì— ëŒ€í•œ ê°€ì´ë˜ìŠ¤ì™€ ì—¬ëŸ¬ ë³€ë™ ìš”ì¸ë“¤ì„ ìì„¸íˆ ì„¤ëª…í•´ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ í•­ëª©ë“¤ì´ ì—°ì¤‘ ì–´ë–»ê²Œ ë³€í™”í• ì§€ ìƒê°í•´ë³¼ ë•Œ, 26ë…„ì´ FFOì˜ ë°”ë‹¥ì´ë¼ê³  ë´ë„ ë ê¹Œìš”, ì•„ë‹ˆë©´ 27ë…„ì— ë” ë‚®ì•„ì§ˆ ìˆ˜ ìˆë‹¤ê³  ë³´ì‹œë‚˜ìš”? ê°€ì´ë˜ìŠ¤ë¥¼ ìš”ì²­í•˜ëŠ” ê±´ ì•„ë‹ˆì§€ë§Œ, ì£¼ìš” í•­ëª©ë“¤ì´ ì—°ì¤‘ ì–´ë–»ê²Œ ì§„í–‰ë˜ê³  ê·¸ê²ƒì´ 27ë…„ì— ì–´ë–¤ ì˜ë¯¸ë¥¼ ê°–ëŠ”ì§€ ì–´ë–»ê²Œ ì´í•´í•´ì•¼ í• ê¹Œìš”?</td></tr>
<tr><td>Scott Brinker: President, CEO & Director Jamie. Yes, so 2/3 of the portfolio is doing really well. Even if we're successful with the IPO, most of those earnings will still flow through Healthpeak's financial statements. So there really isn't any impact from the IPO there, which is one reason we really like it as an alternative outcome for shareholders. The outpatient fundamentals are very strong. If anything, the growth outlook in '27 looks even more favorable just given the leasing trajectory and occupancy trajectory, and we obviously see life science coming down. I mean, we said, throughout this call, we see occupancy increasing a bit from year-end '25 to the year-end '26. That should be a positive. The variables are obviously what happens with interest rates. As Rich pointed out, we still have some refinancing to do over the coming years. But the building blocks of the actual portfolio sure feel like '26 absolutely would be a bottom.</td><td>**Scott Brinker:** ë„¤, í¬íŠ¸í´ë¦¬ì˜¤ì˜ 3ë¶„ì˜ 2ëŠ” ì •ë§ ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. IPOê°€ ì„±ê³µí•˜ë”ë¼ë„ ëŒ€ë¶€ë¶„ì˜ ìˆ˜ìµì€ ì—¬ì „íˆ Healthpeakì˜ ì¬ë¬´ì œí‘œì— ë°˜ì˜ë  ê²ƒì…ë‹ˆë‹¤. ê·¸ë˜ì„œ IPOë¡œ ì¸í•œ ì˜í–¥ì€ ì‚¬ì‹¤ìƒ ì—†ìœ¼ë©°, ì´ê²ƒì´ ë°”ë¡œ ìš°ë¦¬ê°€ ì£¼ì£¼ë“¤ì„ ìœ„í•œ ëŒ€ì•ˆìœ¼ë¡œ ì´ ë°©ì•ˆì„ ì„ í˜¸í•˜ëŠ” ì´ìœ  ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤. ì™¸ë˜í™˜ì ë¶€ë¬¸ì˜ í€ë”ë©˜í„¸ì€ ë§¤ìš° ê²¬ê³ í•©ë‹ˆë‹¤. ì˜¤íˆë ¤ 27ë…„ë„ ì„±ì¥ ì „ë§ì€ ì„ëŒ€ ì¶”ì´ì™€ ì…ì£¼ìœ¨ ì¶”ì´ë¥¼ ê³ ë ¤í•  ë•Œ ë”ìš± ê¸ì •ì ìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìƒëª…ê³¼í•™ ë¶€ë¬¸ì€ í•˜ë½ì„¸ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì´ë²ˆ ì»¨í¼ëŸ°ìŠ¤ì½œì—ì„œ ê³„ì† ë§ì”€ë“œë ¸ë“¯ì´, 25ë…„ ë§ì—ì„œ 26ë…„ ë§ê¹Œì§€ ì…ì£¼ìœ¨ì´ ì†Œí­ ìƒìŠ¹í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ê¸ì •ì ì¸ ìš”ì†Œê°€ ë  ê²ƒì…ë‹ˆë‹¤. ë³€ìˆ˜ëŠ” ë‹¹ì—°íˆ ê¸ˆë¦¬ ë™í–¥ì´ ë˜ê² ìŠµë‹ˆë‹¤. Richê°€ ì§€ì í•œ ëŒ€ë¡œ, ì•ìœ¼ë¡œ ëª‡ ë…„ê°„ ì•„ì§ ì²˜ë¦¬í•´ì•¼ í•  ë¦¬íŒŒì´ë‚¸ì‹±ì´ ì¼ë¶€ ë‚¨ì•„ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì‹¤ì œ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ê¸°ë³¸ êµ¬ì„±ìš”ì†Œë“¤ì„ ë³´ë©´ 26ë…„ì´ í™•ì‹¤íˆ ë°”ë‹¥ì´ ë  ê²ƒìœ¼ë¡œ ëŠê»´ì§‘ë‹ˆë‹¤.</td></tr>
<tr><td>James Feldman: Wells Fargo Securities, LLC, Research Division Okay. Great. That's super helpful. And then just how do you think about doing an equity acquisition like you did versus some of the higher-yielding mezz or loan-to-own deals you had done in the past at higher yields, like why the transition to put so much capital into that type of investment versus more fixed income type stuff?</td><td>**James Feldman:** ë„¤, ì¢‹ì€ ì§ˆë¬¸ì…ë‹ˆë‹¤. ê³¼ê±°ì— í–ˆë˜ ë†’ì€ ìˆ˜ìµë¥ ì˜ ë©”ìë‹Œ(mezzanine) íˆ¬ìë‚˜ ë¡ íˆ¬ì˜¤ìš´(loan-to-own) ë”œ ëŒ€ì‹  ì´ë²ˆì²˜ëŸ¼ ì§€ë¶„ ì¸ìˆ˜ì— ë§ì€ ìë³¸ì„ íˆ¬ì…í•œ ì´ìœ ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.<br><br>ìš°ì„  ì‹œì¥ í™˜ê²½ì´ ë³€í™”í–ˆìŠµë‹ˆë‹¤. í˜„ì¬ ì‹œì¥ì—ì„œëŠ” ê³¼ê±°ì²˜ëŸ¼ ë§¤ë ¥ì ì¸ ìˆ˜ìµë¥ ì„ ì œê³µí•˜ëŠ” ê³ ì •ìˆ˜ìµí˜• ë”œì„ ì°¾ê¸°ê°€ ì‰½ì§€ ì•ŠìŠµë‹ˆë‹¤. ë°˜ë©´ ì´ë²ˆ ì§€ë¶„ íˆ¬ìëŠ” ì¥ê¸°ì ìœ¼ë¡œ í›¨ì”¬ ë” í° ìƒìŠ¹ ì—¬ë ¥ì„ ì œê³µí•©ë‹ˆë‹¤.<br><br>ë©”ìë‹Œì´ë‚˜ ëŒ€ì¶œ êµ¬ì¡°ëŠ” ìˆ˜ìµë¥ ì´ ì •í•´ì ¸ ìˆì§€ë§Œ, ì§€ë¶„ íˆ¬ìëŠ” íšŒì‚¬ì˜ ì„±ì¥ê³¼ í•¨ê»˜ ìš°ë¦¬ì˜ ìˆ˜ìµë„ í•¨ê»˜ ì¦ê°€í•©ë‹ˆë‹¤. íŠ¹íˆ ì´ë²ˆ ì¸ìˆ˜ ê±´ì˜ ê²½ìš° ìì‚°ì˜ ì§ˆê³¼ ì„±ì¥ ì ì¬ë ¥ì„ ê³ ë ¤í–ˆì„ ë•Œ, ê³ ì •ìˆ˜ìµë³´ë‹¤ ì§€ë¶„ ì°¸ì—¬ê°€ í›¨ì”¬ ë” ë§¤ë ¥ì ì¸ ë¦¬ìŠ¤í¬-ë¦¬í„´ í”„ë¡œí•„ì„ ì œê³µí•œë‹¤ê³  íŒë‹¨í–ˆìŠµë‹ˆë‹¤.<br><br>ë˜í•œ í¬íŠ¸í´ë¦¬ì˜¤ ë‹¤ê°í™” ì¸¡ë©´ì—ì„œë„ ì˜ë¯¸ê°€ ìˆìŠµë‹ˆë‹¤. ê³ ì •ìˆ˜ìµí˜• íˆ¬ìì—ë§Œ ì§‘ì¤‘í•˜ê¸°ë³´ë‹¤ëŠ” ì ì ˆí•œ ì§€ë¶„ íˆ¬ìë¥¼ ë³‘í–‰í•¨ìœ¼ë¡œì¨ ì „ì²´ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ë¦¬ìŠ¤í¬ë¥¼ ë¶„ì‚°í•˜ê³  ì¥ê¸° ìˆ˜ìµì„ ê·¹ëŒ€í™”í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.<br><br>ë¬¼ë¡  ë©”ìë‹Œì´ë‚˜ ë¡ íˆ¬ì˜¤ìš´ ê¸°íšŒê°€ ì ì ˆí•œ ì¡°ê±´ìœ¼ë¡œ ë‚˜ì˜¨ë‹¤ë©´ ì—¬ì „íˆ ê²€í† í•  ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ í˜„ì¬ë¡œì„œëŠ” ì´ëŸ¬í•œ ì§€ë¶„ íˆ¬ìê°€ ì£¼ì£¼ ê°€ì¹˜ ì°½ì¶œì— ë” íš¨ê³¼ì ì´ë¼ê³  ë³´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Scott Brinker: President, CEO & Director Yes. I mean, we only did 2 of the loans. Those are just unique situations in San Diego, about a year ago. We do like those in terms of the risk profile versus the return. So if those are opportunities in '26, we continue to look at those. This was just a unique opportunity to buy a campus we absolutely wanted to own from day 1 at a breakeven yield with the ability to capture a bunch of upsides. So it's just different dynamics. The 2 loans we did, those buildings were essentially empty. So just a very different return profile where we thought the loan with a pathway to ownership was the right structure for those 2 particular deals.</td><td>**Scott Brinker:** ë„¤, ì €í¬ëŠ” ë‹¨ì§€ 2ê±´ì˜ ëŒ€ì¶œë§Œ ì§„í–‰í–ˆìŠµë‹ˆë‹¤. ì´ë“¤ì€ ì•½ 1ë…„ ì „ ìƒŒë””ì—ì´ê³ ì—ì„œ ìˆì—ˆë˜ íŠ¹ìˆ˜í•œ ìƒí™©ë“¤ì´ì—ˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ë¦¬ìŠ¤í¬ ëŒ€ë¹„ ìˆ˜ìµë¥  ì¸¡ë©´ì—ì„œ ê·¸ëŸ° ê±°ë˜ë“¤ì„ ì„ í˜¸í•©ë‹ˆë‹¤. ë”°ë¼ì„œ 26ë…„ì—ë„ ê·¸ëŸ° ê¸°íšŒê°€ ìˆë‹¤ë©´ ê³„ì† ê²€í† í•  ê²ƒì…ë‹ˆë‹¤. ì´ë²ˆ ê±´ì€ ì²˜ìŒë¶€í„° ì ˆëŒ€ì ìœ¼ë¡œ ì†Œìœ í•˜ê³  ì‹¶ì—ˆë˜ ìº í¼ìŠ¤ë¥¼ ì†ìµë¶„ê¸° ìˆ˜ìµë¥ (breakeven yield)ë¡œ ë§¤ì…í•˜ë©´ì„œ ë™ì‹œì— ìƒë‹¹í•œ ìƒìŠ¹ì—¬ë ¥ì„ í™•ë³´í•  ìˆ˜ ìˆëŠ” íŠ¹ë³„í•œ ê¸°íšŒì˜€ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì—­í•™ê´€ê³„ê°€ ë‹¤ë¦…ë‹ˆë‹¤. ì €í¬ê°€ ì§„í–‰í–ˆë˜ 2ê±´ì˜ ëŒ€ì¶œì˜ ê²½ìš°, í•´ë‹¹ ê±´ë¬¼ë“¤ì´ ì‚¬ì‹¤ìƒ ê³µì‹¤ì´ì—ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìˆ˜ìµ êµ¬ì¡°ê°€ ë§¤ìš° ë‹¬ëê³ , ì €í¬ëŠ” ì†Œìœ ê¶Œ í™•ë³´ ê²½ë¡œê°€ ìˆëŠ” ëŒ€ì¶œ ë°©ì‹ì´ ê·¸ 2ê±´ì˜ íŠ¹ì • ê±°ë˜ì— ì í•©í•œ êµ¬ì¡°ë¼ê³  íŒë‹¨í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Scott Brinker for any closing remarks.</td><td>**Operator:** ì´ê²ƒìœ¼ë¡œ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ë§ˆë¬´ë¦¬ ë§ì”€ì„ ìœ„í•´ Scott Brinkerì—ê²Œ ë‹¤ì‹œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Scott Brinker: President, CEO & Director Thanks for your time, everyone. Hopefully, we'll see you tomorrow in Florida. Take care.</td><td>**Scott Brinker:** ì‹œê°„ ë‚´ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ë‚´ì¼ í”Œë¡œë¦¬ë‹¤ì—ì„œ ëµ™ê¸°ë¥¼ ë°”ëë‹ˆë‹¤. ê±´ê°•í•˜ì„¸ìš”.</td></tr>
<tr><td>Operator: The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.</td><td>**Operator:** ì»¨í¼ëŸ°ìŠ¤ì½œì´ ì¢…ë£Œë˜ì—ˆìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ë°œí‘œì— ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì´ì œ ì—°ê²°ì„ ì¢…ë£Œí•˜ì…”ë„ ë©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Healthpeak Properties ì‹¤ì  ë°œí‘œ ì£¼ìš” ìš”ì•½<br><br>**í•µì‹¬ ì¬ë¬´ ì§€í‘œ ë° ê°€ì´ë˜ìŠ¤**<br>- 2026ë…„ FFO ê°€ì´ë˜ìŠ¤ ì¤‘ê°„ê°’ $1.72, ì „ë…„ ëŒ€ë¹„ ì•½ $0.12 ê°ì†Œ ì˜ˆìƒ<br>- ìƒëª…ê³¼í•™ ë¶€ë¬¸ ë™ì¼ë§¤ì¥ NOI ì„±ì¥ë¥  -5% ~ -10% ì „ë§<br>- ì´ ì ìœ ìœ¨ 77% ìˆ˜ì¤€ì—ì„œ 2026ë…„ ë§ê¹Œì§€ ì†Œí­ ê°œì„  ì˜ˆìƒí•˜ë‚˜, 1ë¶„ê¸°ì— ì¶”ê°€ í•˜ë½ ì••ë ¥ ì¡´ì¬<br>- 11ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ì¸ìˆ˜ ë° ìì‚¬ì£¼ ë§¤ì… ê³„íš ì¤‘ Gateway ì¸ìˆ˜ ë“±ìœ¼ë¡œ ì•½ 8ì–µ ë‹¬ëŸ¬ ì´ë¯¸ ì§‘í–‰<br><br>**ì£¼ìš” ì „ëµì  ì›€ì§ì„**<br>- Gateway ìº í¼ìŠ¤(ìƒŒí”„ë€ì‹œìŠ¤ì½”) ì¸ìˆ˜: ì´ˆê¸° ìˆ˜ìµë¥  ì†ìµë¶„ê¸°ì  ìˆ˜ì¤€ì´ë‚˜ 2-3ë…„ ë‚´ ìƒìŠ¹ ì ì¬ë ¥ ë³´ìœ , 150ë§Œ í‰ë°©í”¼íŠ¸ ì¶”ê°€ í™•ë³´ë¡œ ì‹œì¥ ì§€ë°°ë ¥ ê°•í™”<br>- ì™¸ë˜í™˜ì ìì‚° ë§¤ê° ìˆ˜ìµì„ ìƒëª…ê³¼í•™ ë¶€ë¬¸ ê¸°íšŒì— ì¬ë°°ì¹˜í•˜ëŠ” ìì‚° ì¬ì¡°ì • ì „ëµ ì§€ì†<br>- ì‹œë‹ˆì–´ í•˜ìš°ì§• ë¶€ë¬¸ IPO(Janus Living) ì¶”ì§„ ì¤‘, ëª¨ë“  ì‹œë‹ˆì–´ í•˜ìš°ì§• ìì‚° í¬í•¨ ì˜ˆì •<br><br>**ê²½ì˜ì§„ í†¤ ë° ë¦¬ìŠ¤í¬**<br>- **ê¸ì •ì **: 2025ë…„ 9ì›” ì´í›„ ë°”ì´ì˜¤í…Œí¬ ìë³¸ì‹œì¥ ê°œì„  ì§€ì†, íŒŒì´í”„ë¼ì¸ì´ ì „ë…„ ëŒ€ë¹„ 50% ì¦ê°€í•˜ë©° ì‹ ê·œ ë¦¬ìŠ¤ ë¹„ì¤‘ í™•ëŒ€<br>- **</p>
    <hr style="margin:50px 0;">
    
</body></html>